Quorum Health (QHCCQ) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 06, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	QUORUM HEALTH CORPORATION
Entity Central Index Key	1,650,445
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Trading Symbol	QHC
Amendment Flag	false
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,890,995

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Operating revenues		$ 585,215		$ 1,173,160
Provision for bad debts		55,069		115,374
Net operating revenues	$ 472,632	530,146	$ 959,452	1,057,786
Operating costs and expenses:
Salaries and benefits	232,631	265,309	479,631	529,911
Supplies	52,897	64,112	111,783	127,934
Other operating expenses	144,456	157,613	297,194	321,037
Depreciation and amortization	17,142	20,586	35,403	42,706
Rent	11,358	12,152	23,890	24,254
Electronic health records incentives earned	(445)	(1,777)	(586)	(4,229)
Legal, professional and settlement costs	5,417	3,934	8,830	4,469
Impairment of long-lived assets and goodwill	0	12,900	39,760	16,200
Loss (gain) on sale of hospitals, net	307	(4,321)	8,122	(5,191)
Loss on closure of hospitals, net	3,338	0	17,084	0
Transaction costs related to the Spin-off	0	0	0	31
Total operating costs and expenses	467,101	530,508	1,021,111	1,057,122
Income (loss) from operations	5,531	(362)	(61,659)	664
Interest expense, net	31,926	30,458	62,857	57,988
Income (loss) before income taxes	(26,395)	(30,820)	(124,516)	(57,324)
Provision for (benefit from) income taxes	(454)	(245)	(88)	456
Net income (loss)	(25,941)	(30,575)	(124,428)	(57,780)
Less: Net income (loss) attributable to noncontrolling interests	665	55	1,146	411
Net income (loss) attributable to Quorum Health Corporation	$ (26,606)	$ (30,630)	$ (125,574)	$ (58,191)
Earnings (loss) per share attributable to Quorum Health Corporation stockholders:
Basic and diluted	$ (0.92)	$ (1.09)	$ (4.37)	$ (2.08)
Weighted-average shares outstanding:
Basic and diluted	28,995,564	28,145,215	28,726,445	27,977,738

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ (25,941)	$ (30,575)	$ (124,428)	$ (57,780)
Amortization and recognition of unrecognized pension cost components, net of income taxes	(189)	120	(75)	242
Comprehensive income (loss)	(26,130)	(30,455)	(124,503)	(57,538)
Less: Comprehensive income (loss) attributable to noncontrolling interests	665	55	1,146	411
Comprehensive income (loss) attributable to Quorum Health Corporation	$ (26,795)	$ (30,510)	$ (125,649)	$ (57,949)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Apr. 29, 2016	Apr. 27, 2016
Current assets:
Cash and cash equivalents	$ 2,822	$ 5,617
Patient accounts receivable, net of allowance for doubtful accounts of $352,509 at December 31, 2017	327,480	343,145
Inventories	46,780	53,459
Prepaid expenses	25,364	21,167
Due from third-party payors	69,189	97,202
Current assets of hospitals held for sale	0	8,112
Other current assets	45,442	47,440
Total current assets	517,077	576,142
Property and equipment, at cost	1,335,404	1,405,184
Less: Accumulated depreciation and amortization	(730,623)	(729,905)
Total property and equipment, net	604,781	675,279
Goodwill	401,456	409,229
Intangible assets, net	53,445	64,850
Long-term assets of hospitals held for sale	0	7,734
Other long-term assets	87,824	95,607
Total assets	1,664,583	1,828,841
Current liabilities:
Current maturities of long-term debt	1,733	1,855
Accounts payable	154,575	171,250
Accrued liabilities:
Accrued salaries and benefits	82,125	77,803
Accrued interest	10,221	10,466
Due to third-party payors	40,670	47,705
Current liabilities of hospitals held for sale	0	2,577
Other current liabilities	45,912	43,687
Total current liabilities	335,236	355,343
Long-term debt	1,197,679	1,212,035			$ 1,250,497	$ 24,179
Deferred income tax liabilities, net	7,799	7,774
Other long-term liabilities	130,163	137,954
Total liabilities	1,670,877	1,713,106
Redeemable noncontrolling interests	2,301	2,325	$ 5,614	$ 6,807
Quorum Health Corporation stockholders' equity (deficit):
Preferred stock, $0.0001 par value per share, 100,000,000 shares authorized, none issued	0	0
Common stock, $0.0001 par value per share, 300,000,000 shares authorized; 30,898,710 shares issued and outstanding at June 30, 2018, and 30,294,895 shares issued and outstanding at December 31, 2017	3	3
Additional paid-in capital	552,511	549,610
Accumulated other comprehensive income (loss)	(2,031)	(1,956)
Accumulated deficit	(573,790)	(448,216)
Total Quorum Health Corporation stockholders' equity (deficit)	(23,307)	99,441
Nonredeemable noncontrolling interests	14,712	13,969
Total equity (deficit)	(8,595)	113,410	$ 159,212	$ 215,569
Total liabilities and equity	$ 1,664,583	$ 1,828,841

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Allowance for doubtful patient accounts	$ 0	$ 352,509
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	30,898,710	30,294,895
Common stock, shares outstanding	30,898,710	30,294,895

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Nonredeemable Noncontrolling Interests [Member]
Stockholders' equity, beginning balance at Dec. 31, 2016	$ 215,569	$ 3	$ 537,911	$ (2,760)	$ (334,026)	$ 14,441
Stockholders' equity, beginning balance, shares at Dec. 31, 2016		29,482,050
Comprehensive income (loss)	(56,411)			242	(58,191)	1,538
Stock-based compensation expense	5,328		5,328
Stock-based compensation expense, shares		1,033,324
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,489)		(1,489)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares, shares		(217,850)
Cash distributions to noncontrolling investors	(3,809)					(3,809)
Adjustments to redemption values of redeemable noncontrolling interests	24		24
Stockholders' equity, ending balance at Jun. 30, 2017	159,212	$ 3	541,774	(2,518)	(392,217)	12,170
Stockholders' equity, ending balance, shares at Jun. 30, 2017		30,297,524
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2016	6,807
Redeemable Noncontrolling Interests, Comprehensive income (loss)	(1,127)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(42)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests	(24)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2017	5,614
Stockholders' equity, beginning balance at Dec. 31, 2017	$ 113,410	$ 3	549,610	(1,956)	(448,216)	13,969
Stockholders' equity, beginning balance, shares at Dec. 31, 2017	30,294,895	30,294,895
Comprehensive income (loss)	$ (124,165)			(75)	(125,574)	1,484
Stock-based compensation expense	5,220		5,220
Stock-based compensation expense, shares		929,016
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,943)		(1,943)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares, shares		(325,201)
Cash distributions to noncontrolling investors	(741)					(741)
Adjustments to redemption values of redeemable noncontrolling interests	(376)		(376)
Stockholders' equity, ending balance at Jun. 30, 2018	$ (8,595)	$ 3	$ 552,511	$ (2,031)	$ (573,790)	$ 14,712
Stockholders' equity, ending balance, shares at Jun. 30, 2018	30,898,710
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2017	$ 2,325
Redeemable Noncontrolling Interests, Comprehensive income (loss)	(338)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(62)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests	376
Redeemable noncontrolling interests, ending balance at Jun. 30, 2018	$ 2,301

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Nonredeemable Noncontrolling Interests [Member]
Stockholders' equity, beginning balance at Dec. 31, 2016	$ 215,569	$ 3	$ 537,911	$ (2,760)	$ (334,026)	$ 14,441
Stockholders' equity, beginning balance, shares at Dec. 31, 2016		29,482,050
Comprehensive income (loss)	(56,411)			242	(58,191)	1,538
Stock-based compensation expense	5,328		5,328
Stock-based compensation expense, shares		1,033,324
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,489)		(1,489)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares, shares		(217,850)
Cash distributions to noncontrolling investors	(3,809)					(3,809)
Adjustments to redemption values of redeemable noncontrolling interests	24		24
Stockholders' equity, ending balance at Jun. 30, 2017	159,212	$ 3	541,774	(2,518)	(392,217)	12,170
Stockholders' equity, ending balance, shares at Jun. 30, 2017		30,297,524
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2016	6,807
Redeemable Noncontrolling Interests, Comprehensive income (loss)	(1,127)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(42)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests	(24)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2017	5,614
Stockholders' equity, beginning balance at Dec. 31, 2017	$ 113,410	$ 3	549,610	(1,956)	(448,216)	13,969
Stockholders' equity, beginning balance, shares at Dec. 31, 2017	30,294,895	30,294,895
Comprehensive income (loss)	$ (124,165)			(75)	(125,574)	1,484
Stock-based compensation expense	5,220		5,220
Stock-based compensation expense, shares		929,016
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,943)		(1,943)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares, shares		(325,201)
Cash distributions to noncontrolling investors	(741)					(741)
Adjustments to redemption values of redeemable noncontrolling interests	(376)		(376)
Stockholders' equity, ending balance at Jun. 30, 2018	$ (8,595)	$ 3	$ 552,511	$ (2,031)	$ (573,790)	$ 14,712
Stockholders' equity, ending balance, shares at Jun. 30, 2018	30,898,710
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2017	$ 2,325
Redeemable Noncontrolling Interests, Comprehensive income (loss)	(338)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(62)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests	376
Redeemable noncontrolling interests, ending balance at Jun. 30, 2018	$ 2,301

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income (loss)	$ (25,941)	$ (30,575)	$ (124,428)	$ (57,780)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	17,142	20,586	35,403	42,706
Non-cash interest expense, net	2,723	700	4,534	1,430
Provision for (benefit from) deferred income taxes	(511)	(346)	25	255
Stock-based compensation expense	2,756	2,531	5,220	5,328
Impairment of long-lived assets and goodwill	0	12,900	39,760	16,200
Loss (gain) on sale of hospitals, net	307	(4,321)	8,122	(5,191)
Non-cash portion of loss on hospital closures	1,089	0	6,394	0
Changes in reserves for self-insurance claims, net of payments	4,355	7,042	10,380	11,254
Changes in reserves for legal, professional and settlement costs, net of payments	0	0	0	(3,651)
Other non-cash expense (income), net	56	47	7	5
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Patient accounts receivable, net	19,645	(13,186)	21,074	(30,349)
Due from and due to third-party payors, net	19,761	4,366	20,978	15,407
Inventories, prepaid expenses and other current assets	(1,519)	8,942	(229)	(7,732)
Accounts payable and accrued liabilities	(19,301)	(36,773)	(9,714)	1,292
Long-term assets and liabilities, net	(3,368)	606	(2,925)	1,871
Net cash provided by (used in) operating activities	17,194	(27,481)	14,601	(8,955)
Cash flows from investing activities:
Capital expenditures for property and equipment	(10,791)	(15,925)	(25,319)	(39,142)
Capital expenditures for software	(531)	(1,663)	(1,044)	(3,169)
Acquisitions, net of cash acquired	(26)	(1,887)	(58)	(1,887)
Proceeds from the sale of hospitals	507	15,874	39,170	20,156
Other investing activities, net	52	0	249	0
Net cash provided by (used in) investing activities	(10,789)	(3,601)	12,998	(24,042)
Cash flows from financing activities:
Borrowings under revolving credit facilities	115,000	130,000	247,000	302,000
Repayments under revolving credit facilities	(119,000)	(158,000)	(233,000)	(252,000)
Borrowings of long-term debt	55	72	67	72
Repayments of long-term debt	(30,820)	(4,738)	(31,447)	(11,847)
Payments of debt issuance costs	0	(2,891)	(2,268)	(2,938)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,309)	(461)	(1,943)	(1,489)
Cash distributions to noncontrolling investors	0	(37)	(803)	(3,851)
Net cash provided by (used in) financing activities	(36,074)	(36,055)	(22,394)	29,947
Net change in cash, cash equivalents and restricted cash	(29,669)	(67,137)	5,205	(3,050)
Cash, cash equivalents and restricted cash at beginning of period	40,491	89,542	5,617	25,455
Cash, cash equivalents and restricted cash at end of period	10,822	22,405	10,822	22,405
Supplemental cash flow information:
Interest payments, net	41,224	51,104	58,711	66,572
Income tax payments, net of refunds	341	28	487	28
Non-cash purchases of property and equipment under capital lease obligations	$ 0	$ 54	$ 0	$ 54

Description of the Business and

Description of the Business and Spin-Off	6 Months Ended
	Jun. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of the Business and Spin-off	NOTE 1 – DESCRIPTION OF THE BUSINESS AND SPIN-OFF Description of the Business The principal business of Quorum Health Corporation, a Delaware corporation, and its subsidiaries (collectively, “QHC” or the “Company”) is to provide hospital and outpatient healthcare services in its markets across the United States. As of June 30, 2018, the Company owned or leased a diversified portfolio of 28 hospitals in rural and mid-sized markets, which are located in 14 states and have a total of 2,649 licensed beds. The Company provides outpatient healthcare services through its hospitals and affiliated facilities, including urgent care centers, diagnostic and imaging centers, physician clinics and surgery centers. The Company’s wholly-owned subsidiary, Quorum Health Resources, LLC (“QHR”), provides hospital management advisory and healthcare consulting services to non-affiliated hospitals located throughout the United States. Over 95% of the Company’s net operating revenues are attributable to its hospital operations business. Description of the Spin-off On April 29, 2016, Community Health Systems, Inc. (“CHS”, or “Parent” when referring to the carve-out period prior to April 29, 2016) completed the spin-off of 38 hospitals, including their affiliated facilities, and QHR to form Quorum Health Corporation through the distribution of 100% of the common stock of QHC, issued at a par value of $0.0001 per share, to CHS stockholders of record as of the close of business on April 22, 2016 (the “Record Date”) and cash proceeds to CHS of $1.2 billion (the “Spin-off”). Each CHS stockholder received a distribution of one share of QHC common stock for every four shares of CHS common stock held as of the Record Date plus cash in lieu of fractional shares. Quorum Health Corporation began trading on the New York Stock Exchange (“NYSE”) under the ticker symbol “QHC” on May 2, 2016. In connection with the Spin-off, QHC issued $400 million in aggregate principal amount of 11.625% Senior Notes due 2023 (the “Senior Notes”) on April 22, 2016, pursuant to an indenture (the “Indenture”) by and between the Company and Regions Bank, as Trustee. The Senior Notes were issued at a discount of $6.9 million, or 1.734%. The gross offering proceeds of the Senior Notes were deposited into a segregated escrow account at the closing of the offering on April 22, 2016. On April 29, 2016, the Company entered into a credit agreement (the “Senior Credit Facility”) consisting of an $880 million senior secured term loan facility (the “Term Loan Facility”), which was issued at a discount of $17.6 million, or 98% of par value, and a $100 million senior secured revolving credit facility (the “Revolving Credit Facility”). In addition, the Company entered into a $125 million senior secured asset-based revolving credit facility (the “ABL Credit Facility”) on April 29, 2016. The net offering proceeds of the Senior Notes were released to QHC from the escrow account on April 29, 2016. The net offering proceeds of the Senior Notes, together with the net borrowings under the Term Loan Facility, were used to pay $1.2 billion of the cash proceeds to CHS, as mentioned above, and to pay the Company’s fees and expenses related to the Spin-off. The cash proceeds paid to CHS were characterized as a one-time, tax-free cash distribution. In connection with the Spin-off, QHC and CHS entered into a Separation and Distribution Agreement, a Tax Matters Agreement and an Employee Matters Agreement on April 29, 2016, which, collectively, governed or continue to govern the allocation of employees, assets and liabilities that were transferred to QHC from CHS, including but not limited to investments, working capital, property and equipment, employee benefits and deferred tax assets and liabilities. In addition, QHC and CHS entered into various transition services agreements and other ancillary agreements that govern certain relationships and activities of QHC and CHS for five years following the Spin-off. See Note 16 — Related Party Transactions for additional information on the agreements that exist between QHC and CHS after the Spin-off. In connection with the Spin-off, CHS contributed $530.6 million of additional paid-in capital to QHC and made a $13.5 million cash contribution to QHC, pursuant to the Separation and Distribution Agreement. This contribution consisted of $20.0 million of cash contributed to fund a portion of QHC’s initial working capital, reduced by $6.5 million for the difference in estimated and actual financing transaction fees related to the Spin-off. The following table provides a summary of the major transactions to effect the Spin-off of QHC as a newly formed, independent company (dollars in thousands): Additional Long-Term Due to Common Stock Paid-in Parent's Debt Parent, Net Shares Amount Capital Equity Balance at April 29, 2016 (prior to the Spin-off) $ 24,179 $ 1,813,836 — $ — $ — $ 3,137 Borrowings of long-term debt, net of debt issuance discounts 1,255,464 — — — — — Payments of debt issuance costs (29,146 ) — — — — — Cash proceeds paid to Parent — (1,217,336 ) — — — — Transfer of liabilities from Parent — (22,292 ) — — — — Net deferred income tax liability resulting from the Spin-off — (46,783 ) — — — — Non-cash capital contribution from Parent — (527,425 ) — — 530,562 (3,137 ) Distribution of common stock — — 27,719,645 3 (3 ) — Distribution of restricted stock awards — — 692,409 — — — Balance at April 29, 2016 (after the Spin-off) $ 1,250,497 $ — 28,412,054 $ 3 $ 530,559 $ —

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	NOTE 2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The condensed consolidated financial statements and accompanying notes of the Company presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”). In the opinion of the Company’s management, the condensed consolidated financial information presented herein includes all adjustments necessary to present fairly the results of operations, financial position and cash flows of the Company for the interim periods presented. Results of operations for interim periods should not be considered indicative of the results of operations expected for the full year ending December 31, 2018. Certain information and disclosures have been condensed or omitted as presented herein and as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim period presentation. The Company’s management believes the financial statements and disclosures presented herein are adequate in order to make the information presented not misleading. The condensed consolidated financial statements should be read in conjunction with the consolidated and combined financial statements and accompanying notes thereto for the year ended December 31, 2017, contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2018 (the “2017 Annual Report on Form 10-K”). Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its subsidiaries in which it holds either a direct or indirect ownership of a majority voting interest. Investments in less-than-wholly-owned consolidated subsidiaries of QHC are presented separately in the equity component of the Company’s consolidated balance sheets to distinguish between the interests of QHC and the interests of the noncontrolling investors. Revenues and expenses from these subsidiaries are included in the respective individual line items of the Company’s consolidated statements of income, and net income is presented both in total and separately to distinguish the amounts attributable to the Company and the amounts attributable to the interests of the noncontrolling investors. Noncontrolling interests that are redeemable, or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company, are presented in mezzanine equity in the Company’s consolidated balance sheets. Intercompany transactions and accounts of the Company are eliminated in consolidation. Reclassifications and Immaterial Restatements Certain revisions have been made to prior period balances as follows: Beginning in the fourth quarter of 2017, the Company reclassified and separately presented in its consolidated statements of cash flows the gross borrowings and repayments of its revolving credit facilities. Both items are included in cash flows from financing activities. Previously, these amounts were netted in the Company’s presentation of its consolidated statements of cash flow. This reclassification is considered immaterial and had no effect on the Company’s consolidated results of operations or financial position. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. Actual results could differ from those estimates under different assumptions or conditions. Revenues and Accounts Receivable Adoption of ASC Topic 606 “Revenue from Contracts with Customers” On January 1, 2018, the Company adopted Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”) using the modified retrospective method to all contracts existing on January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to • Prior to the adoption of ASC 606, a significant portion of the Company’s allowance for doubtful accounts related to amounts due from self-pay patients, as well as co-pays and deductibles owed to the Company by patients with insurance. Under ASC 606, the estimated allowance for these patients is generally considered a direct reduction to net operating revenues rather than as a provision for bad debts. • Prior to the adoption of ASC 606, the Company’s presentation and disclosure of net revenue by payor included the portion of the revenue related to co-pays and deductibles as third party revenues. Under ASC 606, the co-pays and deductibles portions of net revenue are classified as self-pay after insurance. Revenue Recognition The Company reports revenues from patient services at its hospitals and affiliated facilities at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients, governmental programs and third-party payors such as Medicare, Medicaid, health maintenance organizations, preferred provider organizations, private insurers and others, and include variable consideration for retroactive revenue adjustments due to settlements of audits, reviews and investigations. Generally, the Company bills the patient and third-party payors several days after the services are performed or the patient is discharged. Revenue is recognized as the performance obligations are satisfied. Billings and collections are outsourced to CHS under the transition services agreements that were entered into in connection with the Spin-off. See Note 16 — Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges for services anticipated to be provided. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Company’s hospitals receiving inpatient acute care services. The Company measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Company does not believe it is required to provide additional goods or services to the patient. Because all of its performance obligations relate to contracts with a duration of less than one year, the Company has elected to apply the optional exemption provided in ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patient is discharged, which generally occurs within days or weeks following the end of the reporting period. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and patient responsibility after insurance in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients and patient responsibility after insurance. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. The Company recognizes revenues related to its QHR business when either the performance obligation has been satisfied or over time as the hospital management advisory and healthcare consulting services are provided, and reports these revenues at the amount expected to be collected from the non-affiliated hospital clients of QHR. Payor Sources The primary sources of payment for patient healthcare services are third-party payors, including federal and state agencies administering the Medicare and Medicaid programs, other governmental agencies, managed care health plans, commercial insurance companies, workers’ compensation carriers and employers. Self-pay revenues are the portion of patient service revenues derived from patients who do not have health insurance coverage and the patient responsibility portion of services that are not covered by health insurance plans. Non-patient revenues primarily include revenues from QHR’s hospital management advisory and consulting services business, rental income and hospital cafeteria sales. The following table provides a summary of net operating revenues by payor source (dollars in thousands): Three Months Ended June 30, 2018 2017 $ Amount % of Total $ Amount % of Total Medicare $ 130,106 27.5 % $ 148,987 28.1 % Medicaid 87,141 18.4 % 104,854 19.8 % Managed care and commercial plans 189,726 40.3 % 203,087 38.3 % Self-pay and self-pay after insurance 42,288 8.9 % 49,269 9.3 % Non-patient 23,371 4.9 % 23,949 4.5 % Total net operating revenues $ 472,632 100.0 % $ 530,146 100.0 % Six Months Ended June 30, 2018 2017 $ Amount % of Total $ Amount % of Total Medicare $ 274,689 28.6 % $ 312,080 29.5 % Medicaid 172,244 18.0 % 199,817 18.9 % Managed care and commercial plans 374,952 39.0 % 398,683 37.6 % Self-pay and self-pay after insurance 91,972 9.6 % 97,911 9.3 % Non-patient 45,595 4.8 % 49,295 4.7 % Total net operating revenues $ 959,452 100.0 % $ 1,057,786 100.0 % Revenues from Medicare Advantage Plans that are included in Medicare revenues in the table above were $30.0 million and $41.5 million for the three months ended June 30, 2018 and 2017, respectively, and $71.4 million and $86.4 million for the six months ended June 30, 2018 and 2017, respectively. Contractual Adjustments and Discounts Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: • Medicare: • Medicaid: • Other: Government programs, including Medicare and Medicaid programs, which represent a large portion of the Company’s operating revenues, are highly complex programs to administer and are subject to interpretation of federal and state-specific reimbursement rates, new legislation and final cost report settlements. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations. In some instances, these investigations have resulted in organizations entering into significant settlement agreements or findings of criminal and civil liability. Compliance with such laws and regulations may be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have on the Company. Contractual adjustments, or differences in standard billing rates and the payments derived from contractual terms with governmental and non-governmental third-party payors, are recorded based on management’s best estimates in the period in which services are performed and a payment methodology is established with the patient. Recorded estimates for past contractual adjustments are subject to change, in large part, due to ongoing contract negotiations and regulation changes, which are typical in the U.S. healthcare industry. Revisions to estimates are recorded as contractual adjustments in the periods in which they become known and may be subject to further revisions. In addition, the contracts the Company has with commercial payors may provide for retroactive audit and review of claims. Subsequent changes in estimates for third-party payors that are determined to be the result of an adverse change in a payor’s ability to pay are recorded as bad debt expense. Bad debt expense for the three and six months ended June 30, 2018 was not material and is included in other operating expenses in the Company’s consolidated statement of income. Billing and collections are outsourced to CHS under certain transition services agreements that were put in place by CHS in connection with the Spin-off. The Company’s contractual adjustments are impacted by the timing and ability of CHS to monitor the classification and collection of the Company’s patient accounts receivable. Self-pay and other payor discounts are incentives offered by the Company to uninsured or underinsured patients and other payors to reduce their costs of healthcare services. Third-Party Program Reimbursements Cost report settlements under reimbursement programs with Medicare, Medicaid and other managed care plans for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical experience, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as new information becomes available, or as years are settled or are no longer subject to such audits, reviews, and investigations. Previous program reimbursements and final cost report settlements are included in due from and due to third-party payors in the consolidated balance sheets. Net adjustments arising from a change in the transaction price for estimated cost report settlements favorably (unfavorably) impacted net operating revenues by $(0.4) million and $1.4 million during the three months ended June 30, 2018 and 2017, respectively and $0.1 million and less than $(0.1) million during the six months ended June 30, 2018 and 2017, respectively. Currently, several states utilize supplemental payment programs, including disproportionate share programs, for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of federal and state resources, including, in certain instances, taxes, fees or other program expenses (collectively, “provider taxes”) levied on the providers. The receivables and payables associated with these programs are included in due from and due to third-party payors in the Company’s consolidated balance sheets. The following table provides a summary of the components of amounts due from and due to third-party payors (in thousands): June 30, December 31, 2018 2017 Amounts due from third-party payors: Previous program reimbursements and final cost report settlements $ 18,958 $ 17,383 State supplemental payment programs 50,231 79,819 Total amounts due from third-party payors $ 69,189 $ 97,202 Amounts due to third-party payors: Previous program reimbursements and final cost report settlements $ 27,664 $ 33,163 State supplemental payment programs 13,006 14,542 Total amounts due to third-party payors $ 40,670 $ 47,705 After a state supplemental payment program is approved and fully authorized by the appropriate state legislative or governmental agency, the Company recognizes revenue and related expenses based on the terms of the program in the period in which amounts are estimable and revenue collection is reasonably assured. The revenues earned by the Company under these programs are included in net operating revenues and the expenses associated with these programs are included in other operating expenses in the Company’s consolidated statements of income. The following table provides a summary of the portion of Medicaid reimbursements included in the Company’s consolidated statements of income that are attributable to state supplemental payment programs (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Medicaid revenues $ 52,070 $ 46,381 $ 100,631 $ 91,678 Provider taxes and other expenses 17,051 17,230 36,195 34,123 Reimbursements attributable to state supplemental payment programs, net of expenses $ 35,019 $ 29,151 $ 64,436 $ 57,555 The California Department of Health Care Services administers the Hospital Quality Assurance Fee (“HQAF”) program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California’s Medi-Cal and uninsured patients. Under Phase V of the program, covering the period from January 2017 through June 2019, the Company recognized $7.9 million of Medicaid revenues and $2.1 million of provider taxes for the three months ended June 30, 2018 and $15.8 million of Medicaid revenues and $4.2 million of provider taxes for the six months ended June 30, 2018. There were no corresponding amounts recognized in the three months and six months ended June 30, 2017. The revenues and fees for the full year 2017 were recognized in the fourth quarter of 2017 when CMS approved the program. Self-Pay and Self-Pay After Insurance Generally patients who are covered by third-party payors are responsible for related co-pays and deductibles, which vary in amount. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from the Company’s standard charges. The Company estimates the transaction price for patients with co-pays and deductibles, and for uninsured patients based on historical collection experience and current market conditions. The initial estimate of the transaction price is determined by reducing the Company’s standard charges by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price, if any, are generally recorded as an adjustment to patient service revenue in the period of the change. Charity Care In the ordinary course of business, the Company provides services to patients who are financially unable to pay for hospital care. The related charges for those patients who are financially unable to pay that otherwise do not qualify for reimbursement from a governmental program are classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the poverty level guidelines established by the federal government. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges are recorded in operating revenues at the standard billing rates and fully offset in contractual adjustments. The Company’s gross amounts of charity care revenues were $6.0 million and $7.5 million for the three months ended June 30, 2018 and 2017, respectively, and $19.3 million and $20.0 million for the six months ended June 30, 2018 and 2017, respectively. Accounts Receivable Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated outpatient facilities. For self-pay and self-pay after insurance receivables, the Company estimates the implicit price concession by reserving a percentage of all self-pay and self-pay after insurance accounts receivable without regard to aging category. The estimate of the implicit price concession is based on a model that considers historical cash collections, expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the implicit price concessions is not significantly impacted by the aging of accounts receivable, as management believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. Significant changes in payor mix, CHS’s business office operations, including the CHS shared services centers’ efforts in collecting the Company’s accounts receivables, economic conditions, or trends in federal and state governmental healthcare coverage, among others, could affect the Company’s estimates of implicit price concessions. The Company also continually reviews its overall estimate of implicit price concessions by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net operating revenues and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, and the impact of recent divestitures. Collections are impacted by the economic ability of patients to pay, the effectiveness of CHS’ billing and collection efforts, including their current policies on collections, and the ability of the Company to further attempt collection efforts. Billings and collections are outsourced to CHS under the transition services agreements that were established with the Spin-off. See Note 16 — Related Party Transactions for additional information on these agreements. The following table provides a summary of the changes in the allowance for doubtful accounts (in thousands): Six Months Ended June 30, 2018 Balance at beginning of period $ 352,509 Provision for bad debts — Impact of adoption of ASC 606 (352,509 ) Balance at end of period $ — The Company has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Company’s expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Company does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract. The Company has applied the practical expedient provided by FASB ASC 340-40-25-4 and all incremental customer contract acquisition costs are expensed as incurred, as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration. Concentration of Credit Risk The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s hospitals and affiliated outpatient facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s markets and non-governmental third-party payors, Medicare represents a significant concentration of credit risk from payors. Accounts receivable, net of contractual adjustments, from Medicare were $60.9 million and $66.6 million, or 18.6% and 18.2% of total patient accounts receivable, net as of June 30, 2018 and December 31, 2017, respectively. Additionally, the Company believes Illinois Medicaid represents a concentration of credit risk to the Company due to the fiscal problems in the state of Illinois that affect the timing and extent of payments due to providers, which are administered by the state of Illinois under the Medicaid program. The Company’s accounts receivable, net of contractual adjustments, from Illinois Medicaid were $21.7 million and $28.8 million, or 6.6% and 7.9% of total patient accounts receivable, net as of June 30, 2018 and December 31, 2017, respectively. The Company’s state supplemental program receivables from Illinois Medicaid were $7.5 million and $22.9 million, or 10.9% and 23.5% of total due from third-party payors, as of June 30, 2018 and December 31, 2017, respectively. The Company’s state supplemental program receivables from California Medicaid were $30.8 million and $48.4 million, or 44.5% and 49.8% of total due from third-party payors, as of June 30, 2018 and December 31, 2017, respectively. The Company’s revenues are particularly sensitive to regulatory and economic changes in certain states where the Company generates significant revenues. Accordingly, any changes in the current demographic, economic, competitive or regulatory conditions in certain states in which revenues are significant could have an adverse effect on the Company’s results of operations, financial condition or cash flows. Changes to Medicaid and other government-managed payor programs in these states, including reductions in reimbursement rates or delays in reimbursement payments under state supplemental payment or other programs, could also have a similar adverse effect. The following table provides a summary of the states in which the Company generates more than 5% of its total net patient revenues as determined in each period (dollars in thousands): Number of Six Months Ended June 30, Hospitals at 2018 2017 June 30, 2018 $ Amount % of Total $ Amount % of Total Illinois 8 $ 373,372 40.9 % $ 379,420 37.6 % Oregon 1 116,013 12.7 % 103,175 10.2 % California 2 89,972 9.8 % 74,675 7.4 % Kentucky 3 58,115 6.4 % 56,833 5.6 % Other Operating Expenses The following table provides a summary of the major components of other operating expenses (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Purchased services $ 37,502 $ 43,843 $ 78,582 $ 89,439 Taxes and insurance 33,627 33,610 66,682 67,853 Medical specialist fees 26,433 28,888 53,381 57,351 Transition services agreements 14,066 15,986 29,183 32,268 Repairs and maintenance 9,060 9,759 18,697 21,202 Utilities 5,592 6,727 11,715 13,392 Other miscellaneous operating expenses 18,176 18,800 38,954 39,532 Total other operating expenses $ 144,456 $ 157,613 $ 297,194 $ 321,037 The Company records costs associated with the transition services agreements and other ancillary agreements with CHS in accordance with the terms of these agreements. These costs, which primarily include the costs of providing information technology, patient billing and collections and payroll services, are included in “Transition services agreements” in the table above. See Note 16 — Related Party Transactions and Note 17 — Commitments and Contingencies for additional information on the transition services agreements with CHS. General and Administrative Costs Substantially all of the Company’s operating costs and expenses are “cost of revenues” items. Operating expenses that could be classified as general and administrative by the Company are costs related to corporate office functions, including, but not limited to tax, treasury, audit, risk management, legal, investor relations and human resources. These costs primarily consist of salaries and benefits expenses associated with these corporate office functions. General and administrative costs of the Company were $20.0 million and $14.5 million during the three months ended June 30, 2018 and 2017, respectively, and $34.9 million and $30.1 million during the six months ended June 30, 2018 and 2017, respectively. General and administrative costs of the Company include severance costs related to headcount reductions at the corporate office of $2.7 million and $0.6 million during the three months ended June 30, 2018 and 2017, respectively, and $4.6 million and $0.6 million during the six months ended June 30, 2018 and 2017, respectively. Electronic Health Records Incentives Earned Pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), the Company receives incentive payments under the Medicare and Medicaid programs for its eligible hospitals and physician clinics that demonstrate meaningful use of certified Electronic Health Records (“EHR”) technology. EHR incentive payments are subject to audit and potential recoupment if it is determined that the applicable meaningful use standards were not met. EHR incentive payments are also subject to retrospective adjustment because the cost report data upon which the incentive payments are based are further subject to audit. The Company incurs both capital expenditures and operating expenses in connection with the implementation of EHR technology initiatives. The amounts and timing of these expenditures does not directly correlate with the timing of the Company’s receipt or recognition of EHR incentive payments as earned. The Company is nearing completion of its full implementation of certified EHR, and therefore, its EHR incentive payments are declining and will ultimately end. The Company recognized EHR incentives earned of $0.4 million and $1.8 million for the three months ended June 30, 2018 and 2017, respectively, and $0.6 million and $4.2 million for the six months ended June 30, 2018 and 2017, respectively, which are recorded as a reduction to operating expenses in the Company’s consolidated statements of income. Legal, Professional and Settlement Costs Legal, professional and settlement costs in the Company’s consolidated statements of income primarily include legal costs and related settlements, if any, associated with arbitration costs, regulatory claims, government investigations into reimbursement payments and other litigation matters. Loss (Gain) on Sale of Hospitals, Net Loss (gain) on sale of hospitals, net relates to the Company’s divestiture of hospitals and outpatient facilities. It is calculated as the difference between the cash proceeds from the sale and the carrying values of the associated net assets sold at the date of sale, less certain incremental direct selling costs. Loss on Closure of Hospitals, Net Loss on closure of hospitals, net relates to costs incurred by the Company for closure of hospitals and outpatient facilities, and includes severance, loss on disposal of property and equipment, write-down of assets, legal costs and other costs incurred by the Company during the closure. Transaction Costs Related to the Spin-off Transaction costs related to the Spin-off consists of QHC’s portion of the costs to effect the Spin-off and the costs associated with forming a new company. These costs include audit, management advisory and consulting costs, investment advisory costs, legal expenses and other miscellaneous costs. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the provision for (benefit from) income taxes in the consolidated statements of income in the period that includes the enactment date. The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income. To the extent the Company believes that recovery is not likely, a valuation allowance is established. To the extent the Company establishes a valuation allowance or increases this allowance, the related expense is included in the provision for (benefit from) income taxes in the consolidated statements of income. The Company classifies interest and penalties, if any, related to its tax positions as a component of provision for (benefit from) income taxes. Cash

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets and Goodwill	6 Months Ended
	Jun. 30, 2018
Disclosure Text Block Supplement [Abstract]
Impairment of Long-Lived Assets and Goodwill	NOTE 3 – IMPAIRMENT OF LONG-LIVED ASSETS AND GOODWILL During the three months ended June 30, 2018, the Company evaluated the fair value of hospitals intended for divestiture. In connection with this evaluation, the Company determined there were no indicators of impairment as of June 30, 2018. During the three months ended March 31, 2018, the Company evaluated the fair value of hospitals intended for divestiture. In connection with this evaluation, the Company recognized long-lived asset impairment of $39.8 million during the three months ended March 31, 2018, which consisted of $34.7 million of property and equipment and $5.1 million of capitalized software costs. During the three months ended June 30, 2017, the Company evaluated the fair value of hospitals classified as held for sale and other hospitals intended for potential divestiture. In connection with this evaluation, the Company recognized $12.9 million of impairment to property and equipment during the three months ended June 30, 2017. During the three months ended March 31, 2017, management made a decision to classify certain hospitals as held for sale. In connection with this decision, the Company evaluated the estimated relative fair value of the hospitals classified as held for sale in relation to the overall fair value of the hospital operations reporting unit utilizing a September 30, 2016 measurement date, which was the measurement date of the Company’s most recent annual goodwill impairment analysis, and recognized long-lived asset and goodwill impairment of $3.3 million during the three months ended March 31, 2017, which consisted of $1.1 million of property and equipment, $0.8 million of capitalized software costs and $1.4 million of goodwill.

Divestitures

Divestitures	6 Months Ended
	Jun. 30, 2018
Business Combinations [Abstract]
Divestitures	NOTE 4 –DIVESTITURES Clearview Regional Medical Center On March 31, 2018, the Company sold 77-bed Clearview Regional Medical Center and its affiliated facilities (“Clearview”), located in Monroe, Georgia, for proceeds of $37.4 million, of which $8.0 million was placed in an escrow account subject to resolution of certain outstanding litigation initiated before the Spin-off and for which CHS agreed to indemnify the Company for the resulting liability. For the three months ended June 30, 2018 and 2017, the Company’s operating results included pre-tax losses of $0.4 million and $1.4 million, respectively, related to Clearview, and pre-tax losses of $3.6 million and $1.6 million for the six months ended June 30, 2018 and 2017, respectively. In addition to the above, the Company recorded a $7.9 million loss on the sale of Clearview in the six months ended June 30, 2018 which includes a write-off of allocated goodwill of $9.4 million. Vista Medical Center West On March 1, 2018, the Company sold 70-bed Vista Medical Center West and its affiliated facilities (“Vista West”), located in Waukegan, Illinois, for proceeds of $1.2 million. For the three months ended June 30, 2018 and 2017, the Company’s operating results included pre-tax losses of $0.9 million and $1.3 million, respectively, related to Vista West, and pre-tax losses of $0.8 million and $1.3 million for the six months ended June 30, 2018 and 2017, respectively. In addition to the above, the Company recorded a $0.2 million loss on the sale of Vista West in the six months ended June 30, 2018. Affinity Medical Center On January 5, 2018, the Company announced plans to close Affinity Medical Center (“Affinity”) located in Massillon, Ohio. Subsequent to January 5, 2018, the Company’s affiliates entered into an agreement with the City of Massillon related to the closure whereby all of the owned real property and a portion of the related tangible assets located at the hospital would be transferred to the City of Massillon in exchange for nominal consideration and the City of Massillon’s assumption of certain ongoing real property lease obligations and equipment lease obligations. Operations ceased on February 11, 2018 and the Company transferred the agreed-upon assets to the City of Massillon on May 16, 2018. For the three months ended June 30, 2018 and 2017, the Company’s operating results included pre-tax losses of $4.7 million and $1.9 million respectively, related to Affinity, and pre-tax losses of $24.4 million and $6.1 million for the six months ended June 30, 2018 and 2017, respectively. Included in the pre-tax loss for the six months ended June 30, 2018 are $17.1 million of closure costs related to the closure of Affinity which include $8.0 million of severance and salary continuation costs, $5.0 million in losses associated with the disposal of assets that have no future value to the Company and $4.1 million of other costs and fees related to termination of contracts and other miscellaneous items. The Company anticipates that in 2018 it will incur costs, beyond those already incurred, of approximately $0.5 million to $1.0 million related to the wind down and transfer of assets. In addition, beyond 2018, the Company is obligated to maintain health records for approximately 19 years with an estimated annual cost of $0.3 million.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Property and Equipment	NOTE 5 – PROPERTY AND EQUIPMENT The following table provides a summary of the components of property and equipment (in thousands): June 30, December 31, 2018 2017 Property and equipment, at cost: Land and improvements $ 62,658 $ 70,731 Building and improvements 736,887 790,619 Equipment and fixtures 515,485 529,150 Construction in progress 20,374 14,684 Total property and equipment, at cost 1,335,404 1,405,184 Less: Accumulated depreciation and amortization (730,623 ) (729,905 ) Total property and equipment, net $ 604,781 $ 675,279 Depreciation expense was $12.2 million and $14.8 million for the three months ended June 30, 2018 and 2017, respectively, and $25.2 million and $30.5 million for the six months ended June 30, 2018 and 2017, respectively. See Note 6 Purchases of property and equipment accrued in accounts payable were $4.7 million and $6.8 million as of June 30, 2018 and December 31, 2017, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 6 – GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a summary of changes in goodwill (in thousands): Six Months Ended June 30, 2018 Balance at beginning of period $ 409,229 Acquisitions 30 Divestitures (9,396 ) Reclasses from held for sale 1,593 Balance at end of period $ 401,456 Goodwill related to the Company’s hospital operations reporting unit was $368.1 million and $375.9 million as of June 30, 2018 and December 31, 2017, respectively. Goodwill related to the Company’s hospital management advisory and consulting services reporting unit was $33.3 million at both June 30, 2018 and December 31, 2017. Intangible Assets The following table provides a summary of the components of intangible assets (in thousands): June 30, December 31, 2018 2017 Finite-lived intangible assets: Capitalized software costs: Cost $ 150,225 $ 159,449 Accumulated amortization (112,296 ) (111,661 ) Capitalized software costs, net 37,929 47,788 Physician guarantee contracts: Cost 6,536 7,489 Accumulated amortization (3,860 ) (4,290 ) Physician guarantee contracts, net 2,676 3,199 Other finite-lived intangible assets: Cost 43,262 43,376 Accumulated amortization (35,554 ) (34,668 ) Other finite-lived intangible assets, net 7,708 8,708 Total finite-lived intangible assets Cost 200,023 210,314 Accumulated amortization (151,710 ) (150,618 ) Total finite-lived intangible assets, net $ 48,313 $ 59,696 Indefinite-lived intangible assets: Tradenames $ 4,000 $ 4,000 Licenses and other indefinite-lived intangible assets 1,132 1,154 Total indefinite-lived intangible assets $ 5,132 $ 5,154 Total intangible assets: Cost $ 205,155 $ 215,468 Accumulated amortization (151,710 ) (150,618 ) Total intangible assets, net $ 53,445 $ 64,850 As of June 30, 2018, the Company had $0.9 million of capitalized software costs that are currently in the development stage. Amortization of these costs will begin once the software projects are complete and ready for their intended use. Amortization Expense The following table provides a summary of the components of amortization expense (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Amortization of finite-lived intangible assets: Capitalized software costs $ 2,775 $ 3,796 $ 6,098 $ 8,539 Physician guarantee contracts 916 599 1,446 1,156 Other finite-lived intangible assets 507 556 1,014 1,126 Total amortization expense related to finite-lived intangible assets 4,198 4,951 8,558 10,821 Amortization of leasehold improvements and property and equipment assets held under capital lease obligations 783 882 1,676 1,338 Total amortization expense $ 4,981 $ 5,833 $ 10,234 $ 12,159 As of June 30, 2018, the weighted-average remaining amortization period of the Company’s intangible assets subject to amortization, except for capitalized software costs and physician guarantee contracts, was approximately 4.3 years.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Long-Term Debt	NOTE 7 – LONG-TERM DEBT The following table provides a summary of the components of long-term debt (in thousands): June 30, December 31, 2018 2017 Senior Credit Facility: Revolving Credit Facility, maturing 2021 $ — $ — Term Loan Facility, maturing 2022 800,696 831,158 ABL Credit Facility, maturing 2021 14,000 — Senior Notes, maturing 2023 400,000 400,000 Unamortized debt issuance costs and discounts (40,032 ) (42,934 ) Capital lease obligations 23,848 24,411 Other debt 900 1,255 Total debt 1,199,412 1,213,890 Less: Current maturities of long-term debt (1,733 ) (1,855 ) Total long-term debt $ 1,197,679 $ 1,212,035 Senior Credit Facility In connection with the Spin-off, on April 29, 2016, the Company entered into a credit agreement (the “CS Agreement”), among the Company, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch (“Credit Suisse”), as administrative agent and collateral agent. On April 11, 2017, the Company executed an agreement with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility (the “CS Amendment”), as described below. On March 14, 2018, the Company executed a second agreement with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility (the “CS Second Amendment”), as described below. The CS Agreement provides for an $880 million senior secured term loan facility (the “Term Loan Facility”) and a $100 million senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Senior Credit Facility”). The Term Loan Facility was issued at a discount of $17.6 million, or 98% of par value, and has a maturity date of April 29, 2022, subject to customary acceleration events and repayment, extension or refinancing. The Revolving Credit Facility has a maturity date of April 29, 2021, subject to certain customary acceleration events and repayment, extension or refinancing. The CS Amendment reduced the Revolving Credit Facility’s capacity from $100 million to $87.5 million until December 31, 2017, at which time the capacity decreased to $75.0 million through maturity. The CS Second Amendment further reduced the Revolving Credit Facility’s capacity to $62.5 million through maturity, effective with the amendment executed on March 14, 2018. The CS Agreement contains customary covenants, including a maximum permitted Secured Net Leverage Ratio, as determined based on 12 month trailing Consolidated EBITDA, as defined in the CS Agreement. On April 11, 2017, the Company executed the CS Amendment with its Senior Credit Facility lenders to amend the calculation of the Secured Net Leverage Ratio beginning July 1, 2017 through maturity, among other provisions. In addition, the CS Amendment raised the minimum Secured Net Leverage Ratio required for the Company to remain in compliance for certain periods, and also changed the calculation of compliance for specified periods. The CS Second Amendment amended the Secured Net Leverage Ratio for the period July 1, 2017 through maturity. As of June 30, 2018, the Company had a Secured Net Leverage Ratio of 4.17 to 1.00 implying additional borrowing capacity of $116.9 million as of June 30, 2018. After giving effect to the CS Amendment and the CS Second Amendment, the maximum Secured Net Leverage Ratio permitted under the CS Agreement, as determined based on 12 month trailing Consolidated EBITDA and as defined in the CS Agreement follows: Maximum Secured Net Period Leverage Ratio Period from January 1, 2017 to June 30, 2017 4.50 to 1.00 Period from July 1, 2017 to June 30, 2018 4.75 to 1.00 Period from July 1, 2018 to December 31, 2019 5.00 to 1.00 Period from January 1, 2020 and thereafter 4.50 to 1.00 In addition to amending the calculation of the Secured Net Leverage Ratio and the Maximum Secured Net Leverage Ratio, the CS Amendment and the CS Second Amendment also affected other terms of the CS Agreement as follows: • Through April 29, 2022, the Company is required to use asset sales proceeds to make mandatory redemptions under the Term Loan Facility. • Through December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments, as defined in the CS Agreement, only if the Secured Net Leverage Ratio, adjusted for the requested Incremental Term Loan borrowing, is below 3.35 to 1.00. After December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments for the greater of $100 million or an amount which would produce a Secured Net Leverage Ratio of 3.35 to 1.00. • Through December 31, 2018, the Company is allowed to incur Permitted Additional Debt, as defined in the CS Agreement, only if the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 4.50 to 1.00. After December 31, 2018, the Company may incur Permitted Additional Debt so long as the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 5.50 to 1.00. Prior to the CS Amendment, interest under the Term Loan Facility accrued, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 5.75%, or the alternate base rate plus 4.75%. Following the CS Amendment, interest under the Term Loan Facility accrues, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 6.75%, or the alternate base rate plus 5.75%. The effective interest rate on the Term Loan Facility was 9.18% as of June 30, 2018. Interest under the Revolving Credit Facility accrues, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 0% plus 2.75%, or the alternate base rate plus 1.75%, and remains unchanged under the CS Amendment and the CS Second Amendment. Borrowings from the Revolving Credit Facility are used for working capital and general corporate purposes. As of June 30, 2018, the Company had no borrowings outstanding under the Revolving Credit Facility and had $13.1 million of letters of credit outstanding that were primarily related to the self-insured retention levels of professional and general liability and workers’ compensation liability insurance as security for the payment of claims. As of June 30, 2018, the Company had borrowing capacity under its Revolving Credit Facility of $49.4 million. ABL Credit Facility In connection with the Spin-off, on April 29, 2016, the Company entered into an ABL Credit Agreement (the “UBS Agreement,” and together with the CS Agreement, collectively, the “Credit Agreements”), among the Company, the lenders party thereto and UBS AG, Stamford Branch (“UBS”), as administrative agent and collateral agent. The UBS Agreement provides for a $125 million senior secured asset-based revolving credit facility (the “ABL Credit Facility”). The available borrowings from the ABL Credit Facility, which are based on eligible patient accounts receivable, are used for working capital and general corporate purposes. As of June 30, 2018, the Company had $14.0 million outstanding on the ABL Credit Facility and borrowing capacity of $111.0 million. The ABL Credit Facility has a maturity date of April 29, 2021, subject to customary acceleration events and repayment, extension or refinancing. Interest under the ABL Credit Facility accrues, at the option of the Company, at a base rate or LIBOR, subject to statutory reserves The ABL Credit Facility has a “Covenant Trigger Event” definition that requires the Company to maintain excess availability under the ABL Credit Facility equal to or greater than the greater of (i) $12.5 million and (ii) 10% of the aggregate commitments under the ABL Credit Facility. If a Covenant Trigger Event occurs, then the Company is required to maintain a minimum Consolidated Fixed Charge Ratio of 1.10 to 1.00 until such time that a Covenant Trigger Event is no longer continuing. In addition, if excess availability under the ABL Credit Facility were to fall below the greater of (i) 12.5% of the aggregate commitments under the ABL Credit Facility and (ii) $15.0 million, then a “Cash Dominion Event” would be triggered upon which the lenders could assume control of the Company’s cash. Credit Agreement Covenants In addition to the specific covenants described above, the Credit Agreements contain customary negative covenants which limit the Company’s ability to, among other things, incur additional indebtedness, create liens, make investments, transfer assets, merge or acquire assets, and make restricted payments, including dividends, distributions and specified payments on other indebtedness. They include customary events of default, including payment defaults, material breaches of representations and warranties, covenant defaults, default on other material indebtedness, customary Employee Retirement Income Security Act (“ERISA”) Senior Notes On April 22, 2016, the Company issued $400 million aggregate principal amount of 11.625% Senior Notes due 2023, pursuant to the Indenture. The Senior Notes were issued at a discount of $6.9 million, or 1.734%, in a private placement and are senior unsecured obligations of the Company guaranteed on a senior basis by certain of the Company’s subsidiaries (the “Guarantors”). The Senior Notes mature on April 15, 2023 and bear interest at a rate of 11.625% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2016. Interest on the Senior Notes accrues from the date of original issuance and is calculated on the basis of a 360-day year comprised of twelve 30-day months. The effective interest rate on the Senior Notes was 12.49% as of June 30, 2018. The Indenture contains covenants that, among other things, limit the ability of the Company and certain of its subsidiaries to incur or guarantee additional indebtedness, pay dividends or make other restricted payments, make certain investments, create or incur certain liens, sell assets and subsidiary stock, transfer all or substantially all of its assets or enter into merger or consolidation transactions. On May 17, 2017, the Company exchanged the 11.625% Senior Notes due 2023 (the “Initial Notes”) in the aggregate principal amount of $400 million, which were not registered under the Securities Act of 1933, as amended (the “Securities Act”), for a like principal amount of 11.625% Senior Notes due 2023 (the “Exchange Notes”), which have been registered under the Securities Act. The Initial Notes were substantially identical to the Exchange Notes, except that the Exchange Notes are registered under the Securities Act and are not subject to the transfer restrictions and certain registration rights agreement provisions applicable to the Initial Notes. On and after April 15, 2019, the Company is entitled, at its option, to redeem all or a portion of the Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices, plus accrued and unpaid interest, if any, to the redemption date. The redemption prices are expressed as a percentage of the principal amount on the redemption date. Holders of record on the relevant record date have the right to receive interest due on the relevant interest payment date. In addition, prior to April 15, 2019, the Company may redeem some or all of the Senior Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, plus a “make whole” premium, as set forth in the Indenture. The Company is entitled to redeem up to 35% of the aggregate principal amount of the Senior Notes until April 15, 2019 with the net proceeds from certain equity offerings at the redemption price set forth in the Indenture. The following table provides a summary of the redemption dates and prices related to the Senior Notes: Redemption Period Prices Period from April 15, 2019 to April 14, 2020 108.719 % Period from April 15, 2020 to April 14, 2021 105.813 % Period from April 15, 2021 to April 14, 2022 102.906 % Period from April 15, 2022 to April 14, 2023 100.000 % Debt Issuance Costs and Discounts The following table provides a summary of unamortized debt issuance costs and discounts (in thousands): June 30, December 31, 2018 2017 Debt issuance costs $ 34,533 $ 32,265 Debt discounts 24,536 24,536 Total debt issuance costs and discounts at origination 59,069 56,801 Less: Amortization of debt issuance costs and discounts (19,037 ) (13,867 ) Total unamortized debt issuance costs and discounts $ 40,032 $ 42,934 Capital Lease Obligations and Other Debt The Company’s debt arising from capital lease obligations primarily relates to its corporate office in Brentwood, Tennessee. As of June 30, 2018 and December 31, 2017, this capital lease obligation was $17.6 million and $17.9 million, respectively. The remainder of the Company’s capital lease obligations relate to property and equipment at its hospitals and QHR. Other debt consists of physician loans and miscellaneous notes payable to banks. Debt Maturities The following table provides a summary of debt maturities for the next five years and thereafter (in thousands): June 30, 2018 Remainder of 2018 $ 1,038 2019 1,430 2020 1,488 2021 1,556 2022 802,092 Thereafter 431,840 Total debt, excluding unamortized debt issuance costs and discounts $ 1,239,444 Interest Expense, Net The following table provides a summary of the components of interest expense, net (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Senior Credit Facility: Revolving Credit Facility $ 64 $ 192 $ 142 $ 331 Term Loan Facility 17,653 16,642 35,053 31,283 ABL Credit Facility 511 613 839 869 Senior Notes 11,626 11,629 23,239 23,255 Amortization of debt issuance costs and discounts 3,064 2,224 5,170 4,204 All other interest expense (income), net (992 ) (842 ) (1,586 ) (1,954 ) Total interest expense, net from long-term debt $ 31,926 $ 30,458 $ 62,857 $ 57,988

Other Long-Term Assets and Othe

Other Long-Term Assets and Other Long-Term Liabilities	6 Months Ended
	Jun. 30, 2018
Other Noncurrent Assets And Other Noncurrent Liabilities Disclosure [Abstract]
Other Long-Term Assets and Other Long-Term Liabilities	NOTE 8 – OTHER LONG-TERM ASSETS AND OTHER LONG-TERM LIABILITIES The following table provides a summary of the components of other long-term assets (in thousands): June 30, December 31, 2018 2017 Receivable for professional and general liability insurance reserves indemnified by CHS $ 35,128 $ 44,377 Receivable for workers' compensation liability insurance reserves indemnified by CHS 13,218 14,545 Assets of Nonqualified Deferred Compensation Plan 18,911 23,052 Restricted cash 8,000 — Other miscellaneous long-term assets 12,567 13,633 Total other long-term assets $ 87,824 $ 95,607 The following table provides a summary of the components of other long-term liabilities (in thousands): June 30, December 31, 2018 2017 Professional and general liability insurance reserves $ 77,735 $ 76,993 Workers' compensation liability insurance reserves 18,504 18,558 Benefit plan liabilities 28,878 36,103 Deferred rent 3,142 4,268 Other miscellaneous long-term liabilities 1,904 2,032 Total other long-term liabilities $ 130,163 $ 137,954 See Note 17 — Commitments and Contingencies for additional information about the Company’s insurance reserves.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 9 – FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying amounts of the Company’s cash and cash equivalents, patient accounts receivable, amounts due from and due to third-party payors, restricted cash and accounts payable approximate their fair values due to the short-term maturity of these financial instruments. The following table provides a summary of the carrying amounts and estimated fair values of the Company’s long-term debt (in thousands): June 30, 2018 December 31, 2017 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Revolving Credit Facility $ — $ — $ — $ — Term Loan Facility 800,696 815,213 831,158 838,954 ABL Credit Facility 14,000 14,000 — — Senior Notes 400,000 400,672 400,000 393,396 Other debt 24,748 24,748 25,666 25,666 Total debt, excluding unamortized debt issuance costs and discounts $ 1,239,444 $ 1,254,633 $ 1,256,824 $ 1,258,016 The Company considers its long-term debt instruments to be measured based on Level 2 inputs. Information about the valuation methodologies used in the determination of the fair values for the Company’s long-term debt instruments follows: • Term Loan Facility . • Senior Notes . • All other debt .

Equity

Equity	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Equity	NOTE 10 – EQUITY Preferred Stock In connection with the Spin-off, the Company authorized 100,000,000 shares of preferred stock, par value of $0.0001 per share. No shares have been issued as of June 30, 2018. The Board has the discretion, subject to limitations prescribed by Delaware law and by its amended and restated certificate of incorporation, to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock, when and if issued. Common Stock In connection with the Spin-off, the Company authorized 300,000,000 shares of common stock, par value of $0.0001 per share, and issued 28,412,054 shares of common stock on April 29, 2016 to CHS stockholders of record on the Record Date, or April 22, 2016. The common stock began trading on the NYSE on May 2, 2016 under the ticker symbol “QHC.” As of June 30, 2018 and December 31, 2017, the Company had 30,898,710 shares and 30,294,895 shares, respectively, of common stock issued and outstanding. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters for which stockholders may vote. Holders of the Company’s common stock will not have cumulative voting rights in the election of directors. There are no preemptive rights, conversion, redemption or sinking fund provisions applicable to the common stock. In the event of liquidation, dissolution or winding up, holders of common stock are entitled to share ratably in the assets available for distribution. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Company’s Credit Agreements impose restrictions on its ability to pay dividends. Additional Paid-in Capital In connection with the Spin-off, the Company issued common stock, as described above, to CHS stockholders. In addition, pursuant to the Separation and Distribution Agreement, CHS contributed capital in excess of par value of common stock of $530.6 million, in lieu of a cash settlement payment, related to the remaining intercompany indebtedness with CHS and the Parent’s equity attributable to CHS. See Note 1 — Description of the Business and Spin-off for a summary of the major transactions to effect the Spin-off. Accumulated Deficit Accumulated deficit of the Company represents the Company’s cumulative net losses since the Spin-off date.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 – INCOME TAXES The Company and its subsidiaries are subject to U.S. federal income tax and income tax of multiple state and local jurisdictions. The Company provides for income taxes based on the enacted tax laws and rates in jurisdictions in which it conducts its operations. On December 22, 2017, the Tax Act was enacted, significantly decreasing the U.S. federal income tax rate from 35% to 21% for corporations effective January 1, 2018. As a result, The Company remeasured its deferred tax assets, liabilities and related valuation allowances as of the date of enactment. This remeasurement yielded a one-time benefit of approximately $24.0 million due to the lower income tax rate in the fourth quarter of 2017. Given the substantial changes associated with the Tax Act, the estimated financial impacts for 2017 are provisional and subject to further interpretation and clarification of the Tax Act during 2018. The Tax Act also provides for acceleration of depreciation for certain assets placed into service after September 27, 2017, as well as an increased limitation on the deductibility of executive compensation, a limitation on the deductibility of interest expense and new rules surrounding meals and entertainment expense and fines and penalties. The Company will continue to analyze additional information and guidance related to the Tax Act as supplemental legislation, regulatory federal or state guidance, or evolving technical interpretations become available. The Company will continue to refine the provisional amounts within the measurement period provided by Staff Accounting Bulletin No. 118. The Company expects to complete its analysis by the end of 2018. The Company’s effective tax rates were 1.7% and 0.8% for the three months ended June 30, 2018 and 2017, respectively, and 0.1% and (0.8)% for the six months ended June 30, 2018 and 2017, respectively. The increase in the Company’s effective tax rate for the three and six months ended June 30, 2018, when compared to the three and six months ended June 30, 2017, was primarily due to the disposal of certain indefinite lived assets and the change in expected realization of deferred tax assets under the new law established by the Tax Act. The Company’s deferred income tax liabilities, net were $7.8 million as of both June 30, 2018 and December 31, 2017. The change in deferred taxes was flat during the six months ended June 30, 2018 when compared to December 31, 2017. The change was a result of an increase in deferred tax liabilities during the period due to tax deductible amortization on indefinite lived intangibles including goodwill and the reclassification of refundable AMT credit, which was offset by a decrease in deferred tax liabilities due to the impairment and disposal of certain indefinite-lived intangible assets during the period. In the ordinary course of business, there is inherent uncertainty in quantifying the Company’s income tax positions. The Company assesses its income tax positions and records income tax benefits for all tax years subject to examination based on management’s evaluation of the facts, circumstances, and information available at the reporting date. The Company is not aware of any unrecognized tax benefits; therefore, it has not recorded any such amounts for the three and six months ended June 30, 2018 and 2017.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 12 – EARNINGS PER SHARE The following table provides a summary of the computation of basic and diluted earnings (loss) per share (in thousands, except earnings per share and shares): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator: Net income (loss) $ (25,941 ) $ (30,575 ) $ (124,428 ) $ (57,780 ) Less: Net income (loss) attributable to noncontrolling interests 665 55 1,146 411 Net income (loss) attributable to Quorum Health Corporation $ (26,606 ) $ (30,630 ) $ (125,574 ) $ (58,191 ) Denominator: Weighted-average shares outstanding - basic and diluted 28,995,564 28,145,215 28,726,445 27,977,738 Earnings (loss) per share attributable to Quorum Health Corporation stockholders - basic and diluted $ (0.92 ) $ (1.09 ) $ (4.37 ) $ (2.08 ) Due to the net loss attributable to Quorum Health Corporation in the three and six months ended June 30, 2018 and 2017, no incremental shares are included in diluted earnings (loss) per share for these periods because the effect of the incremental shares would be anti-dilutive.

Segments

Segments	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Segments	NOTE 13 – SEGMENTS The Company operates two distinct operating segments, its hospital operations business and its hospital management advisory and healthcare consulting services business. The hospital operations segment includes the operations of the Company’s owned and leased hospitals and their affiliated outpatient facilities. The hospital management advisory and healthcare consulting services segment includes the operations of QHR. Both segments meet the criteria as separate reportable segments. The financial information for the Company’s corporate functions has been reported in the table below as part of the all other reportable segment. The following tables provide a summary of financial information related to the Company’s reportable segments (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Net operating revenues: Hospital operations $ 453,660 $ 509,118 $ 920,826 $ 1,015,536 QHR operations 18,620 20,315 38,208 40,891 All other 352 713 418 1,359 Total net operating revenues $ 472,632 $ 530,146 $ 959,452 $ 1,057,786 Adjusted EBITDA: Hospital operations $ 44,035 $ 41,536 $ 70,318 $ 79,002 QHR operations 4,451 6,316 8,803 10,457 All other (12,163 ) (13,422 ) (24,378 ) (28,887 ) Total Adjusted EBITDA $ 36,323 $ 34,430 $ 54,743 $ 60,572 June 30, December 31, 2018 2017 Assets: Hospital operations $ 1,527,514 $ 1,687,576 QHR operations 59,192 61,752 All other 77,877 79,513 Total assets $ 1,664,583 $ 1,828,841 The following table provides a reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable U.S. GAAP financial measure (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Adjusted EBITDA $ 36,323 $ 34,430 $ 54,743 $ 60,572 Interest expense, net (31,926 ) (30,458 ) (62,857 ) (57,988 ) (Provision for) benefit from income taxes 454 245 88 (456 ) Depreciation and amortization (17,142 ) (20,586 ) (35,403 ) (42,706 ) Legal, professional and settlement costs (5,417 ) (3,934 ) (8,830 ) (4,469 ) Impairment of long-lived assets and goodwill — (12,900 ) (39,760 ) (16,200 ) Loss (gain) on sale of hospitals, net (307 ) 4,321 (8,122 ) 5,191 Loss on closure of hospitals, net (3,338 ) — (17,084 ) — Transition of transition services agreements (520 ) — (1,237 ) — Transaction costs related to the Spin-off — — — (31 ) Post-spin headcount reductions and executive severance (4,068 ) (1,693 ) (5,966 ) (1,693 ) Net income (loss) $ (25,941 ) $ (30,575 ) $ (124,428 ) $ (57,780 )

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	NOTE 14 – STOCK-BASED COMPENSATION On April 1, 2016, the Company adopted the Quorum Health Corporation 2016 Stock Award Plan (“2016 Stock Award Plan”). The Company filed a Registration Statement on Form S-8 on April 29, 2016 to register 4,700,000 shares of QHC common stock that may be issued under the plan. As defined in the Separation and Distribution Agreement pursuant to the Spin-off, QHC and CHS employees who held CHS restricted stock awards on the Record Date received QHC restricted stock awards for the number of whole shares, rounded down, of QHC common stock that they would have received as a shareholder of CHS as if the underlying CHS stock were unrestricted on the Record Date, except, that with respect to a portion of CHS restricted stock awards granted to any QHC employees on March 1, 2016 that were cancelled and forfeited on the Spin-off date. The QHC restricted stock awards received by QHC and CHS employees in connection with the Spin-off vest on the same terms as the CHS restricted stock awards to which they relate, through the continued service by such employees with their respective employer. CHS restricted stock awards were adjusted by increasing the number of shares of CHS stock subject to restricted stock awards by an amount of whole shares, rounded down, necessary to preserve the intrinsic value of such awards at the Spin-off date. QHC did not issue any stock options as part of the distribution of shares to holders of CHS stock options. The following table provides a summary of the activity related to unvested QHC restricted stock awards held by QHC and CHS employees during the six months ended June 30, 2018 that were distributed in the Spin-off (in shares): QHC Awards Distributed in Spin-off Unvested restricted stock awards at December 31, 2017 266,880 Vested (136,562 ) Forfeited (48,467 ) Unvested restricted stock awards at June 30, 2018 81,851 The following table provides a summary of the activity related to unvested restricted stock awards during the six months ended June 30, 2018 that were granted to QHC employees subsequent to the Spin-off: QHC Awards Granted Subsequent to Spin-off Weighted- Average Grant Date Fair Value Shares Per Share Unvested restricted stock awards at December 31, 2017 1,779,488 $ 9.58 Granted 979,817 6.26 Vested (807,360 ) 9.95 Forfeited (328,047 ) 9.10 Unvested restricted stock awards at June 30, 2018 1,623,898 7.49 During the six months ended June 30, 2018, the Company granted 225,000 performance-based restricted stock awards to certain of its executive officers. If the performance-based objectives are attained in accordance with the targets set forth in the performance-based restricted stock award agreement, the restrictions on the restricted stock awards will lapse on the second anniversary of the grant date. In addition, the Company granted 635,000 time-based restricted stock awards in which the restrictions will lapse in equal installments on each of the first three anniversaries of the grant date. In addition, the Company granted 123,780 time-based restricted stock awards to its non-employee directors which will lapse on the first anniversary of the grant date. The Company records stock-based compensation expense related to the vesting of QHC restricted stock awards issued to QHC employees on the Spin-off date, CHS restricted stock awards held by QHC employees on the Spin-off date, and restricted stock awards granted by QHC subsequent to the Spin-off. Stock-based compensation expense is included in salaries and benefits in the consolidated statements of income. The following table provides a summary of stock-based compensation expense (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Stock-based compensation resulting from the Spin-off $ 2 $ 448 $ 372 $ 1,364 Stock-based compensation related to grants following the Spin-off 2,754 2,083 4,848 3,964 Total stock-based compensation expense $ 2,756 $ 2,531 $ 5,220 $ 5,328 As of June 30, 2018, the Company had unrecognized stock-based compensation expense of $9.6 million related to restricted stock awards.

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2018
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	NOTE 15 – EMPLOYEE BENEFIT PLANS The Company maintains various benefit plans, including defined contribution plans, a defined benefit plan and deferred compensation plans, of which certain of the Company’s subsidiaries are the plan sponsors. The rights and obligations of these plans were transferred from CHS in connection with the Spin-off, pursuant to the Separation and Distribution Agreement. Defined Contribution Plans The Quorum Health Retirement Savings Plan (the “Retirement Savings Plan”) is a defined contribution plan, which was established on January 1, 2016 by CHS in anticipation of the Spin-off. The assets and liabilities under this plan were transferred to QHC in connection with the Spin-off. The Retirement Savings Plan covers the majority of the employees at the Company’s subsidiaries. The Company has other minor defined contribution plans at certain of its hospitals that cover employees under the terms of these individual plans. Total expense to the Company under all defined contribution plans was $4.2 million and $4.0 million for the three months ended June 30, 2018 and 2017, respectively, and $4.3 million and $6.9 million for the six months ended June 30, 2018 and 2017, respectively. The benefit costs associated with the Retirement Savings Plan are included in salaries and benefits expense in the consolidated statements of income. Deferred Compensation Plans On August 18, 2016, the Compensation Committee of the Board adopted the Executive Nonqualified Excess Plan Adoption Agreement (the “Adoption Agreement”) and the Executive Nonqualified Excess Plan Document (the “Plan Document”), that together, the Adoption Agreement names as the QHCCS, LLC Nonqualified Deferred Compensation Plan (the “NQDCP”). The NQDCP is an unfunded, nonqualified deferred compensation plan that provides deferred compensation benefits for a select group of management, highly compensated employees and independent contractors of the Company’s wholly-owned subsidiary, QHCCS, LLC, a Delaware limited liability company (“QHCCS”), including the Company’s named executive officers. The NQDCP permits participants to defer a portion of their annual base salary, service bonus and performance-based compensation, as well as up to 100% of their incentive compensation in any calendar year. In addition to participant deferrals, QHCCS and/or its affiliates may make discretionary credits to participants’ accounts for any year. As of June 30, 2018, the assets and liabilities under this plan were $18.9 million and $20.1 million, respectively. As of December 31, 2017, the assets and liabilities under this plan were $23.1 million and $24.3 million, respectively. The assets and liabilities under this plan are included in other long-term assets and other long-term liabilities, respectively, in the consolidated balance sheet. Supplemental Executive Retirement Plan On April 1, 2016, the Board adopted the Quorum Health Corporation Supplemental Executive Retirement Plan (the “Original SERP Plan”). Pursuant to the Employee Matters Agreement between the Company and CHS, the Company assumed the liabilities for all obligations under the Original SERP Plan as of April 29, 2016, the Spin-off date, which related to QHC employees, as defined in the Employee Matters Agreement. In addition, as defined by the Employee Matters Agreement, no additional benefits were to accrue under the Original SERP Plan following the Spin-off and no assets were transferred to the Company related to the Original SERP Plan. The accrued benefit liability transferred to the Company for the Original SERP Plan was $6.0 million. On May 24, 2016, the Board, upon recommendation of the Compensation Committee, approved the Company’s Amended and Restated Supplemental Executive Retirement Plan (the “Amended and Restated SERP Plan”), in order to accrue additional benefits with respect to QHC Employees who otherwise qualify as “Participants” under the Amended and Restated SERP Plan. The Amended and Restated SERP Plan is a noncontributory non-qualified deferred compensation plan under Section 409A of the Internal Revenue Code. The benefit costs under both SERP plans were $0.1 million and $0.5 million for the three months ended June 30, 2018 and 2017, respectively, and $0.5 million and $1.0 million for the six months ended June 30, 2018 and 2017, respectively, and are included in salaries and benefits in the consolidated statements of income. The long-term portion of the benefit liability for the Amended and Restated SERP Plan was $5.5 million and $8.7 million as of June 30, 2018 and December 31, 2017, respectively. The current portion of the benefit liability as of June 30, 2018 was $3.8 million. There was no current portion of the benefit liability as December 31, 2017. The current portion of the benefit liability is included in accrued salaries and benefits and the long-term portion is included in other long-term liabilities in the consolidated balance sheets. Director’s Fees Deferral Plan On September 16, 2016, the Board adopted the Quorum Health Corporation Director’s Fees Deferral Plan (the “Director’s Plan”). Pursuant to the Director’s Plan, members of the Board may elect to defer and accumulate fees, including retainer fees and fees for attendance at Board meetings and Board committees. A director may elect that all or any specified portion of the director’s fees to be earned during a calendar year be credited to a director’s cash account and/or a director’s stock unit account maintained on the individual director’s behalf in lieu of payment. Payment of amounts credited to a director’s cash account and stock unit account will be made upon a payment commencement event, as defined in the Director’s Plan, in accordance with the payment method elected by the individual director, either in lump sum or in a number of annual installments, not to exceed 15 installments. The Director’s Plan extends to directors of the Board not employed by the Company or any of its subsidiaries. Pursuant to the Director’s Plan, the Company registered and made available for issuance under the Director’s Plan a maximum of 150,000 shares of QHC common stock. Defined Benefit Pension Plan QHC provides benefits to employees at one of its hospitals through a defined benefit plan (the “Pension Plan”). The Pension Plan provides benefits to covered individuals satisfying certain age and service requirements. Employer contributions to the Pension Plan are in accordance with the minimum funding requirements of ERISA. Benefit costs related to the Pension Plan were $0.1 million for both the three months ended June 30, 2018 and 2017, and $0.1 million and $0.2 million for the six months ended June 30, 2018 and 2017, respectively. The Company recognizes the unfunded liability of the Pension Plan in other long-term liabilities in its consolidated balance sheets. Unrecognized gains (losses) and prior service credits (costs) are recognized as other comprehensive income (loss). The accrued benefit liability for the Pension Plan was $0.8 million at both June 30, 2018 and December 31, 2017.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 16 – RELATED PARTY TRANSACTIONS CHS was a related party to QHC prior to the Spin-off. The agreements between QHC and CHS as of and subsequent to the Spin-off are described below. Agreements with CHS Related to the Spin-off In connection with the Spin-off and effective as of April 29, 2016, the Company entered into certain agreements with CHS that allocated between the Company and CHS the various assets, employees, liabilities and obligations (including investments, property, employee benefits and tax-related assets and liabilities) that were previously part of CHS. In addition, these agreements govern certain relationships between, and activities of, the Company and CHS for a definitive period of time after the Spin-off, as specified by each individual agreement. The agreements were as follows: • Separation and Distribution Agreement. • Tax Matters Agreement • Employee Matters Agreement. In addition to the agreements referenced above, the Company entered into certain transition services agreements and other ancillary agreements with CHS defining agreed upon services to be provided by CHS to certain or all QHC hospitals, as determined by each agreement, commencing on the Spin-off date. The agreements generally have terms of five years. A summary of the major provisions of the transition services agreements follows: • Shared Services Centers Transition Services Agreement. • Computer and Data Processing Transition Services Agreement. • Receivables Collection Agreement (“PASI”). • Billing and Collection Agreement (“PPSI”). • Employee Service Center Agreement. • Eligibility Screening Services Agreement. The total expenses recorded by the Company under the transition services agreements with CHS were $14.1 million and $16.0 million for the three months ended June 30, 2018 and 2017, respectively, and $29.2 million and $32.3 million for the six months ended June 30, 2018 and 2017, respectively. The Company is disputing in arbitration, among other issues and actions, certain charges and lack of performance of various obligations under the transition services agreements with CHS. See Note 17 — Commitments and Contingencies for additional information on the arbitration.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 17 - COMMITMENTS AND CONTINGENCIES Legal Matters The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental proceedings, including the matters described herein, will have a material adverse effect on the operating results, financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in these matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s consolidated results of operations or cash flows for any particular reporting period. In connection with the Spin-off, CHS agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to the closing of the Spin-off, including (i) certain claims and proceedings known to be outstanding on or prior to the closing date of the Spin-off and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to the Company’s healthcare facilities prior to the closing date of the Spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by CHS, including professional and general liability and workers’ compensation liability. In this regard, CHS will continue to be responsible for certain Health Management Associates, Inc. legal matters covered by its contingent value rights agreement that relate to the portion of CHS’ business now held by QHC. Notwithstanding the foregoing, CHS is not indemnifying QHC in respect of any claims or proceedings arising out of, or related to, the business operations of QHR at any time or its compliance with the Corporate Integrity Agreement (“CIA”) . Subsequent to the Spin-off, the OIG entered into an “Assumption of CIA Liability Letter” with the Company reiterating the applicability of the CIA to certain of the Company’s hospitals, although the OIG declined to enter into a separate agreement with the Company. With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated amount of loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the amount of possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the amount of possible loss or range of loss. However, the Company is unable to estimate an amount of possible loss or range of loss in some instances based on the significant uncertainties involved in, or the preliminary nature of, certain legal, regulatory and governmental matters. Government Investigations • Tooele, Utah – Physician Compensation Commercial Litigation and Other Lawsuits • Arbitration with Community Health Systems, Inc. • Zwick Partners LP and Aparna Rao, Individually and On Behalf of All Others Similarly Situated v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller and Michael J. Culotta • United Tort Claimants v. Quorum Health Resources, LLC (U.S. Bankruptcy Court for the District of New Mexico); Douthitt - Dugger, et al. v. Quorum Health Resources, LLC (Bernalillo County, New Mexico District Court). Plaintiffs sued QHR and Gerald Champion Regional Medical Center in New Mexico state court and bankruptcy court arising from surgical procedures alleged to have been experimental and performed by an unqualified doctor. The parties have now agreed to a global settlement of the United Tort Claimants (“UTC”) claims for a confidential amount to be fully funded by Lexington Insurance Company (“Lexington”). The specific language of releases and related settlement documents is being negotiated and will be subject to bankruptcy court approval. • Lexington Insurance Company v. Quorum Health Resources, LLC, et al. (Williamson County, Tennessee Chancery Court)) Lexington has sued QHR in Williamson County, Tennessee seeking a judicial declaration that the UTC’s claims and the cost of defending QHR are not covered by Lexington. Lexington has now agreed not to seek reimbursement from QHR (1) for any part of the settlement with UTC (as described above); or (2) for the cost of defending QHR in the UTC litigation in New Mexico. The carrier has also agreed • R2 Investments, LDC v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller, Michael J. Culotta, John A. Clerico, James S. Ely, III, John A. Fry, William Norris Jennings, Julia B. North, H. Mitchell Watson, Jr. and H. James Williams . On October 25, 2017, a shareholder filed an action in the Circuit Court of Williamson County, Tennessee against the Company and certain of its officers and directors and CHS and certain of its officers and directors. The complaint alleges that the defendants violated the Tennessee Securities Act and common law by, among other things, making alleged false and/or misleading statements and failing to disclose certain information regarding aspects of the Company’s business, operations and financial condition. Plaintiff is seeking rescissionary, compensatory and punitive damages. The Company filed a motion to dismiss the action on January 16, 2018, which Plaintiff opposed on March 5, 2018. On May 11, 2018, the Court denied the Company’s motion to dismiss. The Company subsequently filed an answer to the complaint, and the case is now proceeding into discovery. The Company is vigorously defending itself in this matter. The Company is unable to predict the outcome of this matter. However, it is reasonably possible that the Company may incur a loss in connection with this matter. The Company is unable to reasonably estimate the amount or range of such reasonably possible loss because discovery has only recently started and the case remains in its early stages. Under some circumstances, losses incurred in connection with adverse outcomes in this matter could be material. Insurance Reserves As part of the business of owning and operating hospitals, the Company is subject to potential professional and general liability and workers’ compensation liability claims or other legal actions alleging liability on its part. The Company is also subject to similar liabilities related to its QHR business. Prior to the Spin-off, CHS provided professional and general liability insurance and workers’ compensation liability insurance to QHC and indemnified QHC from losses under these insurance arrangements related to the hospital operations business assumed by QHC in the Spin-off. The liabilities for claims prior to the Spin-off and related to QHC’s hospital operations business were determined based on an actuarial study of QHC’s operations and historical claims experience at its hospitals, including during the period of ownership by CHS. Corresponding receivables from CHS are established to reflect the indemnification by CHS for each of these liabilities for claims that related to events and circumstances that occurred prior to the Spin-off date. After the Spin-off, QHC entered into its own professional and general liability insurance and workers’ compensation liability insurance arrangements to mitigate the risk for claims related to events occurring after the Spin-off date that exceed its self-insured retention levels. The Company maintains a self-insured retention level for professional and general liability claims of $5 million per claim and maintains a $0.5 million per claim, high deductible program for workers’ compensation. Due to the differing nature of its business operations, the Company maintains separate insurance arrangements related to its subsidiary, QHR. The self-insured retention level for QHR is $6 million for professional and general liability insurance. The following table provides a summary of the Company’s insurance reserves related to professional and general liability and workers’ compensation liability, distinguished between those indemnified by CHS and those related to the Company’s own risks (in thousands): June 30, 2018 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 21,605 $ 35,128 $ 21,605 $ 35,128 All other self-insurance reserves — — 3,483 42,607 Total insurance reserves for professional and general liability 21,605 35,128 25,088 77,735 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 2,562 13,218 2,562 13,218 All other self-insurance reserves — — 2,357 5,286 Total insurance reserves for workers' compensation liability 2,562 13,218 4,919 18,504 Total self-insurance reserves $ 24,167 $ 48,346 $ 30,007 $ 96,239 December 31, 2017 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 21,465 $ 44,377 $ 21,465 $ 44,377 All other self-insurance reserves — — 2,883 32,616 Total insurance reserves for professional and general liability 21,465 44,377 24,348 76,993 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 3,032 14,545 3,032 14,545 All other self-insurance reserves — — 3,120 4,013 Total insurance reserves for workers' compensation liability 3,032 14,545 6,152 18,558 Total self-insurance reserves $ 24,497 $ 58,922 $ 30,500 $ 95,551 The receivables from CHS are included in other current assets and other long-term assets in the consolidated balance sheets. The liability for the current portion of professional and general liability claims is included in other current liabilities, while the current portion of the liability for workers’ compensation claims is included in accrued salaries and benefits. The long-term portions of both claims liabilities are included in other long-term liabilities. Construction and Capital Commitments The Company is in the process of completing construction on a new patient tower and expanding surgical capacity at McKenzie – Willamette Medical Center, its hospital in Springfield, Oregon. During the three months ended June 30, 2018 and June 30, 2017, the Company incurred costs of $4.6 million and $12.8 million, respectively, and incurred costs of $10.8 million and $24.5 million during the six months ended June 30, 2018 and 2017, respectively, related to this project. As of June 30, 2018, the Company has incurred a total of $93.7 million of costs for this project, of which $79.0 million has been placed into service as of June 30, 2018. The total estimated cost of this project, including equipment costs, is estimated to be approximately $105.0 million. The project is expected to be completed in late 2018.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 18 - SUBSEQUENT EVENTS On July 27, 2018, the Company announced that it has a definitive agreement to sell the physical assets of 45-bed McKenzie Regional Hospital, located in McKenzie, TN. The definitive agreement covers the hospital and its affiliated outpatient facilities. The Company currently anticipates completing the sale of this hospital in the third quarter of 2018, subject to customary approvals and conditions. In conjunction with the definitive agreement, the Company announced plans to discontinue operations at McKenzie Regional Hospital by September 30, 2018.

Guarantor and Non-Guarantor Sup

Guarantor and Non-Guarantor Supplemental Information	6 Months Ended
	Jun. 30, 2018
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Guarantor and Non-Guarantor Supplemental Information	NOTE 19 - GUARANTOR AND NON-GUARANTOR SUPPLEMENTAL INFORMATION The Senior Notes are senior unsecured obligations of the Company guaranteed on a senior basis by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries (the “Guarantors”). The Senior Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or when a sale of all of the subsidiary guarantor’s assets used in operations occurs. The condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The accounting policies used in the preparation of this financial information are consistent with the accompanying condensed consolidated financial statements of the Company, except as follows: • Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. • Investments in consolidated subsidiaries, as well as guarantor subsidiaries’ investments in non-guarantor subsidiaries, are presented under the equity method of accounting with the related investments presented within the line items net investment in subsidiaries and other long-term liabilities in the supplemental condensed consolidating balance sheets. • Income tax expense is allocated from the parent issuer to the income producing operations (other guarantors and non-guarantors) through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes. The Company’s intercompany activity consists primarily of daily cash transfers, the allocation of certain expenses and expenditures paid by the parent issuer on behalf of its subsidiaries, and the push down of investment in its subsidiaries. The parent issuer’s investment in its subsidiaries reflects the activity since the Spin-off. Likewise, the parent issuer’s equity in earnings of unconsolidated affiliates represents the Company’s earnings since the Spin-off. Condensed Consolidating Statement of Income (Loss) Three Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net operating revenues $ — $ 362,258 $ 110,374 $ — $ 472,632 Operating costs and expenses: Salaries and benefits — 160,448 72,183 — 232,631 Supplies — 36,841 16,056 — 52,897 Other operating expenses 27 116,930 27,499 — 144,456 Depreciation and amortization — 13,820 3,322 — 17,142 Rent — 6,567 4,791 — 11,358 Electronic health records incentives earned — (381 ) (64 ) — (445 ) Legal, professional and settlement costs — 5,417 — — 5,417 Impairment of long-lived assets and goodwill — — — — — Loss (gain) on sale of hospitals, net — 313 (6 ) — 307 Loss on closure of hospitals, net — 3,338 — — 3,338 Total operating costs and expenses 27 343,293 123,781 — 467,101 Income (loss) from operations (27 ) 18,965 (13,407 ) — 5,531 Interest expense, net 32,934 (1,026 ) 18 — 31,926 Equity in earnings of affiliates (5,934 ) (3,022 ) — 8,956 — Income (loss) before income taxes (27,027 ) 23,013 (13,425 ) (8,956 ) (26,395 ) Provision for (benefit from) income taxes (421 ) (84 ) 51 — (454 ) Net income (loss) (26,606 ) 23,097 (13,476 ) (8,956 ) (25,941 ) Less: Net income (loss) attributable to noncontrolling interests — — 665 — 665 Net income (loss) attributable to Quorum Health Corporation $ (26,606 ) $ 23,097 $ (14,141 ) $ (8,956 ) $ (26,606 ) Condensed Consolidating Statement of Income (Loss) Three Months Ended June 30, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues $ — $ 455,874 $ 129,341 $ — $ 585,215 Provision for bad debts — 48,050 7,019 — 55,069 Net operating revenues — 407,824 122,322 — 530,146 Operating costs and expenses: Salaries and benefits — 182,437 82,872 — 265,309 Supplies — 45,403 18,709 — 64,112 Other operating expenses 2,892 124,634 30,087 — 157,613 Depreciation and amortization — 17,591 2,995 — 20,586 Rent — 7,064 5,088 — 12,152 Electronic health records incentives earned — (1,981 ) 204 — (1,777 ) Legal, professional and settlement costs — 3,934 — — 3,934 Impairment of long-lived assets and goodwill — 12,900 — — 12,900 Loss (gain) on sale of hospitals, net — — (4,321 ) — (4,321 ) Total operating costs and expenses 2,892 391,982 135,634 — 530,508 Income (loss) from operations (2,892 ) 15,842 (13,312 ) — (362 ) Interest expense, net 31,349 (970 ) 79 — 30,458 Equity in earnings of affiliates (3,344 ) 2,554 — 790 — Income (loss) before income taxes (30,897 ) 14,258 (13,391 ) (790 ) (30,820 ) Provision for (benefit from) income taxes (267 ) (140 ) 162 — (245 ) Net income (loss) (30,630 ) 14,398 (13,553 ) (790 ) (30,575 ) Less: Net income (loss) attributable to noncontrolling interests — — 55 — 55 Net income (loss) attributable to Quorum Health Corporation $ (30,630 ) $ 14,398 $ (13,608 ) $ (790 ) $ (30,630 ) Condensed Consolidating Statement of Income (Loss) Six Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net operating revenues $ — $ 734,795 $ 224,657 $ — $ 959,452 Operating costs and expenses: Salaries and benefits — 330,181 149,450 — 479,631 Supplies — 79,441 32,342 — 111,783 Other operating expenses 1,897 239,096 56,201 — 297,194 Depreciation and amortization — 28,525 6,878 — 35,403 Rent — 13,884 10,006 — 23,890 Electronic health records incentives earned — (430 ) (156 ) — (586 ) Legal, professional and settlement costs — 8,830 — — 8,830 Impairment of long-lived assets and goodwill — 37,960 1,800 — 39,760 Loss (gain) on sale of hospitals, net — 8,128 (6 ) — 8,122 Loss on closure of hospitals, net — 17,084 — — 17,084 Total operating costs and expenses 1,897 762,699 256,515 — 1,021,111 Income (loss) from operations (1,897 ) (27,904 ) (31,858 ) — (61,659 ) Interest expense, net 64,408 (1,548 ) (3 ) — 62,857 Equity in earnings of affiliates 58,917 40,831 — (99,748 ) — Income (loss) before income taxes (125,222 ) (67,187 ) (31,855 ) 99,748 (124,516 ) Provision for (benefit from) income taxes 352 (420 ) (20 ) — (88 ) Net income (loss) (125,574 ) (66,767 ) (31,835 ) 99,748 (124,428 ) Less: Net income (loss) attributable to noncontrolling interests — — 1,146 — 1,146 Net income (loss) attributable to Quorum Health Corporation $ (125,574 ) $ (66,767 ) $ (32,981 ) $ 99,748 $ (125,574 ) Condensed Consolidating Statement of Income (Loss) Six Months Ended June 30, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues — 904,874 268,286 — $ 1,173,160 Provision for bad debts — 97,609 17,765 — 115,374 Net operating revenues — 807,265 250,521 — 1,057,786 Operating costs and expenses: Salaries and benefits — 363,459 166,452 — 529,911 Supplies — 91,276 36,658 — 127,934 Other operating expenses 2,892 253,944 64,201 — 321,037 Depreciation and amortization — 36,119 6,587 — 42,706 Rent — 14,162 10,092 — 24,254 Electronic health records incentives earned — (3,438 ) (791 ) — (4,229 ) Legal, professional and settlement costs — 4,469 — — 4,469 Impairment of long-lived assets and goodwill — 16,200 — — 16,200 Loss (gain) on sale of hospitals, net — — (5,191 ) — (5,191 ) Transaction costs related to the Spin-off — 23 8 — 31 Total operating costs and expenses 2,892 776,214 278,016 — 1,057,122 Income (loss) from operations (2,892 ) 31,051 (27,495 ) — 664 Interest expense, net 59,933 (2,026 ) 81 — 57,988 Equity in earnings of affiliates (5,091 ) 5,132 — (41 ) — Income (loss) before income taxes (57,734 ) 27,945 (27,576 ) 41 (57,324 ) Provision for (benefit from) income taxes 457 222 (223 ) — 456 Net income (loss) (58,191 ) 27,723 (27,353 ) 41 (57,780 ) Less: Net income (loss) attributable to noncontrolling interests — — 411 — 411 Net income (loss) attributable to Quorum Health Corporation $ (58,191 ) $ 27,723 $ (27,764 ) $ 41 $ (58,191 ) Condensed Consolidating Statement of Comprehensive Income (Loss) Three Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (26,606 ) $ 23,097 $ (13,476 ) $ (8,956 ) $ (25,941 ) Amortization and recognition of unrecognized pension cost components, net of income taxes (189 ) (189 ) — 189 (189 ) Comprehensive income (loss) (26,795 ) 22,908 (13,476 ) (8,767 ) (26,130 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 665 — 665 Comprehensive income (loss) attributable to Quorum Health Corporation $ (26,795 ) $ 22,908 $ (14,141 ) $ (8,767 ) $ (26,795 ) Condensed Consolidating Statement of Comprehensive Income (Loss) Three Months Ended June 30, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (30,630 ) $ 14,398 $ (13,553 ) $ (790 ) $ (30,575 ) Amortization and recognition of unrecognized pension cost components, net of income taxes 120 120 — (120 ) 120 Comprehensive income (loss) (30,510 ) 14,518 (13,553 ) (910 ) (30,455 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 55 — 55 Comprehensive income (loss) attributable to Quorum Health Corporation $ (30,510 ) $ 14,518 $ (13,608 ) $ (910 ) $ (30,510 ) Condensed Consolidating Statement of Comprehensive Income (Loss) Six Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (125,574 ) $ (66,767 ) $ (31,835 ) $ 99,748 $ (124,428 ) Amortization and recognition of unrecognized pension cost components, net of income taxes (75 ) (75 ) — 75 (75 ) Comprehensive income (loss) (125,649 ) (66,842 ) (31,835 ) 99,823 (124,503 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 1,146 — 1,146 Comprehensive income (loss) attributable to Quorum Health Corporation $ (125,649 ) $ (66,842 ) $ (32,981 ) $ 99,823 $ (125,649 ) Condensed Consolidating Statement of Comprehensive Income (Loss) Six Months Ended June 30, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (58,191 ) $ 27,723 $ (27,353 ) $ 41 $ (57,780 ) Amortization and recognition of unrecognized pension cost components, net of income taxes 242 242 — (242 ) 242 Comprehensive income (loss) (57,949 ) 27,965 (27,353 ) (201 ) (57,538 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 411 — 411 Comprehensive income (loss) attributable to Quorum Health Corporation $ (57,949 ) $ 27,965 $ (27,764 ) $ (201 ) $ (57,949 ) Condensed Consolidating Balance Sheet June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 1,455 $ 958 $ 409 $ — $ 2,822 Patient accounts receivable, net of allowance for doubtful accounts — 252,286 75,194 — 327,480 Inventories — 37,453 9,327 — 46,780 Prepaid expenses 83 19,972 5,309 — 25,364 Due from third-party payors — 59,286 9,903 — 69,189 Other current assets — 31,957 13,485 — 45,442 Total current assets 1,538 401,912 113,627 — 517,077 Intercompany receivable 3 540,784 259,905 (800,692 ) — Property and equipment, net — 468,084 136,697 — 604,781 Goodwill — 235,814 165,642 — 401,456 Intangible assets, net — 47,864 5,581 — 53,445 Other long-term assets — 61,079 26,745 — 87,824 Net investment in subsidiaries 1,431,461 — — (1,431,461 ) — Total assets $ 1,433,002 $ 1,755,537 $ 708,197 $ (2,232,153 ) $ 1,664,583 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ — $ 1,387 $ 346 $ — $ 1,733 Accounts payable 39 134,533 20,003 — 154,575 Accrued liabilities: Accrued salaries and benefits — 60,803 21,322 — 82,125 Accrued interest 10,221 — — — 10,221 Due to third-party payors — 34,200 6,470 — 40,670 Other current liabilities 222 31,370 14,320 — 45,912 Total current liabilities 10,482 262,293 62,461 — 335,236 Long-term debt 1,174,663 23,000 16 — 1,197,679 Intercompany payable 263,365 259,908 277,419 (800,692 ) — Deferred income tax liabilities, net 7,799 — — — 7,799 Other long-term liabilities — 226,605 32,667 (129,109 ) 130,163 Total liabilities 1,456,309 771,806 372,563 (929,801 ) 1,670,877 Redeemable noncontrolling interests — — 2,301 — 2,301 Equity: Quorum Health Corporation stockholders' equity (deficit): Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 552,511 1,186,270 573,212 (1,759,482 ) 552,511 Accumulated other comprehensive income (loss) (2,031 ) (2,031 ) — 2,031 (2,031 ) Accumulated deficit (573,790 ) (200,508 ) (254,591 ) 455,099 (573,790 ) Total Quorum Health Corporation stockholders' equity (deficit) (23,307 ) 983,731 318,621 (1,302,352 ) (23,307 ) Nonredeemable noncontrolling interests — — 14,712 — 14,712 Total equity (23,307 ) 983,731 333,333 (1,302,352 ) (8,595 ) Total liabilities and equity $ 1,433,002 $ 1,755,537 $ 708,197 $ (2,232,153 ) $ 1,664,583 Condensed Consolidating Balance Sheet December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 1,051 $ 4,222 $ 344 $ — $ 5,617 Patient accounts receivable, net of allowance for doubtful accounts — 262,690 80,455 — 343,145 Inventories — 43,276 10,183 — 53,459 Prepaid expenses 33 16,980 4,154 — 21,167 Due from third-party payors — 93,323 3,879 — 97,202 Current assets of hospitals held for sale — 8,112 — — 8,112 Other current assets — 32,867 14,573 — 47,440 Total current assets 1,084 461,470 113,588 — 576,142 Intercompany receivable 3 402,817 172,098 (574,918 ) — Property and equipment, net — 543,073 132,206 — 675,279 Goodwill — 243,618 165,611 — 409,229 Intangible assets, net — 58,240 6,610 — 64,850 Long-term assets of hospitals held for sale — 7,730 4 — 7,734 Other long-term assets — 74,918 20,689 — 95,607 Net investment in subsidiaries 1,488,021 — — (1,488,021 ) — Total assets $ 1,489,108 $ 1,791,866 $ 610,806 $ (2,062,939 ) $ 1,828,841 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ — $ 1,434 $ 421 $ — $ 1,855 Accounts payable 132 146,193 24,925 — 171,250 Accrued liabilities: Accrued salaries and benefits — 56,522 21,281 — 77,803 Accrued interest 10,466 — — — 10,466 Due to third-party payors — 46,381 1,324 — 47,705 Current liabilities of hospitals held for sale — 2,577 — — 2,577 Other current liabilities 516 30,664 12,507 — 43,687 Total current liabilities 11,114 283,771 60,458 — 355,343 Long-term debt 1,188,224 23,809 2 — 1,212,035 Intercompany payable 182,555 173,341 219,022 (574,918 ) — Deferred income tax liabilities, net 7,774 — — — 7,774 Other long-term liabilities — 195,132 31,100 (88,278 ) 137,954 Total liabilities 1,389,667 676,053 310,582 (663,196 ) 1,713,106 Redeemable noncontrolling interests — — 2,325 — 2,325 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 549,610 1,291,581 471,767 (1,763,348 ) 549,610 Accumulated other comprehensive income (loss) (1,956 ) (1,956 ) — 1,956 (1,956 ) Accumulated deficit (448,216 ) (173,812 ) (187,837 ) 361,649 (448,216 ) Total Quorum Health Corporation stockholders' equity 99,441 1,115,813 283,930 (1,399,743 ) 99,441 Nonredeemable noncontrolling interests — — 13,969 — 13,969 Total equity 99,441 1,115,813 297,899 (1,399,743 ) 113,410 Total liabilities and equity $ 1,489,108 $ 1,791,866 $ 610,806 $ (2,062,939 ) $ 1,828,841 Condensed Consolidating Statement of Cash Flows Six Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (62,144 ) $ 75,865 $ 880 $ — $ 14,601 Cash flows from investing activities: Capital expenditures for property and equipment — (16,707 ) (8,612 ) — (25,319 ) Capital expenditures for software — (957 ) (87 ) — (1,044 ) Acquisitions, net of cash acquired — — (58 ) — (58 ) Proceeds from the sale of hospitals — 38,612 558 — 39,170 Other investing activities — 262 (13 ) — 249 Changes in intercompany balances with affiliates, net — (97,540 ) — 97,540 — Net cash provided by (used in) investing activities — (76,330 ) (8,212 ) 97,540 12,998 Cash flows from financing activities: Borrowings under of revolving credit facilities 247,000 — — — 247,000 Repayments under revolving credit facilities (233,000 ) — — — (233,000 ) Borrowings of long-term debt — 12 55 — 67 Repayments of long-term debt (30,463 ) (868 ) (116 ) — (31,447 ) Payments of debt issuance costs (2,268 ) — — — (2,268 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (1,943 ) — — (1,943 ) Cash distributions to noncontrolling investors — — (803 ) — (803 ) Changes in intercompany balances with affiliates, net 81,279 — 16,261 (97,540 ) — Net cash provided by (used in) financing activities 62,548 (2,799 ) 15,397 (97,540 ) (22,394 ) Net change in cash, cash equivalents and restricted cash 404 (3,264 ) 8,065 — 5,205 Cash, cash equivalents and restricted cash at beginning of period 1,051 4,222 344 — 5,617 Cash, cash equivalents and restricted cash at end of period $ 1,455 $ 958 $ 8,409 $ — $ 10,822 Condensed Consolidating Statement of Cash Flows Six Months Ended June 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (68,468 ) $ 52,472 $ 7,041 $ — $ (8,955 ) Cash flows from investing activities: Capital expenditures for property and equipment — (13,390 ) (25,752 ) — (39,142 ) Capital expenditures for software — (2,670 ) (499 ) — (3,169 ) Acquisitions, net of cash acquired — (20 ) (1,867 ) — (1,887 ) Proceeds from sale of hospitals — — 20,156 — 20,156 Changes in intercompany balances with affiliates, net — (30,637 ) — 30,637 — Net cash provided by (used in) investing activities — (46,717 ) (7,962 ) 30,637 (24,042 ) Cash flows from financing activities: Borrowings under revolving credit facilities 302,000 — — — 302,000 Repayments under revolving credit facilities (252,000 ) — — — (252,000 ) Borrowings of long-term debt — 72 — — 72 Repayments of long-term debt (10,832 ) (835 ) (180 ) — (11,847 ) Payments of debt issuance costs (2,938 ) — — — (2,938 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (1,489 ) — — (1,489 ) Cash distributions to noncontrolling investors — — (3,851 ) — (3,851 ) Changes in intercompany balances with affiliates, net 25,659 — 4,978 (30,637 ) — Net cash provided by (used in) financing activities 61,889 (2,252 ) 947 (30,637 ) 29,947 Net change in cash and cash equivalents (6,579 ) 3,503 26 — (3,050 ) Cash and cash equivalents at beginning of period 21,609 3,498 348 — 25,455 Cash and cash equivalents at end of period $ 15,030 $ 7,001 $ 374 $ — $ 22,405

Basis of Presentation and Sig28

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation (Policies)	Basis of Presentation The condensed consolidated financial statements and accompanying notes of the Company presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”). In the opinion of the Company’s management, the condensed consolidated financial information presented herein includes all adjustments necessary to present fairly the results of operations, financial position and cash flows of the Company for the interim periods presented. Results of operations for interim periods should not be considered indicative of the results of operations expected for the full year ending December 31, 2018. Certain information and disclosures have been condensed or omitted as presented herein and as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim period presentation. The Company’s management believes the financial statements and disclosures presented herein are adequate in order to make the information presented not misleading. The condensed consolidated financial statements should be read in conjunction with the consolidated and combined financial statements and accompanying notes thereto for the year ended December 31, 2017, contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2018 (the “2017 Annual Report on Form 10-K”).
Principles of Consolidation (Policies)	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its subsidiaries in which it holds either a direct or indirect ownership of a majority voting interest. Investments in less-than-wholly-owned consolidated subsidiaries of QHC are presented separately in the equity component of the Company’s consolidated balance sheets to distinguish between the interests of QHC and the interests of the noncontrolling investors. Revenues and expenses from these subsidiaries are included in the respective individual line items of the Company’s consolidated statements of income, and net income is presented both in total and separately to distinguish the amounts attributable to the Company and the amounts attributable to the interests of the noncontrolling investors. Noncontrolling interests that are redeemable, or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company, are presented in mezzanine equity in the Company’s consolidated balance sheets. Intercompany transactions and accounts of the Company are eliminated in consolidation.
Reclassifications and Immaterial Restatements (Policies)	Reclassifications and Immaterial Restatements Certain revisions have been made to prior period balances as follows: Beginning in the fourth quarter of 2017, the Company reclassified and separately presented in its consolidated statements of cash flows the gross borrowings and repayments of its revolving credit facilities. Both items are included in cash flows from financing activities. Previously, these amounts were netted in the Company’s presentation of its consolidated statements of cash flow. This reclassification is considered immaterial and had no effect on the Company’s consolidated results of operations or financial position.
Use of Estimates (Policies)	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. Actual results could differ from those estimates under different assumptions or conditions.
Revenue Recognition (Policies)	Adoption of ASC Topic 606 “Revenue from Contracts with Customers” On January 1, 2018, the Company adopted Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”) using the modified retrospective method to all contracts existing on January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to • Prior to the adoption of ASC 606, a significant portion of the Company’s allowance for doubtful accounts related to amounts due from self-pay patients, as well as co-pays and deductibles owed to the Company by patients with insurance. Under ASC 606, the estimated allowance for these patients is generally considered a direct reduction to net operating revenues rather than as a provision for bad debts. • Prior to the adoption of ASC 606, the Company’s presentation and disclosure of net revenue by payor included the portion of the revenue related to co-pays and deductibles as third party revenues. Under ASC 606, the co-pays and deductibles portions of net revenue are classified as self-pay after insurance. Revenue Recognition The Company reports revenues from patient services at its hospitals and affiliated facilities at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients, governmental programs and third-party payors such as Medicare, Medicaid, health maintenance organizations, preferred provider organizations, private insurers and others, and include variable consideration for retroactive revenue adjustments due to settlements of audits, reviews and investigations. Generally, the Company bills the patient and third-party payors several days after the services are performed or the patient is discharged. Revenue is recognized as the performance obligations are satisfied. Billings and collections are outsourced to CHS under the transition services agreements that were entered into in connection with the Spin-off. See Note 16 — Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges for services anticipated to be provided. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Company’s hospitals receiving inpatient acute care services. The Company measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Company does not believe it is required to provide additional goods or services to the patient. Because all of its performance obligations relate to contracts with a duration of less than one year, the Company has elected to apply the optional exemption provided in ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patient is discharged, which generally occurs within days or weeks following the end of the reporting period. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and patient responsibility after insurance in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients and patient responsibility after insurance. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. The Company recognizes revenues related to its QHR business when either the performance obligation has been satisfied or over time as the hospital management advisory and healthcare consulting services are provided, and reports these revenues at the amount expected to be collected from the non-affiliated hospital clients of QHR. Payor Sources The primary sources of payment for patient healthcare services are third-party payors, including federal and state agencies administering the Medicare and Medicaid programs, other governmental agencies, managed care health plans, commercial insurance companies, workers’ compensation carriers and employers. Self-pay revenues are the portion of patient service revenues derived from patients who do not have health insurance coverage and the patient responsibility portion of services that are not covered by health insurance plans. Non-patient revenues primarily include revenues from QHR’s hospital management advisory and consulting services business, rental income and hospital cafeteria sales. Revenues from Medicare Advantage Plans that are included in Medicare revenues in the table above were $30.0 million and $41.5 million for the three months ended June 30, 2018 and 2017, respectively, and $71.4 million and $86.4 million for the six months ended June 30, 2018 and 2017, respectively. Contractual Adjustments and Discounts Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: • Medicare: • Medicaid: • Other: Government programs, including Medicare and Medicaid programs, which represent a large portion of the Company’s operating revenues, are highly complex programs to administer and are subject to interpretation of federal and state-specific reimbursement rates, new legislation and final cost report settlements. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations. In some instances, these investigations have resulted in organizations entering into significant settlement agreements or findings of criminal and civil liability. Compliance with such laws and regulations may be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have on the Company. Contractual adjustments, or differences in standard billing rates and the payments derived from contractual terms with governmental and non-governmental third-party payors, are recorded based on management’s best estimates in the period in which services are performed and a payment methodology is established with the patient. Recorded estimates for past contractual adjustments are subject to change, in large part, due to ongoing contract negotiations and regulation changes, which are typical in the U.S. healthcare industry. Revisions to estimates are recorded as contractual adjustments in the periods in which they become known and may be subject to further revisions. In addition, the contracts the Company has with commercial payors may provide for retroactive audit and review of claims. Subsequent changes in estimates for third-party payors that are determined to be the result of an adverse change in a payor’s ability to pay are recorded as bad debt expense. Bad debt expense for the three and six months ended June 30, 2018 was not material and is included in other operating expenses in the Company’s consolidated statement of income. Billing and collections are outsourced to CHS under certain transition services agreements that were put in place by CHS in connection with the Spin-off. The Company’s contractual adjustments are impacted by the timing and ability of CHS to monitor the classification and collection of the Company’s patient accounts receivable. Self-pay and other payor discounts are incentives offered by the Company to uninsured or underinsured patients and other payors to reduce their costs of healthcare services. Third-Party Program Reimbursements Cost report settlements under reimbursement programs with Medicare, Medicaid and other managed care plans for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical experience, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as new information becomes available, or as years are settled or are no longer subject to such audits, reviews, and investigations. Previous program reimbursements and final cost report settlements are included in due from and due to third-party payors in the consolidated balance sheets. Net adjustments arising from a change in the transaction price for estimated cost report settlements favorably (unfavorably) impacted net operating revenues by $(0.4) million and $1.4 million during the three months ended June 30, 2018 and 2017, respectively and $0.1 million and less than $(0.1) million during the six months ended June 30, 2018 and 2017, respectively. Currently, several states utilize supplemental payment programs, including disproportionate share programs, for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of federal and state resources, including, in certain instances, taxes, fees or other program expenses (collectively, “provider taxes”) levied on the providers. The receivables and payables associated with these programs are included in due from and due to third-party payors in the Company’s consolidated balance sheets. After a state supplemental payment program is approved and fully authorized by the appropriate state legislative or governmental agency, the Company recognizes revenue and related expenses based on the terms of the program in the period in which amounts are estimable and revenue collection is reasonably assured. The revenues earned by the Company under these programs are included in net operating revenues and the expenses associated with these programs are included in other operating expenses in the Company’s consolidated statements of income. The California Department of Health Care Services administers the Hospital Quality Assurance Fee (“HQAF”) program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California’s Medi-Cal and uninsured patients. Under Phase V of the program, covering the period from January 2017 through June 2019, the Company recognized $7.9 million of Medicaid revenues and $2.1 million of provider taxes for the three months ended June 30, 2018 and $15.8 million of Medicaid revenues and $4.2 million of provider taxes for the six months ended June 30, 2018. There were no corresponding amounts recognized in the three months and six months ended June 30, 2017. The revenues and fees for the full year 2017 were recognized in the fourth quarter of 2017 when CMS approved the program. Self-Pay and Self-Pay After Insurance Generally patients who are covered by third-party payors are responsible for related co-pays and deductibles, which vary in amount. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from the Company’s standard charges. The Company estimates the transaction price for patients with co-pays and deductibles, and for uninsured patients based on historical collection experience and current market conditions. The initial estimate of the transaction price is determined by reducing the Company’s standard charges by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price, if any, are generally recorded as an adjustment to patient service revenue in the period of the change. Charity Care In the ordinary course of business, the Company provides services to patients who are financially unable to pay for hospital care. The related charges for those patients who are financially unable to pay that otherwise do not qualify for reimbursement from a governmental program are classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the poverty level guidelines established by the federal government. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges are recorded in operating revenues at the standard billing rates and fully offset in contractual adjustments. The Company’s gross amounts of charity care revenues were $6.0 million and $7.5 million for the three months ended June 30, 2018 and 2017, respectively, and $19.3 million and $20.0 million for the six months ended June 30, 2018 and 2017, respectively.
Accounts Receivable (Policies)	Accounts Receivable Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated outpatient facilities. For self-pay and self-pay after insurance receivables, the Company estimates the implicit price concession by reserving a percentage of all self-pay and self-pay after insurance accounts receivable without regard to aging category. The estimate of the implicit price concession is based on a model that considers historical cash collections, expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the implicit price concessions is not significantly impacted by the aging of accounts receivable, as management believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. Significant changes in payor mix, CHS’s business office operations, including the CHS shared services centers’ efforts in collecting the Company’s accounts receivables, economic conditions, or trends in federal and state governmental healthcare coverage, among others, could affect the Company’s estimates of implicit price concessions. The Company also continually reviews its overall estimate of implicit price concessions by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net operating revenues and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, and the impact of recent divestitures. Collections are impacted by the economic ability of patients to pay, the effectiveness of CHS’ billing and collection efforts, including their current policies on collections, and the ability of the Company to further attempt collection efforts. Billings and collections are outsourced to CHS under the transition services agreements that were established with the Spin-off. See Note 16 — Related Party Transactions for additional information on these agreements. The Company has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Company’s expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Company does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract. The Company has applied the practical expedient provided by FASB ASC 340-40-25-4 and all incremental customer contract acquisition costs are expensed as incurred, as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration.
Concentration of Credit Risk (Policies)	Concentration of Credit Risk The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s hospitals and affiliated outpatient facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s markets and non-governmental third-party payors, Medicare represents a significant concentration of credit risk from payors. Accounts receivable, net of contractual adjustments, from Medicare were $60.9 million and $66.6 million, or 18.6% and 18.2% of total patient accounts receivable, net as of June 30, 2018 and December 31, 2017, respectively. Additionally, the Company believes Illinois Medicaid represents a concentration of credit risk to the Company due to the fiscal problems in the state of Illinois that affect the timing and extent of payments due to providers, which are administered by the state of Illinois under the Medicaid program. The Company’s accounts receivable, net of contractual adjustments, from Illinois Medicaid were $21.7 million and $28.8 million, or 6.6% and 7.9% of total patient accounts receivable, net as of June 30, 2018 and December 31, 2017, respectively. The Company’s state supplemental program receivables from Illinois Medicaid were $7.5 million and $22.9 million, or 10.9% and 23.5% of total due from third-party payors, as of June 30, 2018 and December 31, 2017, respectively. The Company’s state supplemental program receivables from California Medicaid were $30.8 million and $48.4 million, or 44.5% and 49.8% of total due from third-party payors, as of June 30, 2018 and December 31, 2017, respectively. The Company’s revenues are particularly sensitive to regulatory and economic changes in certain states where the Company generates significant revenues. Accordingly, any changes in the current demographic, economic, competitive or regulatory conditions in certain states in which revenues are significant could have an adverse effect on the Company’s results of operations, financial condition or cash flows. Changes to Medicaid and other government-managed payor programs in these states, including reductions in reimbursement rates or delays in reimbursement payments under state supplemental payment or other programs, could also have a similar adverse effect.
Other Operating Expenses (Policies)	Other Operating Expenses The Company records costs associated with the transition services agreements and other ancillary agreements with CHS in accordance with the terms of these agreements. These costs, which primarily include the costs of providing information technology, patient billing and collections and payroll services, are included in “Transition services agreements” in the table above. See Note 16 — Related Party Transactions and Note 17 — Commitments and Contingencies for additional information on the transition services agreements with CHS.
General and Administrative Costs (Policies)	General and Administrative Costs Substantially all of the Company’s operating costs and expenses are “cost of revenues” items. Operating expenses that could be classified as general and administrative by the Company are costs related to corporate office functions, including, but not limited to tax, treasury, audit, risk management, legal, investor relations and human resources. These costs primarily consist of salaries and benefits expenses associated with these corporate office functions. General and administrative costs of the Company were $20.0 million and $14.5 million during the three months ended June 30, 2018 and 2017, respectively, and $34.9 million and $30.1 million during the six months ended June 30, 2018 and 2017, respectively. General and administrative costs of the Company include severance costs related to headcount reductions at the corporate office of $2.7 million and $0.6 million during the three months ended June 30, 2018 and 2017, respectively, and $4.6 million and $0.6 million during the six months ended June 30, 2018 and 2017, respectively.
Electronic Health Records Incentives Earned (Policies)	Electronic Health Records Incentives Earned Pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), the Company receives incentive payments under the Medicare and Medicaid programs for its eligible hospitals and physician clinics that demonstrate meaningful use of certified Electronic Health Records (“EHR”) technology. EHR incentive payments are subject to audit and potential recoupment if it is determined that the applicable meaningful use standards were not met. EHR incentive payments are also subject to retrospective adjustment because the cost report data upon which the incentive payments are based are further subject to audit. The Company incurs both capital expenditures and operating expenses in connection with the implementation of EHR technology initiatives. The amounts and timing of these expenditures does not directly correlate with the timing of the Company’s receipt or recognition of EHR incentive payments as earned. The Company is nearing completion of its full implementation of certified EHR, and therefore, its EHR incentive payments are declining and will ultimately end. The Company recognized EHR incentives earned of $0.4 million and $1.8 million for the three months ended June 30, 2018 and 2017, respectively, and $0.6 million and $4.2 million for the six months ended June 30, 2018 and 2017, respectively, which are recorded as a reduction to operating expenses in the Company’s consolidated statements of income.
Legal, Professional and Settlement Costs (Policies)	Legal, Professional and Settlement Costs Legal, professional and settlement costs in the Company’s consolidated statements of income primarily include legal costs and related settlements, if any, associated with arbitration costs, regulatory claims, government investigations into reimbursement payments and other litigation matters. With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated amount of loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the amount of possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the amount of possible loss or range of loss. However, the Company is unable to estimate an amount of possible loss or range of loss in some instances based on the significant uncertainties involved in, or the preliminary nature of, certain legal, regulatory and governmental matters.
Loss (Gain) on Sale of Hospitals, Net (Policies)	Loss (Gain) on Sale of Hospitals, Net Loss (gain) on sale of hospitals, net relates to the Company’s divestiture of hospitals and outpatient facilities. It is calculated as the difference between the cash proceeds from the sale and the carrying values of the associated net assets sold at the date of sale, less certain incremental direct selling costs.
Loss on Closure of Hospitals, Net (Policies)	Loss on Closure of Hospitals, Net Loss on closure of hospitals, net relates to costs incurred by the Company for closure of hospitals and outpatient facilities, and includes severance, loss on disposal of property and equipment, write-down of assets, legal costs and other costs incurred by the Company during the closure.
Transaction Costs Related to the Spin-off (Policies)	Transaction Costs Related to the Spin-off Transaction costs related to the Spin-off consists of QHC’s portion of the costs to effect the Spin-off and the costs associated with forming a new company. These costs include audit, management advisory and consulting costs, investment advisory costs, legal expenses and other miscellaneous costs.
Income Taxes (Policies)	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the provision for (benefit from) income taxes in the consolidated statements of income in the period that includes the enactment date. The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income. To the extent the Company believes that recovery is not likely, a valuation allowance is established. To the extent the Company establishes a valuation allowance or increases this allowance, the related expense is included in the provision for (benefit from) income taxes in the consolidated statements of income. The Company classifies interest and penalties, if any, related to its tax positions as a component of provision for (benefit from) income taxes.
Cash and Cash Equivalents (Policies)	Cash and Cash Equivalents Cash includes cash on hand and cash with banks. Cash equivalents are short-term, highly liquid investments with a maturity of three months or less from the date acquired that are subject to an insignificant risk of change in value.
Restricted Cash (Policies)	Restricted Cash Restricted cash consists of cash included in escrow accounts that are utilized to secure the Company’s indemnification obligations under purchase agreements related to the sale of hospitals. The Company expects these obligations will be settled more than twelve months into the future. As a result, the Company’s restricted cash is recorded in other long-term assets in the consolidated balance sheet as of June 30, 2018.
Inventories (Policies)	Inventories Inventories, primarily consisting of medical supplies and drugs, are stated at the lower of cost or market on a first-in, first-out basis.
Other Current Assets (Policies)	Other Current Assets Other current assets consists of the current portion of the receivables from CHS related to professional and general liability and workers’ compensation liability insurance reserves that were indemnified by CHS in connection with the Spin-off, non-patient accounts receivable primarily related to QHR, receivables related to EHR incentives and other miscellaneous current assets.
Property and Equipment (Policies)	Property and Equipment Purchases of property and equipment are recorded at cost. Property and equipment acquired in a business combination are recorded at estimated fair value. Routine maintenance and repairs are expensed as incurred. Expenditures that increase capacities or extend useful lives are capitalized. The Company capitalizes interest related to financing of major capital additions with the respective asset. Depreciation is recognized using the straight-line method over the estimated useful life of an asset. The Company depreciates land improvements over 3 to 20 years, buildings and improvements over 5 to 40 years, and equipment and fixtures over 3 to 18 years. The Company also leases certain facilities and equipment under capital lease obligations. These assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the asset. Property and equipment assets that are held for sale are not depreciated.
Goodwill (Policies)	Goodwill The Company’s hospital operations and QHR’s hospital management advisory and consulting services operations meet the criteria to be classified as reporting units for goodwill. Goodwill was initially determined for QHC’s hospital operations reporting unit based on a relative fair value approach as of September 30, 2013 (CHS’ goodwill impairment testing date). Additional goodwill was allocated on a similar basis for four hospitals acquired by CHS in 2014 and included in the group of hospitals spun-off to QHC. For the QHR reporting unit, goodwill was allocated based on the amount recorded by CHS at the time of its acquisition in 2007. All subsequent goodwill generated from hospital, physician practice or other ancillary business acquisitions is recorded at fair value at the time of acquisition.
Intangible Assets (Policies)	Intangible Assets The Company’s intangible assets primarily consist of purchase and development costs of software for internal use and contract-based intangible assets, including physician guarantee contracts, medical licenses, hospital management contracts, non-compete agreements and certificates of need. There are no expected residual values related to the Company’s intangible assets. Capitalized software costs are generally amortized over three years, except for software costs for significant system conversions, which are amortized over 8 to 10 years. Capitalized software costs that are in the development stage are not amortized until the related projects are complete. Assets for physician guarantee contracts, hospital management contracts, non-compete agreements and certificates of need are amortized over the life of the individual contracts. Intangible assets held for sale are not amortized.
Impairment of Long-Lived Assets and Goodwill (Policies)	Impairment of Long-Lived Assets and Goodwill Whenever an event occurs or changes in circumstances indicate that the carrying values of certain long-lived assets may be impaired, the Company projects the undiscounted cash flows expected to be generated by these assets. If the projections indicate that the carrying values are not expected to be recovered, such amounts are reduced to their estimated fair value based on a quoted market price, if available, or an estimated fair value based on valuation techniques available in the circumstances. Goodwill arising from business combinations is not amortized. Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. The fair value of the related reporting units is estimated using both a discounted cash flow model as well as a multiple model based on earnings before interest, taxes, depreciation and amortization. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s best estimate of a market participant’s weighted-average cost of capital. Both models are based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions of the Company. See Note 3 —
Other Long-Term Assets (Policies)	Other Long-Term Assets Other long-term assets consists of the long-term portion of the receivables from CHS related to professional and general liability and workers’ compensation liability insurance reserves that were indemnified by CHS in connection with the Spin-off, as well as deferred compensation plan assets, deposits, investments in unconsolidated subsidiaries, restricted cash and other miscellaneous long-term assets.
Other Current Liabilities (Policies)	Other Current Liabilities Other current liabilities consists of the current portion of professional and general liability insurance reserves, including the portion indemnified by CHS in connection with the Spin-off, as well as property tax accruals, legal accruals, deferred revenue related to EHR incentives, physician guarantee liabilities and other miscellaneous current liabilities.
Professional and General Liability and Workers' Compensation Liability Insurance Reserves (Policies)	Professional and General Liability and Workers’ Compensation Liability Insurance Reserves As part of the business of owning and operating hospitals, the Company is subject to legal actions alleging liability on its part. To mitigate a portion of these risks, the Company maintains insurance exceeding a self-insured retention level for these types of claims. The Company’s self-insurance reserves reflect the current estimate of all outstanding losses, including incurred but not reported losses, based on actuarial calculations as of period end. The loss estimates included in the actuarial calculations may change in the future based on updated facts and circumstances. The Company’s insurance expense includes the actuarially determined estimates of losses for the current year, including claims incurred but not reported, the change in the estimates of losses for prior years based upon actual claims development experience as compared to prior actuarial projections, the insurance premiums for losses in excess of the Company’s self-insured retention levels, the administrative costs of the insurance programs, and interest expense related to the discounted portion of the liability. The Company’s reserves for professional and general liability and workers’ compensation liability claims are based on semi-annual actuarial calculations, which are discounted to present value and consider historical claims data, demographic factors, severity factors and other actuarial assumptions. The reserves for self-insured claims are discounted based on the Company’s risk-free interest rate that corresponds to the period when the self-insured claims are incurred and projected to be paid. See Note 17 — Commitments and Contingencies for information related to the portion of the Company’s insurance reserves for professional and general liability and workers’ compensation liability that are indemnified by CHS. Self-Insured Employee Health Benefits The Company is self-insured for substantially all of the medical benefits of its employees. The Company maintains a liability for its current estimate of incurred but not reported employee health claims based on historical claims data provided by third-party administrators. The undiscounted reserve for self-insured employee health benefits was $8.1 million and $8.8 million as of June 30, 2018 and December 31, 2017, respectively, and is included in accrued salaries and benefits in the consolidated balance sheets. Expense each period is based on the actual claims received during the period plus the impact of any adjustment to the liability for incurred but not reported employee health claims.
Noncontrolling Interests and Redeemable Noncontrolling Interests (Policies)	Noncontrolling Interests and Redeemable Noncontrolling Interests The Company’s consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned entities that it controls. Certain of the Company’s consolidated subsidiaries have noncontrolling physician ownership interests with redemption features that require the Company to deliver cash upon the occurrence of certain events outside of its control, such as the retirement, death, or disability of a physician-owner. The carrying amount of redeemable noncontrolling interests is recognized in the Company’s consolidated balance sheets at the greater of: (1) the initial carrying amount of these investments, increased or decreased for the noncontrolling interests' share of cumulative net income (loss), net of cumulative amounts distributed to the noncontrolling interest partners, if any, or (2) the redemption value of the investments held by the noncontrolling interest partners.
Assets and Liabilities of Hospitals Held for Sale (Policies)	Assets and Liabilities of Hospitals Held for Sale The Company reports separately from other assets in the consolidated balance sheet those assets that meet the criteria for classification as held for sale. Generally, assets that meet the criteria include those for which the carrying amount will be settled principally through a sale transaction rather than through continuing use. The asset must be available for immediate sale in its present condition, subject to usual or customary terms, and the sale must be probable to occur in the next 12 months. Similarly, the liabilities of a disposal group are classified as held for sale upon meeting these criteria. Immediately following classification as held for sale, the Company remeasures these assets and liabilities and adjusts the value to the lesser of the carrying amount or fair value less costs to sell. The assets and liabilities classified as held for sale are no longer depreciated or amortized into expense. The carrying value of assets classified as held for sale are reported net of impairment charges.
Stock-Based Compensation (Policies)	Stock-Based Compensation The Company issues restricted stock awards to key employees and directors under the Quorum Health Corporation 2016 Stock Award Plan (the “2016 Stock Award Plan”). The Company recognizes compensation expense over each of the restricted stock award’s requisite service periods based on the estimated grant date fair value of each restricted stock award. See Note 14 —
Benefit Plans (Policies)	Benefit Plans The Company maintains various benefit plans, including defined contribution plans, a defined benefit plan and a deferred compensation plan, for which certain of the Company’s subsidiaries are the plan sponsors. The rights and obligations of these plans were transferred from CHS to the Company, pursuant to the Separation and Distribution Agreement. Benefits costs are recorded as salaries and benefits in the consolidated statements of income. The cumulative liability for these benefit costs is recorded in other long-term liabilities in the consolidated balance sheets. The Company recognizes the unfunded liability of its defined benefit plan in other long-term liabilities in the consolidated balance sheets. Unrecognized gains (losses) and prior service credits (costs) are recorded as changes in other comprehensive income (loss). The measurement date of the plan’s assets and liabilities coincides with the Company’s year end. The Company’s pension benefit obligation is measured using actuarial calculations that incorporate discount rates, rate of compensation increases and expected long-term returns on plan assets. The calculations additionally consider expectations related to the retirement age and mortality of plan participants. The Company records pension benefit costs related to all of its plans as salaries and benefits expenses in the consolidated statements of income.
Fair Value of Financial Instruments (Policies)	Fair Value of Financial Instruments The Company utilizes the U.S. GAAP fair value hierarchy to measure the fair value of its financial instruments. The fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). The inputs used to measure fair value are classified into the following fair value hierarchy: • Level 1 • Level 2 • Level 3
Segment Reporting (Policies)	Segment Reporting The principal business of the Company is to provide healthcare services at its hospitals and affiliated outpatient facilities. The Company’s only other line of business is the hospital management advisory and consulting services it provides through QHR. The Company has determined that its hospital operations business and QHR’s business meet the criteria for separate segment reporting. The Company’s corporate functions are reported in the all other reportable segment. See Note 13 — Segments for additional information related to the Company’s segment reporting.
New Accounting Pronouncements (Policies)	New Accounting Pronouncements In February 2018, the FASB issued ASU 2018-02, which allows for reclassification from accumulated other comprehensive income to retained earnings of the stranded tax effects in accumulated other comprehensive income resulting from the enactment of the comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) and corresponding accounting treatment recorded in the fourth quarter of 2017. The ASU is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this ASU is permitted, including adoption in any interim period for reporting periods for which financial statements have not yet been issued. The Company does not anticipate that the adoption of this standard would have a significant impact on its consolidated balance sheet. In January 2017, the FASB issued ASU No. 2017-04, Intangibles — In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows — Restricted Cash, which addressed classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires a reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents; however, the nature of the restrictions should be disclosed. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. This ASU is to be applied using a retrospective transition method for each period presented. The Company adopted ASU 2016-18 on January 1, 2018 and concurrently revised its presentation of cash and cash equivalents on the consolidated statement of cash flows. For periods prior to January 1, 2018, the presentation of cash and cash equivalents on the consolidated statement of cash flows has been revised to conform to the current presentation. In February 2016, the FASB issued ASU No. 2016-02, Leases, which amends the accounting for leases and requires the rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. Under ASU 2016-02, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients In July 2018, the FASB issued ASU 2018-11 Leases (Topic 842) Targeted Improvements, which allows lessees and lessors to recognize and measure leases at the beginning of the period of adoption without modifying the comparative period financial statements. and the Company intends to use the retrospective method as of the period of adoption rather than the earliest period presented

Description of the Business a29

Description of the Business and Spin-Off (Tables)	6 Months Ended
	Jun. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Transactions to Effect the Spin-Off	The following table provides a summary of the major transactions to effect the Spin-off of QHC as a newly formed, independent company (dollars in thousands): Additional Long-Term Due to Common Stock Paid-in Parent's Debt Parent, Net Shares Amount Capital Equity Balance at April 29, 2016 (prior to the Spin-off) $ 24,179 $ 1,813,836 — $ — $ — $ 3,137 Borrowings of long-term debt, net of debt issuance discounts 1,255,464 — — — — — Payments of debt issuance costs (29,146 ) — — — — — Cash proceeds paid to Parent — (1,217,336 ) — — — — Transfer of liabilities from Parent — (22,292 ) — — — — Net deferred income tax liability resulting from the Spin-off — (46,783 ) — — — — Non-cash capital contribution from Parent — (527,425 ) — — 530,562 (3,137 ) Distribution of common stock — — 27,719,645 3 (3 ) — Distribution of restricted stock awards — — 692,409 — — — Balance at April 29, 2016 (after the Spin-off) $ 1,250,497 $ — 28,412,054 $ 3 $ 530,559 $ —

Basis of Presentation and Sig30

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Net Operating Revenues by Payor Source (Details)	The following table provides a summary of net operating revenues by payor source (dollars in thousands): Three Months Ended June 30, 2018 2017 $ Amount % of Total $ Amount % of Total Medicare $ 130,106 27.5 % $ 148,987 28.1 % Medicaid 87,141 18.4 % 104,854 19.8 % Managed care and commercial plans 189,726 40.3 % 203,087 38.3 % Self-pay and self-pay after insurance 42,288 8.9 % 49,269 9.3 % Non-patient 23,371 4.9 % 23,949 4.5 % Total net operating revenues $ 472,632 100.0 % $ 530,146 100.0 % Six Months Ended June 30, 2018 2017 $ Amount % of Total $ Amount % of Total Medicare $ 274,689 28.6 % $ 312,080 29.5 % Medicaid 172,244 18.0 % 199,817 18.9 % Managed care and commercial plans 374,952 39.0 % 398,683 37.6 % Self-pay and self-pay after insurance 91,972 9.6 % 97,911 9.3 % Non-patient 45,595 4.8 % 49,295 4.7 % Total net operating revenues $ 959,452 100.0 % $ 1,057,786 100.0 %
Summary of Components of Amounts Due from and Due to Third-Party Payors	The following table provides a summary of the components of amounts due from and due to third-party payors (in thousands): June 30, December 31, 2018 2017 Amounts due from third-party payors: Previous program reimbursements and final cost report settlements $ 18,958 $ 17,383 State supplemental payment programs 50,231 79,819 Total amounts due from third-party payors $ 69,189 $ 97,202 Amounts due to third-party payors: Previous program reimbursements and final cost report settlements $ 27,664 $ 33,163 State supplemental payment programs 13,006 14,542 Total amounts due to third-party payors $ 40,670 $ 47,705
Summary of Portion of Medicaid Reimbursements Included in Consolidated Statement of Income that are Attributable to State Supplemental Payment Programs	The following table provides a summary of the portion of Medicaid reimbursements included in the Company’s consolidated statements of income that are attributable to state supplemental payment programs (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Medicaid revenues $ 52,070 $ 46,381 $ 100,631 $ 91,678 Provider taxes and other expenses 17,051 17,230 36,195 34,123 Reimbursements attributable to state supplemental payment programs, net of expenses $ 35,019 $ 29,151 $ 64,436 $ 57,555
Summary of Changes in Allowance for Doubtful Accounts	The following table provides a summary of the changes in the allowance for doubtful accounts (in thousands): Six Months Ended June 30, 2018 Balance at beginning of period $ 352,509 Provision for bad debts — Impact of adoption of ASC 606 (352,509 ) Balance at end of period $ —
Summary of States in Which Company Generates More Than 5% of its Total Revenues	The following table provides a summary of the states in which the Company generates more than 5% of its total net patient revenues as determined in each period (dollars in thousands): Number of Six Months Ended June 30, Hospitals at 2018 2017 June 30, 2018 $ Amount % of Total $ Amount % of Total Illinois 8 $ 373,372 40.9 % $ 379,420 37.6 % Oregon 1 116,013 12.7 % 103,175 10.2 % California 2 89,972 9.8 % 74,675 7.4 % Kentucky 3 58,115 6.4 % 56,833 5.6 %
Summary of Major Components of Other Operating Expenses	The following table provides a summary of the major components of other operating expenses (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Purchased services $ 37,502 $ 43,843 $ 78,582 $ 89,439 Taxes and insurance 33,627 33,610 66,682 67,853 Medical specialist fees 26,433 28,888 53,381 57,351 Transition services agreements 14,066 15,986 29,183 32,268 Repairs and maintenance 9,060 9,759 18,697 21,202 Utilities 5,592 6,727 11,715 13,392 Other miscellaneous operating expenses 18,176 18,800 38,954 39,532 Total other operating expenses $ 144,456 $ 157,613 $ 297,194 $ 321,037
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the combined total as reported in the Company’s consolidated statements of cash flows (dollars in thousands): June 30, December 31, 2018 2017 Cash and cash equivalents $ 2,822 $ 5,617 Restricted cash included in other long-term assets 8,000 — Cash, cash equivalents and restricted cash $ 10,822 $ 5,617

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Summary of Components of Property and Equipment	The following table provides a summary of the components of property and equipment (in thousands): June 30, December 31, 2018 2017 Property and equipment, at cost: Land and improvements $ 62,658 $ 70,731 Building and improvements 736,887 790,619 Equipment and fixtures 515,485 529,150 Construction in progress 20,374 14,684 Total property and equipment, at cost 1,335,404 1,405,184 Less: Accumulated depreciation and amortization (730,623 ) (729,905 ) Total property and equipment, net $ 604,781 $ 675,279

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Changes in Goodwill	The following table provides a summary of changes in goodwill (in thousands): Six Months Ended June 30, 2018 Balance at beginning of period $ 409,229 Acquisitions 30 Divestitures (9,396 ) Reclasses from held for sale 1,593 Balance at end of period $ 401,456
Summary of the Components of Intangible Assets	The following table provides a summary of the components of intangible assets (in thousands): June 30, December 31, 2018 2017 Finite-lived intangible assets: Capitalized software costs: Cost $ 150,225 $ 159,449 Accumulated amortization (112,296 ) (111,661 ) Capitalized software costs, net 37,929 47,788 Physician guarantee contracts: Cost 6,536 7,489 Accumulated amortization (3,860 ) (4,290 ) Physician guarantee contracts, net 2,676 3,199 Other finite-lived intangible assets: Cost 43,262 43,376 Accumulated amortization (35,554 ) (34,668 ) Other finite-lived intangible assets, net 7,708 8,708 Total finite-lived intangible assets Cost 200,023 210,314 Accumulated amortization (151,710 ) (150,618 ) Total finite-lived intangible assets, net $ 48,313 $ 59,696 Indefinite-lived intangible assets: Tradenames $ 4,000 $ 4,000 Licenses and other indefinite-lived intangible assets 1,132 1,154 Total indefinite-lived intangible assets $ 5,132 $ 5,154 Total intangible assets: Cost $ 205,155 $ 215,468 Accumulated amortization (151,710 ) (150,618 ) Total intangible assets, net $ 53,445 $ 64,850
Summary of the Components of Amortization Expense	The following table provides a summary of the components of amortization expense (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Amortization of finite-lived intangible assets: Capitalized software costs $ 2,775 $ 3,796 $ 6,098 $ 8,539 Physician guarantee contracts 916 599 1,446 1,156 Other finite-lived intangible assets 507 556 1,014 1,126 Total amortization expense related to finite-lived intangible assets 4,198 4,951 8,558 10,821 Amortization of leasehold improvements and property and equipment assets held under capital lease obligations 783 882 1,676 1,338 Total amortization expense $ 4,981 $ 5,833 $ 10,234 $ 12,159

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Summary of Components of Long-Term Debt	The following table provides a summary of the components of long-term debt (in thousands): June 30, December 31, 2018 2017 Senior Credit Facility: Revolving Credit Facility, maturing 2021 $ — $ — Term Loan Facility, maturing 2022 800,696 831,158 ABL Credit Facility, maturing 2021 14,000 — Senior Notes, maturing 2023 400,000 400,000 Unamortized debt issuance costs and discounts (40,032 ) (42,934 ) Capital lease obligations 23,848 24,411 Other debt 900 1,255 Total debt 1,199,412 1,213,890 Less: Current maturities of long-term debt (1,733 ) (1,855 ) Total long-term debt $ 1,197,679 $ 1,212,035
Summary of Maximum Secured Net Leverage Ratio Permitted Under Credit Facility	After giving effect to the CS Amendment and the CS Second Amendment, the maximum Secured Net Leverage Ratio permitted under the CS Agreement, as determined based on 12 month trailing Consolidated EBITDA and as defined in the CS Agreement follows: Maximum Secured Net Period Leverage Ratio Period from January 1, 2017 to June 30, 2017 4.50 to 1.00 Period from July 1, 2017 to June 30, 2018 4.75 to 1.00 Period from July 1, 2018 to December 31, 2019 5.00 to 1.00 Period from January 1, 2020 and thereafter 4.50 to 1.00
Summary of Redemption Dates and Prices of Senior Notes	The following table provides a summary of the redemption dates and prices related to the Senior Notes: Redemption Period Prices Period from April 15, 2019 to April 14, 2020 108.719 % Period from April 15, 2020 to April 14, 2021 105.813 % Period from April 15, 2021 to April 14, 2022 102.906 % Period from April 15, 2022 to April 14, 2023 100.000 %
Summary of Unamortized Debt Issuance Costs and Discounts	The following table provides a summary of unamortized debt issuance costs and discounts (in thousands): June 30, December 31, 2018 2017 Debt issuance costs $ 34,533 $ 32,265 Debt discounts 24,536 24,536 Total debt issuance costs and discounts at origination 59,069 56,801 Less: Amortization of debt issuance costs and discounts (19,037 ) (13,867 ) Total unamortized debt issuance costs and discounts $ 40,032 $ 42,934
Summary of Debt Maturities for Next Five Years and Thereafter	The following table provides a summary of debt maturities for the next five years and thereafter (in thousands): June 30, 2018 Remainder of 2018 $ 1,038 2019 1,430 2020 1,488 2021 1,556 2022 802,092 Thereafter 431,840 Total debt, excluding unamortized debt issuance costs and discounts $ 1,239,444
Summary of Components of Interest Expense, Net	The following table provides a summary of the components of interest expense, net (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Senior Credit Facility: Revolving Credit Facility $ 64 $ 192 $ 142 $ 331 Term Loan Facility 17,653 16,642 35,053 31,283 ABL Credit Facility 511 613 839 869 Senior Notes 11,626 11,629 23,239 23,255 Amortization of debt issuance costs and discounts 3,064 2,224 5,170 4,204 All other interest expense (income), net (992 ) (842 ) (1,586 ) (1,954 ) Total interest expense, net from long-term debt $ 31,926 $ 30,458 $ 62,857 $ 57,988

Other Long-Term Assets and Ot34

Other Long-Term Assets and Other Long-Term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2018
Other Noncurrent Assets And Other Noncurrent Liabilities Disclosure [Abstract]
Summary of Major Components of Other Long-Term Assets	The following table provides a summary of the components of other long-term assets (in thousands): June 30, December 31, 2018 2017 Receivable for professional and general liability insurance reserves indemnified by CHS $ 35,128 $ 44,377 Receivable for workers' compensation liability insurance reserves indemnified by CHS 13,218 14,545 Assets of Nonqualified Deferred Compensation Plan 18,911 23,052 Restricted cash 8,000 — Other miscellaneous long-term assets 12,567 13,633 Total other long-term assets $ 87,824 $ 95,607
Summary of Components of Other Long-Term Liabilities	The following table provides a summary of the components of other long-term liabilities (in thousands): June 30, December 31, 2018 2017 Professional and general liability insurance reserves $ 77,735 $ 76,993 Workers' compensation liability insurance reserves 18,504 18,558 Benefit plan liabilities 28,878 36,103 Deferred rent 3,142 4,268 Other miscellaneous long-term liabilities 1,904 2,032 Total other long-term liabilities $ 130,163 $ 137,954

Fair Value of Financial Instr35

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Summary of Carrying Amounts and Estimated Fair Values of Long-Term Debt	The following table provides a summary of the carrying amounts and estimated fair values of the Company’s long-term debt (in thousands): June 30, 2018 December 31, 2017 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Revolving Credit Facility $ — $ — $ — $ — Term Loan Facility 800,696 815,213 831,158 838,954 ABL Credit Facility 14,000 14,000 — — Senior Notes 400,000 400,672 400,000 393,396 Other debt 24,748 24,748 25,666 25,666 Total debt, excluding unamortized debt issuance costs and discounts $ 1,239,444 $ 1,254,633 $ 1,256,824 $ 1,258,016

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Earnings (Loss) Per Share	The following table provides a summary of the computation of basic and diluted earnings (loss) per share (in thousands, except earnings per share and shares): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator: Net income (loss) $ (25,941 ) $ (30,575 ) $ (124,428 ) $ (57,780 ) Less: Net income (loss) attributable to noncontrolling interests 665 55 1,146 411 Net income (loss) attributable to Quorum Health Corporation $ (26,606 ) $ (30,630 ) $ (125,574 ) $ (58,191 ) Denominator: Weighted-average shares outstanding - basic and diluted 28,995,564 28,145,215 28,726,445 27,977,738 Earnings (loss) per share attributable to Quorum Health Corporation stockholders - basic and diluted $ (0.92 ) $ (1.09 ) $ (4.37 ) $ (2.08 )

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Summary of Financial Information Related to Segments	The following tables provide a summary of financial information related to the Company’s reportable segments (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Net operating revenues: Hospital operations $ 453,660 $ 509,118 $ 920,826 $ 1,015,536 QHR operations 18,620 20,315 38,208 40,891 All other 352 713 418 1,359 Total net operating revenues $ 472,632 $ 530,146 $ 959,452 $ 1,057,786 Adjusted EBITDA: Hospital operations $ 44,035 $ 41,536 $ 70,318 $ 79,002 QHR operations 4,451 6,316 8,803 10,457 All other (12,163 ) (13,422 ) (24,378 ) (28,887 ) Total Adjusted EBITDA $ 36,323 $ 34,430 $ 54,743 $ 60,572 June 30, December 31, 2018 2017 Assets: Hospital operations $ 1,527,514 $ 1,687,576 QHR operations 59,192 61,752 All other 77,877 79,513 Total assets $ 1,664,583 $ 1,828,841
Summary of Reconciliation of Adjusted EBITDA to Net Income (Loss)	The following table provides a reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable U.S. GAAP financial measure (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Adjusted EBITDA $ 36,323 $ 34,430 $ 54,743 $ 60,572 Interest expense, net (31,926 ) (30,458 ) (62,857 ) (57,988 ) (Provision for) benefit from income taxes 454 245 88 (456 ) Depreciation and amortization (17,142 ) (20,586 ) (35,403 ) (42,706 ) Legal, professional and settlement costs (5,417 ) (3,934 ) (8,830 ) (4,469 ) Impairment of long-lived assets and goodwill — (12,900 ) (39,760 ) (16,200 ) Loss (gain) on sale of hospitals, net (307 ) 4,321 (8,122 ) 5,191 Loss on closure of hospitals, net (3,338 ) — (17,084 ) — Transition of transition services agreements (520 ) — (1,237 ) — Transaction costs related to the Spin-off — — — (31 ) Post-spin headcount reductions and executive severance (4,068 ) (1,693 ) (5,966 ) (1,693 ) Net income (loss) $ (25,941 ) $ (30,575 ) $ (124,428 ) $ (57,780 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Summary of Stock-Based Compensation Expense	The following table provides a summary of stock-based compensation expense (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Stock-based compensation resulting from the Spin-off $ 2 $ 448 $ 372 $ 1,364 Stock-based compensation related to grants following the Spin-off 2,754 2,083 4,848 3,964 Total stock-based compensation expense $ 2,756 $ 2,531 $ 5,220 $ 5,328
QHC Awards Distributed in Spin-off [Member]
Summary of Activity Related to Unvested Restricted Stock Awards	The following table provides a summary of the activity related to unvested QHC restricted stock awards held by QHC and CHS employees during the six months ended June 30, 2018 that were distributed in the Spin-off (in shares): QHC Awards Distributed in Spin-off Unvested restricted stock awards at December 31, 2017 266,880 Vested (136,562 ) Forfeited (48,467 ) Unvested restricted stock awards at June 30, 2018 81,851
QHC Restricted Stock Awards Granted Following Spin-off [Member]
Summary of Activity Related to Unvested Restricted Stock Awards	The following table provides a summary of the activity related to unvested restricted stock awards during the six months ended June 30, 2018 that were granted to QHC employees subsequent to the Spin-off: QHC Awards Granted Subsequent to Spin-off Weighted- Average Grant Date Fair Value Shares Per Share Unvested restricted stock awards at December 31, 2017 1,779,488 $ 9.58 Granted 979,817 6.26 Vested (807,360 ) 9.95 Forfeited (328,047 ) 9.10 Unvested restricted stock awards at June 30, 2018 1,623,898 7.49

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Summary of Insurance Reserves Related to Professional and General Liability Claims and Workers' Compensation Claims	The following table provides a summary of the Company’s insurance reserves related to professional and general liability and workers’ compensation liability, distinguished between those indemnified by CHS and those related to the Company’s own risks (in thousands): June 30, 2018 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 21,605 $ 35,128 $ 21,605 $ 35,128 All other self-insurance reserves — — 3,483 42,607 Total insurance reserves for professional and general liability 21,605 35,128 25,088 77,735 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 2,562 13,218 2,562 13,218 All other self-insurance reserves — — 2,357 5,286 Total insurance reserves for workers' compensation liability 2,562 13,218 4,919 18,504 Total self-insurance reserves $ 24,167 $ 48,346 $ 30,007 $ 96,239 December 31, 2017 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 21,465 $ 44,377 $ 21,465 $ 44,377 All other self-insurance reserves — — 2,883 32,616 Total insurance reserves for professional and general liability 21,465 44,377 24,348 76,993 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 3,032 14,545 3,032 14,545 All other self-insurance reserves — — 3,120 4,013 Total insurance reserves for workers' compensation liability 3,032 14,545 6,152 18,558 Total self-insurance reserves $ 24,497 $ 58,922 $ 30,500 $ 95,551

Guarantor and Non-Guarantor S40

Guarantor and Non-Guarantor Supplemental Information (Tables)	6 Months Ended
	Jun. 30, 2018
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Schedule of Condensed Consolidating and Combining Statement of Income (Loss)	Condensed Consolidating Statement of Income (Loss) Three Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net operating revenues $ — $ 362,258 $ 110,374 $ — $ 472,632 Operating costs and expenses: Salaries and benefits — 160,448 72,183 — 232,631 Supplies — 36,841 16,056 — 52,897 Other operating expenses 27 116,930 27,499 — 144,456 Depreciation and amortization — 13,820 3,322 — 17,142 Rent — 6,567 4,791 — 11,358 Electronic health records incentives earned — (381 ) (64 ) — (445 ) Legal, professional and settlement costs — 5,417 — — 5,417 Impairment of long-lived assets and goodwill — — — — — Loss (gain) on sale of hospitals, net — 313 (6 ) — 307 Loss on closure of hospitals, net — 3,338 — — 3,338 Total operating costs and expenses 27 343,293 123,781 — 467,101 Income (loss) from operations (27 ) 18,965 (13,407 ) — 5,531 Interest expense, net 32,934 (1,026 ) 18 — 31,926 Equity in earnings of affiliates (5,934 ) (3,022 ) — 8,956 — Income (loss) before income taxes (27,027 ) 23,013 (13,425 ) (8,956 ) (26,395 ) Provision for (benefit from) income taxes (421 ) (84 ) 51 — (454 ) Net income (loss) (26,606 ) 23,097 (13,476 ) (8,956 ) (25,941 ) Less: Net income (loss) attributable to noncontrolling interests — — 665 — 665 Net income (loss) attributable to Quorum Health Corporation $ (26,606 ) $ 23,097 $ (14,141 ) $ (8,956 ) $ (26,606 ) Condensed Consolidating Statement of Income (Loss) Three Months Ended June 30, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues $ — $ 455,874 $ 129,341 $ — $ 585,215 Provision for bad debts — 48,050 7,019 — 55,069 Net operating revenues — 407,824 122,322 — 530,146 Operating costs and expenses: Salaries and benefits — 182,437 82,872 — 265,309 Supplies — 45,403 18,709 — 64,112 Other operating expenses 2,892 124,634 30,087 — 157,613 Depreciation and amortization — 17,591 2,995 — 20,586 Rent — 7,064 5,088 — 12,152 Electronic health records incentives earned — (1,981 ) 204 — (1,777 ) Legal, professional and settlement costs — 3,934 — — 3,934 Impairment of long-lived assets and goodwill — 12,900 — — 12,900 Loss (gain) on sale of hospitals, net — — (4,321 ) — (4,321 ) Total operating costs and expenses 2,892 391,982 135,634 — 530,508 Income (loss) from operations (2,892 ) 15,842 (13,312 ) — (362 ) Interest expense, net 31,349 (970 ) 79 — 30,458 Equity in earnings of affiliates (3,344 ) 2,554 — 790 — Income (loss) before income taxes (30,897 ) 14,258 (13,391 ) (790 ) (30,820 ) Provision for (benefit from) income taxes (267 ) (140 ) 162 — (245 ) Net income (loss) (30,630 ) 14,398 (13,553 ) (790 ) (30,575 ) Less: Net income (loss) attributable to noncontrolling interests — — 55 — 55 Net income (loss) attributable to Quorum Health Corporation $ (30,630 ) $ 14,398 $ (13,608 ) $ (790 ) $ (30,630 ) Condensed Consolidating Statement of Income (Loss) Six Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net operating revenues $ — $ 734,795 $ 224,657 $ — $ 959,452 Operating costs and expenses: Salaries and benefits — 330,181 149,450 — 479,631 Supplies — 79,441 32,342 — 111,783 Other operating expenses 1,897 239,096 56,201 — 297,194 Depreciation and amortization — 28,525 6,878 — 35,403 Rent — 13,884 10,006 — 23,890 Electronic health records incentives earned — (430 ) (156 ) — (586 ) Legal, professional and settlement costs — 8,830 — — 8,830 Impairment of long-lived assets and goodwill — 37,960 1,800 — 39,760 Loss (gain) on sale of hospitals, net — 8,128 (6 ) — 8,122 Loss on closure of hospitals, net — 17,084 — — 17,084 Total operating costs and expenses 1,897 762,699 256,515 — 1,021,111 Income (loss) from operations (1,897 ) (27,904 ) (31,858 ) — (61,659 ) Interest expense, net 64,408 (1,548 ) (3 ) — 62,857 Equity in earnings of affiliates 58,917 40,831 — (99,748 ) — Income (loss) before income taxes (125,222 ) (67,187 ) (31,855 ) 99,748 (124,516 ) Provision for (benefit from) income taxes 352 (420 ) (20 ) — (88 ) Net income (loss) (125,574 ) (66,767 ) (31,835 ) 99,748 (124,428 ) Less: Net income (loss) attributable to noncontrolling interests — — 1,146 — 1,146 Net income (loss) attributable to Quorum Health Corporation $ (125,574 ) $ (66,767 ) $ (32,981 ) $ 99,748 $ (125,574 ) Condensed Consolidating Statement of Income (Loss) Six Months Ended June 30, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues — 904,874 268,286 — $ 1,173,160 Provision for bad debts — 97,609 17,765 — 115,374 Net operating revenues — 807,265 250,521 — 1,057,786 Operating costs and expenses: Salaries and benefits — 363,459 166,452 — 529,911 Supplies — 91,276 36,658 — 127,934 Other operating expenses 2,892 253,944 64,201 — 321,037 Depreciation and amortization — 36,119 6,587 — 42,706 Rent — 14,162 10,092 — 24,254 Electronic health records incentives earned — (3,438 ) (791 ) — (4,229 ) Legal, professional and settlement costs — 4,469 — — 4,469 Impairment of long-lived assets and goodwill — 16,200 — — 16,200 Loss (gain) on sale of hospitals, net — — (5,191 ) — (5,191 ) Transaction costs related to the Spin-off — 23 8 — 31 Total operating costs and expenses 2,892 776,214 278,016 — 1,057,122 Income (loss) from operations (2,892 ) 31,051 (27,495 ) — 664 Interest expense, net 59,933 (2,026 ) 81 — 57,988 Equity in earnings of affiliates (5,091 ) 5,132 — (41 ) — Income (loss) before income taxes (57,734 ) 27,945 (27,576 ) 41 (57,324 ) Provision for (benefit from) income taxes 457 222 (223 ) — 456 Net income (loss) (58,191 ) 27,723 (27,353 ) 41 (57,780 ) Less: Net income (loss) attributable to noncontrolling interests — — 411 — 411 Net income (loss) attributable to Quorum Health Corporation $ (58,191 ) $ 27,723 $ (27,764 ) $ 41 $ (58,191 )
Schedule of Condensed Consolidating and Combining Statement of Comprehensive Income (Loss)	Condensed Consolidating Statement of Comprehensive Income (Loss) Three Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (26,606 ) $ 23,097 $ (13,476 ) $ (8,956 ) $ (25,941 ) Amortization and recognition of unrecognized pension cost components, net of income taxes (189 ) (189 ) — 189 (189 ) Comprehensive income (loss) (26,795 ) 22,908 (13,476 ) (8,767 ) (26,130 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 665 — 665 Comprehensive income (loss) attributable to Quorum Health Corporation $ (26,795 ) $ 22,908 $ (14,141 ) $ (8,767 ) $ (26,795 ) Condensed Consolidating Statement of Comprehensive Income (Loss) Three Months Ended June 30, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (30,630 ) $ 14,398 $ (13,553 ) $ (790 ) $ (30,575 ) Amortization and recognition of unrecognized pension cost components, net of income taxes 120 120 — (120 ) 120 Comprehensive income (loss) (30,510 ) 14,518 (13,553 ) (910 ) (30,455 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 55 — 55 Comprehensive income (loss) attributable to Quorum Health Corporation $ (30,510 ) $ 14,518 $ (13,608 ) $ (910 ) $ (30,510 ) Condensed Consolidating Statement of Comprehensive Income (Loss) Six Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (125,574 ) $ (66,767 ) $ (31,835 ) $ 99,748 $ (124,428 ) Amortization and recognition of unrecognized pension cost components, net of income taxes (75 ) (75 ) — 75 (75 ) Comprehensive income (loss) (125,649 ) (66,842 ) (31,835 ) 99,823 (124,503 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 1,146 — 1,146 Comprehensive income (loss) attributable to Quorum Health Corporation $ (125,649 ) $ (66,842 ) $ (32,981 ) $ 99,823 $ (125,649 ) Condensed Consolidating Statement of Comprehensive Income (Loss) Six Months Ended June 30, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (58,191 ) $ 27,723 $ (27,353 ) $ 41 $ (57,780 ) Amortization and recognition of unrecognized pension cost components, net of income taxes 242 242 — (242 ) 242 Comprehensive income (loss) (57,949 ) 27,965 (27,353 ) (201 ) (57,538 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 411 — 411 Comprehensive income (loss) attributable to Quorum Health Corporation $ (57,949 ) $ 27,965 $ (27,764 ) $ (201 ) $ (57,949 )
Schedule of Condensed Consolidating and Combining Balance Sheet	Condensed Consolidating Balance Sheet June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 1,455 $ 958 $ 409 $ — $ 2,822 Patient accounts receivable, net of allowance for doubtful accounts — 252,286 75,194 — 327,480 Inventories — 37,453 9,327 — 46,780 Prepaid expenses 83 19,972 5,309 — 25,364 Due from third-party payors — 59,286 9,903 — 69,189 Other current assets — 31,957 13,485 — 45,442 Total current assets 1,538 401,912 113,627 — 517,077 Intercompany receivable 3 540,784 259,905 (800,692 ) — Property and equipment, net — 468,084 136,697 — 604,781 Goodwill — 235,814 165,642 — 401,456 Intangible assets, net — 47,864 5,581 — 53,445 Other long-term assets — 61,079 26,745 — 87,824 Net investment in subsidiaries 1,431,461 — — (1,431,461 ) — Total assets $ 1,433,002 $ 1,755,537 $ 708,197 $ (2,232,153 ) $ 1,664,583 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ — $ 1,387 $ 346 $ — $ 1,733 Accounts payable 39 134,533 20,003 — 154,575 Accrued liabilities: Accrued salaries and benefits — 60,803 21,322 — 82,125 Accrued interest 10,221 — — — 10,221 Due to third-party payors — 34,200 6,470 — 40,670 Other current liabilities 222 31,370 14,320 — 45,912 Total current liabilities 10,482 262,293 62,461 — 335,236 Long-term debt 1,174,663 23,000 16 — 1,197,679 Intercompany payable 263,365 259,908 277,419 (800,692 ) — Deferred income tax liabilities, net 7,799 — — — 7,799 Other long-term liabilities — 226,605 32,667 (129,109 ) 130,163 Total liabilities 1,456,309 771,806 372,563 (929,801 ) 1,670,877 Redeemable noncontrolling interests — — 2,301 — 2,301 Equity: Quorum Health Corporation stockholders' equity (deficit): Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 552,511 1,186,270 573,212 (1,759,482 ) 552,511 Accumulated other comprehensive income (loss) (2,031 ) (2,031 ) — 2,031 (2,031 ) Accumulated deficit (573,790 ) (200,508 ) (254,591 ) 455,099 (573,790 ) Total Quorum Health Corporation stockholders' equity (deficit) (23,307 ) 983,731 318,621 (1,302,352 ) (23,307 ) Nonredeemable noncontrolling interests — — 14,712 — 14,712 Total equity (23,307 ) 983,731 333,333 (1,302,352 ) (8,595 ) Total liabilities and equity $ 1,433,002 $ 1,755,537 $ 708,197 $ (2,232,153 ) $ 1,664,583 Condensed Consolidating Balance Sheet December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 1,051 $ 4,222 $ 344 $ — $ 5,617 Patient accounts receivable, net of allowance for doubtful accounts — 262,690 80,455 — 343,145 Inventories — 43,276 10,183 — 53,459 Prepaid expenses 33 16,980 4,154 — 21,167 Due from third-party payors — 93,323 3,879 — 97,202 Current assets of hospitals held for sale — 8,112 — — 8,112 Other current assets — 32,867 14,573 — 47,440 Total current assets 1,084 461,470 113,588 — 576,142 Intercompany receivable 3 402,817 172,098 (574,918 ) — Property and equipment, net — 543,073 132,206 — 675,279 Goodwill — 243,618 165,611 — 409,229 Intangible assets, net — 58,240 6,610 — 64,850 Long-term assets of hospitals held for sale — 7,730 4 — 7,734 Other long-term assets — 74,918 20,689 — 95,607 Net investment in subsidiaries 1,488,021 — — (1,488,021 ) — Total assets $ 1,489,108 $ 1,791,866 $ 610,806 $ (2,062,939 ) $ 1,828,841 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ — $ 1,434 $ 421 $ — $ 1,855 Accounts payable 132 146,193 24,925 — 171,250 Accrued liabilities: Accrued salaries and benefits — 56,522 21,281 — 77,803 Accrued interest 10,466 — — — 10,466 Due to third-party payors — 46,381 1,324 — 47,705 Current liabilities of hospitals held for sale — 2,577 — — 2,577 Other current liabilities 516 30,664 12,507 — 43,687 Total current liabilities 11,114 283,771 60,458 — 355,343 Long-term debt 1,188,224 23,809 2 — 1,212,035 Intercompany payable 182,555 173,341 219,022 (574,918 ) — Deferred income tax liabilities, net 7,774 — — — 7,774 Other long-term liabilities — 195,132 31,100 (88,278 ) 137,954 Total liabilities 1,389,667 676,053 310,582 (663,196 ) 1,713,106 Redeemable noncontrolling interests — — 2,325 — 2,325 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 549,610 1,291,581 471,767 (1,763,348 ) 549,610 Accumulated other comprehensive income (loss) (1,956 ) (1,956 ) — 1,956 (1,956 ) Accumulated deficit (448,216 ) (173,812 ) (187,837 ) 361,649 (448,216 ) Total Quorum Health Corporation stockholders' equity 99,441 1,115,813 283,930 (1,399,743 ) 99,441 Nonredeemable noncontrolling interests — — 13,969 — 13,969 Total equity 99,441 1,115,813 297,899 (1,399,743 ) 113,410 Total liabilities and equity $ 1,489,108 $ 1,791,866 $ 610,806 $ (2,062,939 ) $ 1,828,841
Schedule of Condensed Consolidating and Combining Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Six Months Ended June 30, 2018 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (62,144 ) $ 75,865 $ 880 $ — $ 14,601 Cash flows from investing activities: Capital expenditures for property and equipment — (16,707 ) (8,612 ) — (25,319 ) Capital expenditures for software — (957 ) (87 ) — (1,044 ) Acquisitions, net of cash acquired — — (58 ) — (58 ) Proceeds from the sale of hospitals — 38,612 558 — 39,170 Other investing activities — 262 (13 ) — 249 Changes in intercompany balances with affiliates, net — (97,540 ) — 97,540 — Net cash provided by (used in) investing activities — (76,330 ) (8,212 ) 97,540 12,998 Cash flows from financing activities: Borrowings under of revolving credit facilities 247,000 — — — 247,000 Repayments under revolving credit facilities (233,000 ) — — — (233,000 ) Borrowings of long-term debt — 12 55 — 67 Repayments of long-term debt (30,463 ) (868 ) (116 ) — (31,447 ) Payments of debt issuance costs (2,268 ) — — — (2,268 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (1,943 ) — — (1,943 ) Cash distributions to noncontrolling investors — — (803 ) — (803 ) Changes in intercompany balances with affiliates, net 81,279 — 16,261 (97,540 ) — Net cash provided by (used in) financing activities 62,548 (2,799 ) 15,397 (97,540 ) (22,394 ) Net change in cash, cash equivalents and restricted cash 404 (3,264 ) 8,065 — 5,205 Cash, cash equivalents and restricted cash at beginning of period 1,051 4,222 344 — 5,617 Cash, cash equivalents and restricted cash at end of period $ 1,455 $ 958 $ 8,409 $ — $ 10,822 Condensed Consolidating Statement of Cash Flows Six Months Ended June 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (68,468 ) $ 52,472 $ 7,041 $ — $ (8,955 ) Cash flows from investing activities: Capital expenditures for property and equipment — (13,390 ) (25,752 ) — (39,142 ) Capital expenditures for software — (2,670 ) (499 ) — (3,169 ) Acquisitions, net of cash acquired — (20 ) (1,867 ) — (1,887 ) Proceeds from sale of hospitals — — 20,156 — 20,156 Changes in intercompany balances with affiliates, net — (30,637 ) — 30,637 — Net cash provided by (used in) investing activities — (46,717 ) (7,962 ) 30,637 (24,042 ) Cash flows from financing activities: Borrowings under revolving credit facilities 302,000 — — — 302,000 Repayments under revolving credit facilities (252,000 ) — — — (252,000 ) Borrowings of long-term debt — 72 — — 72 Repayments of long-term debt (10,832 ) (835 ) (180 ) — (11,847 ) Payments of debt issuance costs (2,938 ) — — — (2,938 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (1,489 ) — — (1,489 ) Cash distributions to noncontrolling investors — — (3,851 ) — (3,851 ) Changes in intercompany balances with affiliates, net 25,659 — 4,978 (30,637 ) — Net cash provided by (used in) financing activities 61,889 (2,252 ) 947 (30,637 ) 29,947 Net change in cash and cash equivalents (6,579 ) 3,503 26 — (3,050 ) Cash and cash equivalents at beginning of period 21,609 3,498 348 — 25,455 Cash and cash equivalents at end of period $ 15,030 $ 7,001 $ 374 $ — $ 22,405

Description of the Business a41

Description of the Business and Spin-Off (Narrative) (Details)	Apr. 29, 2016USD ($)Hospital$ / sharesshares	Apr. 22, 2016USD ($)	Jun. 30, 2018USD ($)Hospitalbedstate$ / shares	Mar. 14, 2018USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)$ / shares
Description Of Business And Spin Off [Line Items]
Number of hospitals owned or leased | Hospital			28
Number of licensed beds | bed			2,649
Number of States in which Entity Operates | state			14
Common stock, par value | $ / shares			$ 0.0001			$ 0.0001
Cash proceeds paid to Parent	$ 1,217,336,000
Debt Instrument, Unamortized Discount			$ 24,536,000			$ 24,536,000
Senior Notes, maturing 2023 [Member]
Description Of Business And Spin Off [Line Items]
Debt Instrument, Face Amount		$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage		11.625%
Debt Instrument, Unamortized Discount		$ 6,900,000
Debt instrument issue discount percentage		1.734%
ABL Credit Facility, maturing 2021 [Member]
Description Of Business And Spin Off [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	125,000,000		$ 111,000,000
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Description Of Business And Spin Off [Line Items]
Debt Instrument, Face Amount	880,000,000
Debt Instrument, Unamortized Discount	$ 17,600,000
Term Facility Issued Percentage on Par Value	98.00%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Description Of Business And Spin Off [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000,000			$ 62,500,000	$ 75,000,000	$ 87,500,000
Spin-off from CHS [Member]
Description Of Business And Spin Off [Line Items]
Number of hospitals owned or leased | Hospital	38
Percentage ownership of number of stock shares held by the parent	100.00%
Common stock, par value | $ / shares	$ 0.0001
Record date for stockholders of the parent to be eligible to receive share distribution in spin-off	Apr. 22, 2016
Number of shares distributed to each stockholder in spin-off | shares	1
Number of shares held by each stockholder of the parent used to determine share distribution in spin-off | shares	4
Contributed capital, in excess of par value of common stock	$ 530,600,000
Cash contribution from parent	13,500,000
Cash contribution from parent for initial working capital	20,000,000
Differences in estimated and actual financing transaction fees for the Spin-off	$ 6,500,000
Sales Revenue, Segment [Member] | Segment Concentration Risk [Member] | Hospital Operations Reporting Unit [Member]
Description Of Business And Spin Off [Line Items]
Concentration risk, percentage			95.00%

Description of the Business a42

Description of the Business and Spin-Off - Summary of Transactions to Effect the Spin-Off (Details) - USD ($) $ in Thousands	Apr. 29, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Description Of Business And Spin Off [Line Items]
Long-Term Debt, balance at April 29, 2016 (prior to the spin-off)	$ 24,179			$ 1,212,035
Borrowings of long-term debt, net of debt issuance discounts	1,255,464
Payments of debt issuance costs	(29,146)	$ 0	$ (2,891)	(2,268)	$ (2,938)
Long-Term Debt, balance at April 29, 2016 (after the spin-off)	1,250,497	1,197,679		1,197,679
Due to Parent, Net, balance at April 29, 2016 (prior to the spin-off)	1,813,836
Cash proceeds paid to Parent	(1,217,336)
Transfer of liabilities from Parent	(22,292)
Net deferred income tax liability resulting from the Spin-off	(46,783)
Non-cash capital contribution from Parent	(527,425)
Due to Parent, Net, balance at April 29, 2016 (after the spin-off)	0
Stockholders' equity, beginning balance				$ 113,410	215,569
Stockholders' equity, beginning balance, shares				30,294,895
Stockholders' equity, ending balance		$ (8,595)	159,212	$ (8,595)	159,212
Stockholders' equity, ending balance, shares		30,898,710		30,898,710
Common Stock [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	$ 0			$ 3	$ 3
Stockholders' equity, beginning balance, shares	0			30,294,895	29,482,050
Distribution of common stock	$ 3
Distribution of common stock, shares	27,719,645
Distribution of restricted stock awards	$ 0
Distribution of restricted stock awards, shares	692,409
Stockholders' equity, ending balance	$ 3	$ 3	$ 3	$ 3	$ 3
Stockholders' equity, ending balance, shares	28,412,054		30,297,524		30,297,524
Additional Paid-In Capital [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	$ 0			549,610	$ 537,911
Non-cash capital contribution from Parent	530,562
Distribution of common stock	(3)
Stockholders' equity, ending balance	530,559	$ 552,511	$ 541,774	$ 552,511	$ 541,774
Parent [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	3,137
Non-cash capital contribution from Parent	(3,137)
Stockholders' equity, ending balance	$ 0

Basis of Presentation and Sig43

Basis of Presentation and Significant Accounting Policies (Summary of Net Operating Revenues by Payor Source) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Net operating revenues	$ 472,632	$ 530,146	$ 959,452	$ 1,057,786
Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	100.00%	100.00%	100.00%	100.00%
Medicare [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Net operating revenues	$ 130,106	$ 148,987	$ 274,689	$ 312,080
Medicare [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	27.50%	28.10%	28.60%	29.50%
Medicaid [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Net operating revenues	$ 87,141	$ 104,854	$ 172,244	$ 199,817
Medicaid [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	18.40%	19.80%	18.00%	18.90%
Managed Care and Commercial Plans [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Net operating revenues	$ 189,726	$ 203,087	$ 374,952	$ 398,683
Managed Care and Commercial Plans [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	40.30%	38.30%	39.00%	37.60%
Self-Pay and Self-Pay After Insurance [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Net operating revenues	$ 42,288	$ 49,269	$ 91,972	$ 97,911
Self-Pay and Self-Pay After Insurance [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	8.90%	9.30%	9.60%	9.30%
Non-Patient [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Net operating revenues	$ 23,371	$ 23,949	$ 45,595	$ 49,295
Non-Patient [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	4.90%	4.50%	4.80%	4.70%

Basis of Presentation and Sig44

Basis of Presentation and Significant Accounting Policies (Narrative) (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2014Hospital
Basis Of Presentation And Significant Accounting Policies [Line Items]
Net operating revenues	$ 472,632,000	$ 530,146,000	$ 959,452,000	$ 1,057,786,000
Increase (decrease) in net operating revenues during period for transaction price adjustments related to estimated cost report settlements	(400,000)	1,400,000	100,000
Operating revenues		585,215,000		1,173,160,000
Provider taxes	33,627,000	33,610,000	66,682,000	67,853,000
Accounts receivable, net of contractual adjustments	327,480,000		327,480,000		$ 343,145,000
Due from third-party payors	69,189,000		69,189,000		97,202,000
General and administrative costs	20,000,000	14,500,000	34,900,000	30,100,000
Severance costs	4,068,000	1,693,000	5,966,000	1,693,000
Electronic health records incentives earned	400,000	1,800,000	600,000	4,200,000
Acquired finite-lived intangible asset, residual value	0		$ 0
New date of annual goodwill impairment test			The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year.
Noncontrolling interests and redeemable noncontrolling interests			The Company’s consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned entities that it controls.
Maximum period during which assets held for sale sold			12 months
Accrued Salaries and Benefits [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Undiscounted reserve for self-insured employee health benefits	8,100,000		$ 8,100,000		8,800,000
Capitalized Internal Use Software, Except Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life			3 years
Community Health Systems, Inc [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of Hospitals | Hospital						4
General and Administrative Costs [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Severance costs	2,700,000	600,000	$ 4,600,000	600,000
Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Net operating revenues			373,372,000	379,420,000
California [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Net operating revenues			$ 89,972,000	74,675,000
Maximum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Increase (decrease) in net operating revenues during period for transaction price adjustments related to estimated cost report settlements				(100,000)
Maximum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life			10 years
Maximum [Member] | Land Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			20 years
Maximum [Member] | Buildings and Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			40 years
Maximum [Member] | Equipment and Fixtures [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			18 years
Minimum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Purchase agreements indemnification obligations settlement term			12 months
Minimum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life			8 years
Minimum [Member] | Land Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			3 years
Minimum [Member] | Buildings and Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			5 years
Minimum [Member] | Equipment and Fixtures [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			3 years
Medicare Advantage Program Revenues [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Net operating revenues	30,000,000	41,500,000	$ 71,400,000	86,400,000
California Hospital Quality Assurance Fee [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues	7,900,000	0	15,800,000	0
Provider taxes	2,100,000	0	4,200,000	0
Charity Care [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues	6,000,000	7,500,000	19,300,000	20,000,000
Medicare [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Net operating revenues	130,106,000	148,987,000	274,689,000	312,080,000
Accounts receivable, net of contractual adjustments	60,900,000		$ 60,900,000		$ 66,600,000
Medicare [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			18.60%		18.20%
Medicaid [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Net operating revenues	87,141,000	$ 104,854,000	$ 172,244,000	$ 199,817,000
Medicaid [Member] | Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Accounts receivable, net of contractual adjustments	21,700,000		21,700,000		$ 28,800,000
Due from third-party payors	7,500,000		7,500,000		22,900,000
Medicaid [Member] | California [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Due from third-party payors	$ 30,800,000		$ 30,800,000		$ 48,400,000
Medicaid [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member] | Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			6.60%		7.90%
Medicaid [Member] | Supplemental Program Receivables [Member] | Credit Concentration Risk [Member] | Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			10.90%		23.50%
Medicaid [Member] | Supplemental Program Receivables [Member] | Credit Concentration Risk [Member] | California [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			44.50%		49.80%

Basis of Presentation and Sig45

Basis of Presentation and Significant Accounting Policies (Summary of Components of Amounts Due from and Due to Third-Party Payors) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	$ 69,189	$ 97,202
Due to third-party payors	40,670	47,705
Previous Program Reimbursements and Final Cost Report Settlements [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	18,958	17,383
Due to third-party payors	27,664	33,163
State Supplemental Payment Programs [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	50,231	79,819
Due to third-party payors	$ 13,006	$ 14,542

Basis of Presentation and Sig46

Basis of Presentation and Significant Accounting Policies (Summary of Portion of Medicaid Reimbursements Included in Consolidated Statement of Income that are Attributable to State Supplemental Payment Programs) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Medicaid revenues		$ 585,215		$ 1,173,160
Provider taxes and other expenses	$ 33,627	33,610	$ 66,682	67,853
State Supplemental Payment Programs [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Medicaid revenues	52,070	46,381	100,631	91,678
Provider taxes and other expenses	17,051	17,230	36,195	34,123
Reimbursements attributable to state supplemental payment programs, net of expenses	$ 35,019	$ 29,151	$ 64,436	$ 57,555

Basis of Presentation and Sig47

Basis of Presentation and Significant Accounting Policies (Summary of Changes in Allowance for Doubtful Accounts) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Accounts Notes And Loans Receivable [Line Items]
Balance at beginning of period	$ 352,509
Provision for bad debts	0
Balance at end of period	0
Accounting Standard Update 2014-09 [Member] | Impact of Adoption of ASC 606 [Member]
Accounts Notes And Loans Receivable [Line Items]
Impact of adoption of ASC 606	$ (352,509)

Basis of Presentation and Sig48

Basis of Presentation and Significant Accounting Policies (Summary of States in Which Company Generates More Than 5% of its Total Revenues) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018USD ($)Hospital	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)Hospital	Jun. 30, 2017USD ($)
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	28		28
Total net operating revenues, Amount | $	$ 472,632	$ 530,146	$ 959,452	$ 1,057,786
Illinois [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	8		8
Total net operating revenues, Amount | $			$ 373,372	$ 379,420
Illinois [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			40.90%	37.60%
Oregon [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	1		1
Total net operating revenues, Amount | $			$ 116,013	$ 103,175
Oregon [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			12.70%	10.20%
California [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	2		2
Total net operating revenues, Amount | $			$ 89,972	$ 74,675
California [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			9.80%	7.40%
Kentucky [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	3		3
Total net operating revenues, Amount | $			$ 58,115	$ 56,833
Kentucky [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			6.40%	5.60%

Basis of Presentation and Sig49

Basis of Presentation and Significant Accounting Policies (Summary of Major Components of Other Operating Expenses) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Other Operating Expenses [Line Items]
Taxes and insurance	$ 33,627	$ 33,610	$ 66,682	$ 67,853
Transition services agreements	14,066	15,986	29,183	32,268
Repairs and maintenance	9,060	9,759	18,697	21,202
Utilities	5,592	6,727	11,715	13,392
Other miscellaneous operating expenses	18,176	18,800	38,954	39,532
Total other operating expenses	144,456	157,613	297,194	321,037
Purchased Services [Member]
Other Operating Expenses [Line Items]
Professional fees	37,502	43,843	78,582	89,439
Medical Specialist Fees [Member]
Other Operating Expenses [Line Items]
Professional fees	$ 26,433	$ 28,888	$ 53,381	$ 57,351

Basis of Presentation and Sig50

Basis of Presentation and Significant Accounting Policies (Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016
Cash And Cash Equivalents [Abstract]
Cash and cash equivalents	$ 2,822		$ 5,617
Restricted cash included in other long-term assets	8,000
Cash, cash equivalents and restricted cash	$ 10,822	$ 40,491	$ 5,617	$ 22,405	$ 89,542	$ 25,455

Impairment of Long-Lived Asse51

Impairment of Long-Lived Assets and Goodwill (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets and goodwill	$ 0		$ 12,900		$ 39,760	$ 16,200
Hospitals Intended for Divestiture [Member]
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets and goodwill		$ 39,800
Impairment of long-lived assets		34,700
Impairment of capitalized software costs		$ 5,100
Hospitals Held for Sale [Member]
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets and goodwill				$ 3,300
Impairment of long-lived assets			$ 12,900	1,100
Impairment of capitalized software costs				800
Goodwill impairment charge				$ 1,400

Divestitures (Narrative) (Detai

Divestitures (Narrative) (Details) $ in Thousands	Mar. 31, 2018USD ($)bed	Mar. 01, 2018USD ($)bed	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2018USD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Proceeds from sale of hospitals			$ 507	$ 15,874	$ 39,170	$ 20,156
Loss (gain) on sale of hospitals, net			307	(4,321)	8,122	(5,191)
Write-off of allocated goodwill					9,396
Severance and salary continuation costs			4,068	1,693	5,966	1,693
Clearview Regional Medical Center [Member] | Georgia [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Disposal date	Mar. 31, 2018
Number of beds in hospital sold | bed	77
Proceeds from sale of hospitals	$ 37,400
Escrow for litigation liability	$ 8,000
Pre-tax losses from disposal of discontinued operation			400	1,400	3,600	1,600
Loss (gain) on sale of hospitals, net					7,900
Write-off of allocated goodwill					9,400
Vista Medical Center West [Member] | Waukegan, Illinois [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Disposal date		Mar. 1, 2018
Number of beds in hospital sold | bed		70
Proceeds from sale of hospitals		$ 1,200
Pre-tax losses from disposal of discontinued operation			900	1,300	800	1,300
Loss (gain) on sale of hospitals, net					200
Affinity [Member] | Ohio [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Pre-tax losses from discontinued operation			$ 4,700	$ 1,900	24,400	$ 6,100
Affinity closure costs					17,100
Severance and salary continuation costs					8,000
Losses associated with disposal of assets					5,000
Other costs and fees related to termination of contracts and other miscellaneous items					$ 4,100
Affinity [Member] | Ohio [Member] | Facility Closing [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Health records maintenance obligation term from year two onwards					19 years
Annual cost related to closure beyond the current fiscal year					$ 300
Affinity [Member] | Ohio [Member] | Facility Closing [Member] | Minimum [Member] | Scenario, Forecast [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Future costs associated with closure of affinity							$ 500
Affinity [Member] | Ohio [Member] | Facility Closing [Member] | Maximum [Member] | Scenario, Forecast [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Future costs associated with closure of affinity							$ 1,000

Property and Equipment (Summary

Property and Equipment (Summary of Components of Property and Equipment) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	$ 1,335,404	$ 1,405,184
Less: Accumulated depreciation and amortization	(730,623)	(729,905)
Total property and equipment, net	604,781	675,279
Land and Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	62,658	70,731
Buildings and Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	736,887	790,619
Equipment and Fixtures [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	515,485	529,150
Construction in progress [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	$ 20,374	$ 14,684

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Depreciation expense	$ 12.2	$ 14.8	$ 25.2	$ 30.5
Assets held under capital lease obligations, at cost	29.2		29.2		$ 29.2
Assets held under capital lease obligations, net of accumulated amortization	$ 24.6		24.6		25.6
Purchases of property and equipment accrued in accounts payable			$ 4.7		$ 6.8

Goodwill and Intangible Asset55

Goodwill and Intangible Assets (Summary of Changes in Goodwill) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, beginning balance	$ 409,229
Acquisitions	30
Divestitures	(9,396)
Reclasses from held for sale	1,593
Goodwill, ending balance	$ 401,456

Goodwill and Intangible Asset56

Goodwill and Intangible Assets (Goodwill Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Goodwill [Line Items]
Goodwill	$ 401,456	$ 409,229
Hospital Operations Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	368,100	375,900
Hospital Management Advisory and Consulting Services Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	$ 33,300	$ 33,300

Goodwill and Intangible Asset57

Goodwill and Intangible Assets (Summary of the Components of Intangible Assets ) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	$ 200,023	$ 210,314
Accumulated amortization	(151,710)	(150,618)
Total finite-lived intangible assets, net	48,313	59,696
Total indefinite-lived intangible assets	5,132	5,154
Total intangible assets, gross	205,155	215,468
Total intangible assets, net	53,445	64,850
Trade Names [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	4,000	4,000
Licenses And Other Indefinite-Lived Intangible Assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	1,132	1,154
Capitalized Software Costs [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	150,225	159,449
Accumulated amortization	(112,296)	(111,661)
Total finite-lived intangible assets, net	37,929	47,788
Physician Income Guarantee Contracts [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	6,536	7,489
Accumulated amortization	(3,860)	(4,290)
Total finite-lived intangible assets, net	2,676	3,199
Other Finite-Lived Intangible Assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	43,262	43,376
Accumulated amortization	(35,554)	(34,668)
Total finite-lived intangible assets, net	$ 7,708	$ 8,708

Goodwill and Intangible Asset58

Goodwill and Intangible Assets (Intangible Assets Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 200,023	$ 210,314
Capitalized Software Costs in Development Stage [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 900

Goodwill and Intangible Asset59

Goodwill and Intangible Assets (Summary of the Components of Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	$ 4,198	$ 4,951	$ 8,558	$ 10,821
Amortization of leasehold improvements and property and equipment assets held under capital lease obligations	783	882	1,676	1,338
Total amortization expense	4,981	5,833	10,234	12,159
Capitalized Software Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	2,775	3,796	6,098	8,539
Physician Income Guarantee Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	916	599	1,446	1,156
Other Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	$ 507	$ 556	$ 1,014	$ 1,126

Goodwill and Intangible Asset60

Goodwill and Intangible Assets (Amortization Expense Narrative) (Details)	6 Months Ended
	Jun. 30, 2018
Intangible Assets Except Software Costs and Physician Income Guarantee Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, weighted-average useful life	4 years 3 months 18 days

Long-Term Debt (Summary of Comp

Long-Term Debt (Summary of Components of Long-Term Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Apr. 29, 2016	Apr. 27, 2016
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	$ 1,239,444	$ 1,256,824
Unamortized debt issuance costs and discounts	(40,032)	(42,934)
Capital lease obligations	23,848	24,411
Other debt	900	1,255
Total debt	1,199,412	1,213,890
Less: Current maturities of long-term debt	(1,733)	(1,855)
Long-term debt	1,197,679	1,212,035	$ 1,250,497	$ 24,179
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	400,000	400,000
ABL Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	14,000	0
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	0	0
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	$ 800,696	$ 831,158

Long-Term Debt (Senior Credit F

Long-Term Debt (Senior Credit Facility Narrative) (Details) - USD ($)	Apr. 29, 2016	Jun. 30, 2018	Mar. 14, 2018	Jan. 01, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount		$ 24,536,000			$ 24,536,000
Secured net leverage ratio after December 31, 2018		335.00%
Leverage ratio to incur permitted additional debt description		Through December 31, 2018, the Company is allowed to incur Permitted Additional Debt, as defined in the CS Agreement, only if the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 4.50 to 1.00. After December 31, 2018, the Company may incur Permitted Additional Debt so long as the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 5.50 to 1.00.
Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio through December 31, 2018		335.00%
Leverage ratio to incur permitted additional debt through December 31, 2018		450.00%
Leverage ratio to incur permitted additional debt after December 31, 2018		550.00%
Minimum [Member]
Debt Instrument [Line Items]
Incremental term loan commitments		$ 100,000,000
Senior Credit Facility [Member]
Debt Instrument [Line Items]
Secured net leverage ratio		417.00%
Line of credit, additional borrowing capacity		$ 116,900,000
Secured net leverage ratio to exercise incremental term loan commitments description		Through December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments, as defined in the CS Agreement, only if the Secured Net Leverage Ratio, adjusted for the requested Incremental Term Loan borrowing, is below 3.35 to 1.00. After December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments for the greater of $100 million or an amount which would produce a Secured Net Leverage Ratio of 3.35 to 1.00.
Letters of credit outstanding		$ 13,100,000
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 880,000,000
Debt Instrument, Unamortized Discount	$ 17,600,000
Term Facility Issued Percentage on Par Value	98.00%
Debt Instrument, Maturity Date		Apr. 29, 2022
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		9.18%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	5.75%
Derivative, Floor Interest Rate	1.00%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Agreement [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	4.75%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		6.75%
Derivative, Floor Interest Rate		1.00%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Amendment [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		5.75%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000,000		$ 62,500,000	$ 75,000,000	$ 87,500,000
Debt Instrument, Maturity Date		Apr. 29, 2021
Line of credit, outstanding balance		$ 0
Line of credit, borrowing capacity		$ 49,400,000
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member] | CS Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.75%
Derivative, Floor Interest Rate		0.00%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member] | CS Amendment [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.75%

Long-Term Debt (Maximum Secured

Long-Term Debt (Maximum Secured Net Leverage Ratio Permitted) (Details) - Senior Credit Facility [Member]	Jun. 30, 2018
Debt Instrument [Line Items]
Secured net leverage ratio	417.00%
Period from January 1, 2017 to June 30, 2017 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	450.00%
Period from July 1, 2017 to December 31, 2018 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	475.00%
Period from July 1, 2018 to December 31, 2019 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	500.00%
Period from January 1, 2020 and thereafter [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	400.00%

Long-Term Debt (ABL Credit Faci

Long-Term Debt (ABL Credit Facility Narrative) (Details) - ABL Credit Facility, maturing 2021 [Member] - USD ($)	Apr. 29, 2016	Jun. 30, 2018
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 125,000,000	$ 111,000,000
Line of credit, outstanding balance		14,000,000
Line of Credit Facility, Maturity Date	Apr. 29, 2021
Covenant Trigger Event, minimum required excess availability amount		$ 12,500,000
Covenant Trigger Event, minimum required excess availability as percentage of aggregate commitments		10.00%
Minimum Consolidated Fixed Charge Ratio required to be maintained if covenant trigger event occurs		110.00%
Cash Dominion Trigger Event, minimum required excess availability as percentage of aggregate commitments		12.50%
Cash Dominion Trigger Event, minimum required excess availability amount		$ 15,000,000
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	0.00%
London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.75%
Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.25%

Long-Term Debt (Senior Notes Na

Long-Term Debt (Senior Notes Narrative) (Details) - USD ($)	May 17, 2017	Apr. 22, 2016	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount			$ 24,536,000	$ 24,536,000
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage		11.625%
Debt Instrument, Unamortized Discount		$ 6,900,000
Debt instrument issue discount percentage		1.734%
Debt Instrument, Maturity Date		Apr. 15, 2023
Debt Instrument, Payment Terms			Payable semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2016.
Debt Instrument, Frequency of Periodic Payment			semi-annually
Debt Instrument, Date of First Required Payment		Oct. 15, 2016
Debt Instrument, Interest Rate, Effective Percentage			12.49%
Debt Instrument, Redemption Price Percentage		100.00%
Senior Notes, maturing 2023 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price Percentage		35.00%
Debt Instrument, Redemption Notice Period			60 days
Senior Notes, maturing 2023 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Notice Period			30 days
Senior Notes, maturing 2023 [Member] | Initial Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage	11.625%
Debt instrument due date	2,023
Senior Notes, maturing 2023 [Member] | Exchange Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	11.625%
Debt instrument due date	2,023

Long-Term Debt (Summary of Rede

Long-Term Debt (Summary of Redemption Dates and Prices of Senior Notes) (Details) - Senior Notes, maturing 2023 [Member]	Apr. 22, 2016	Jun. 30, 2018
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage	100.00%
Period from April 15, 2019 to April 14, 2020 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		108.719%
Period from April 15, 2020 to April 14, 2021 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		105.813%
Period from April 15, 2021 to April 14, 2022 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		102.906%
Period from April 15, 2022 to April 14, 2023 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		100.00%

Long-Term Debt (Summary of Re67

Long-Term Debt (Summary of Redemption Dates and Prices of Senior Notes) (Parenthetical) (Details) - Senior Notes, maturing 2023 [Member]	6 Months Ended
	Jun. 30, 2018
Period from April 15, 2019 to April 14, 2020 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2019
Debt Instrument, Redemption Period, End Date	Apr. 14, 2020
Period from April 15, 2020 to April 14, 2021 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2020
Debt Instrument, Redemption Period, End Date	Apr. 14, 2021
Period from April 15, 2021 to April 14, 2022 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2021
Debt Instrument, Redemption Period, End Date	Apr. 14, 2022
Period from April 15, 2022 to April 14, 2023 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2022
Debt Instrument, Redemption Period, End Date	Apr. 14, 2023

Long-Term Debt (Summary of Unam

Long-Term Debt (Summary of Unamortized Debt Issuance Costs and Discounts) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt issuance costs	$ 34,533	$ 32,265
Debt discounts	24,536	24,536
Total debt issuance costs and discounts at origination	59,069	56,801
Less: Amortization of debt issuance costs and discounts	(19,037)	(13,867)
Total unamortized debt issuance costs and discounts	$ 40,032	$ 42,934

Long-Term Debt (Capital Lease O

Long-Term Debt (Capital Lease Obligations and Other Debt Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Capital lease obligations	$ 23,848	$ 24,411
New Corporate Office [Member] | Brentwood, Tennessee [Member]
Debt Instrument [Line Items]
Capital lease obligations	$ 17,600	$ 17,900

Long-Term Debt (Summary of Debt

Long-Term Debt (Summary of Debt Maturities for Next Five Years and Thereafter) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Remainder of 2018	$ 1,038
2,019	1,430
2,020	1,488
2,021	1,556
2,022	802,092
Thereafter	431,840
Total debt, excluding unamortized debt issuance costs and discounts	$ 1,239,444	$ 1,256,824

Long-Term Debt (Summary of Co71

Long-Term Debt (Summary of Components of Interest Expense, Net) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Debt Instrument [Line Items]
Amortization of debt issuance costs and discounts	$ 3,064	$ 2,224	$ 5,170	$ 4,204
All other interest expense (income), net	(992)	(842)	(1,586)	(1,954)
Total interest expense, net	31,926	30,458	62,857	57,988
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Interest expense	11,626	11,629	23,239	23,255
ABL Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Interest expense	511	613	839	869
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Interest expense	64	192	142	331
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Interest expense	17,653	16,642	35,053	31,283
Interest Expense Portion From Long Term Debt [Member]
Debt Instrument [Line Items]
Total interest expense, net	$ 31,926	$ 30,458	$ 62,857	$ 57,988

Other Long-Term Assets and Ot72

Other Long-Term Assets and Other Long-Term Liabilities (Summary of Major Components of Other Long-Term Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Other Assets Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term receivable	$ 35,128	$ 44,377
Insurance reserve for workers' compensation liability, long-term receivable	13,218	14,545
Restricted cash	8,000
Other miscellaneous long-term assets	12,567	13,633
Total other long-term assets	87,824	95,607
Nonqualified Plan [Member]
Other Assets Noncurrent [Line Items]
Assets of Nonqualified Deferred Compensation Plan	18,911	23,052
Insurance Reserves Indemnified By CHS [Member]
Other Assets Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term receivable	35,128	44,377
Insurance reserve for workers' compensation liability, long-term receivable	$ 13,218	$ 14,545

Other Long-Term Assets and Ot73

Other Long-Term Assets and Other Long-Term Liabilities (Summary of Components of Other Long-Term Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Other Liabilities Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term liability	$ 77,735	$ 76,993
Insurance reserve for workers' compensation liability, long-term liability	18,504	18,558
Benefit plan liabilities	28,878	36,103
Deferred rent	3,142	4,268
Other miscellaneous long-term liabilities	1,904	2,032
Total other long-term liabilities	130,163	137,954
Professional and General Liability Insurance [Member]
Other Liabilities Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term liability	$ 77,735	$ 76,993

Fair Value of Financial Instr74

Fair Value of Financial Instruments (Summary of Carrying Amounts and Estimated Fair Values of Long-Term Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	$ 1,239,444	$ 1,256,824
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	1,254,633	1,258,016
ABL Credit Facility, maturing 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	14,000	0
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	14,000	0
Senior Notes, maturing 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	400,000	400,000
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	400,672	393,396
Other debt [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	24,748	25,666
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	24,748	25,666
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	0	0
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	0	0
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	800,696	831,158
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	$ 815,213	$ 838,954

Equity (Narrative) (Details)

Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Apr. 29, 2016USD ($)vote / shares$ / sharesshares
Class Of Stock [Line Items]
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, par value | $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	30,898,710	30,294,895
Common stock, shares outstanding	30,898,710	30,294,895
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001
Contributed capital, in excess of par value of common stock | $	$ 552,511	$ 549,610
Spin-off from CHS [Member]
Class Of Stock [Line Items]
Preferred stock, shares authorized			100,000,000
Preferred stock, par value | $ / shares			$ 0.0001
Common stock, shares authorized			300,000,000
Common stock, shares issued			28,412,054
Common stock, par value | $ / shares			$ 0.0001
Common stock voting description	Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters for which stockholders may vote. Holders of the Company’s common stock will not have cumulative voting rights in the election of directors.
Number of vote | vote / shares			1
Contributed capital, in excess of par value of common stock | $			$ 530,600

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income tax rate, percent				21.00%		35.00%
Tax Cuts and Jobs Act of 2017, incomplete accounting, provisional income tax benefit		$ 24,000,000
Effective income tax rate, continuing operations	1.70%		0.80%	0.10%	(0.80%)
Deferred income tax liabilities, net	$ 7,799,000	$ 7,774,000		$ 7,799,000		$ 7,774,000
Unrecognized tax benefit	$ 0		$ 0	$ 0	$ 0

Earnings Per Share (Summary of

Earnings Per Share (Summary of Computation of Basic and Diluted Earnings (Loss) Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator:
Net income (loss)	$ (25,941)	$ (30,575)	$ (124,428)	$ (57,780)
Less: Net income (loss) attributable to noncontrolling interests	665	55	1,146	411
Net income (loss) attributable to Quorum Health Corporation	$ (26,606)	$ (30,630)	$ (125,574)	$ (58,191)
Denominator:
Weighted-average shares outstanding - basic and diluted	28,995,564	28,145,215	28,726,445	27,977,738
Earnings (loss) per share attributable to Quorum Health Corporation stockholders - basic and diluted	$ (0.92)	$ (1.09)	$ (4.37)	$ (2.08)

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Dilutive Shares	0	0	0	0

Segments (Narrative) (Details)

Segments (Narrative) (Details)	6 Months Ended
	Jun. 30, 2018segment
Segment Reporting [Abstract]
Number of operating segments	2

Segments (Summary of Financial

Segments (Summary of Financial Information Related to the Company`s Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net operating revenues	$ 472,632	$ 530,146	$ 959,452	$ 1,057,786
Total adjusted EBITDA	36,323	34,430	54,743	60,572
Total assets	1,664,583		1,664,583		$ 1,828,841
Hospital Operations Reporting Unit [Member]
Segment Reporting Information [Line Items]
Net operating revenues	453,660	509,118	920,826	1,015,536
Total adjusted EBITDA	44,035	41,536	70,318	79,002
Total assets	1,527,514		1,527,514		1,687,576
Quorum Health Resources [Member]
Segment Reporting Information [Line Items]
Net operating revenues	18,620	20,315	38,208	40,891
Total adjusted EBITDA	4,451	6,316	8,803	10,457
Total assets	59,192		59,192		61,752
All Other Operations [Member]
Segment Reporting Information [Line Items]
Net operating revenues	352	713	418	1,359
Total adjusted EBITDA	(12,163)	$ (13,422)	(24,378)	$ (28,887)
Total assets	$ 77,877		$ 77,877		$ 79,513

Segments (Summary of Reconcilia

Segments (Summary of Reconciliation of Adjusted EBITDA to Net Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Segment Reporting [Abstract]
Total adjusted EBITDA	$ 36,323	$ 34,430	$ 54,743	$ 60,572
Interest expense, net	(31,926)	(30,458)	(62,857)	(57,988)
(Provision for) benefit from income taxes	454	245	88	(456)
Depreciation and amortization	(17,142)	(20,586)	(35,403)	(42,706)
Legal, professional and settlement costs	(5,417)	(3,934)	(8,830)	(4,469)
Impairment of long-lived assets and goodwill	0	(12,900)	(39,760)	(16,200)
Loss (gain) on sale of hospitals, net	(307)	4,321	(8,122)	5,191
Loss on closure of hospitals, net	(3,338)	0	(17,084)	0
Transition of transition services agreements	(520)	0	(1,237)	0
Transaction costs related to the Spin-off	0	0	0	(31)
Post-spin headcount reductions and executive severance	(4,068)	(1,693)	(5,966)	(1,693)
Net income (loss)	$ (25,941)	$ (30,575)	$ (124,428)	$ (57,780)

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2018	Apr. 29, 2016
Restricted Stock [Member] | Performance-Based Vesting [Member] | Executive Officers [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted	225,000
Share-based compensation, vesting description	the restrictions on the restricted stock awards will lapse on the second anniversary of the grant date.
Restricted Stock [Member] | Time Based Vesting Lapse in Equal Installments on Each of First Three Anniversaries [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted	635,000
Share-based compensation, vesting period	3 years
Restricted Stock [Member] | Time Based Vesting Lapse in Equal Installments on Second and Third Anniversaries [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation, vesting description	lapse in equal installments on each of the first three anniversaries of the grant date.
Restricted Stock [Member] | Time-Based Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation, vesting description	lapse on the first anniversary of the grant date.
Restricted Stock [Member] | Time-Based Vesting [Member] | Non-Employee Director, Individual [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted	123,780
QHC and CHS Restricted Stock Awards Held By QHC Employees as of Spin-off Date [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense	$ 9.6
2016 Stock Award Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock that may be issued under stock award plan		4,700,000

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Activity Related to Unvested Restricted Stock Awards) (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
QHC Awards Distributed in Spin-off [Member] | QHC Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	266,880
Vested, Shares	(136,562)
Forfeited, Shares	(48,467)
Unvested restricted stock awards at end of period, Shares	81,851
QHC Restricted Stock Awards Granted Following Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	1,779,488
Granted, Shares	979,817
Vested, Shares	(807,360)
Forfeited, Shares	(328,047)
Unvested restricted stock awards at end of period, Shares	1,623,898
Unvested restricted stock awards at beginning of period, Weighted Average Grant Date Fair Value Per Share | $ / shares	$ 9.58
Granted, Weighted Average Grant Date Fair Value Per Share | $ / shares	6.26
Vested, Weighted Average Grant Date Fair Value Per Share | $ / shares	9.95
Forfeited, Weighted Average Grant Date Fair Value Per Share | $ / shares	9.10
Unvested restricted stock awards at end of period, Weighted Average Grant Date Fair Value Per Share | $ / shares	$ 7.49

Stock-Based Compensation (Sum84

Stock-Based Compensation (Summary of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,756	$ 2,531	$ 5,220	$ 5,328
Resulting from Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	2	448	372	1,364
Related to Grants Following Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,754	$ 2,083	$ 4,848	$ 3,964

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details)	Sep. 16, 2016Installmentshares	Aug. 18, 2016	Apr. 29, 2016USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)Hospital	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, total expense				$ 4,200,000	$ 4,000,000	$ 4,300,000	$ 6,900,000
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan net periodic benefit cost				100,000	100,000	$ 100,000	200,000
Number of Hospitals | Hospital						1
Accrued benefit liability				800,000		$ 800,000		$ 800,000
Original SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefit liability			$ 6,000,000
Defined benefit plan, assets transferred			$ 0
Amended and Restated SERP Plan [Member] | Salaries and Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan net periodic benefit cost				100,000	$ 500,000	500,000	$ 1,000,000
Maximum [Member] | Director's Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of annual installments | Installment	15
Common stock shares available for issue | shares	150,000
Other long-term liabilities [Member] | Amended and Restated SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefit liability				5,500,000		5,500,000		8,700,000
Accrued Salaries and Benefits [Member] | Amended and Restated SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Current portion of benefit liability				3,800,000		3,800,000		0
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Percentage of incentive compensation participants are permitted to defer		100.00%
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Other long-term liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefit liability				20,100,000		20,100,000		24,300,000
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Other long-term Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term portion of benefit Asset				$ 18,900,000		$ 18,900,000		$ 23,100,000

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - Community Health Systems, Inc [Member] - Transition Services Agreements [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Related Party Transaction [Line Items]
Terms of transitional service agreements			5 years
Screening service agreement effective date			Jun. 24, 2018
Total expenses incurred	$ 14.1	$ 16	$ 29.2	$ 32.3

Commitments and Contingencies87

Commitments and Contingencies (Narrative) (Details) $ in Millions	Aug. 04, 2017USD ($)Agreement	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)
McKenzie – Willamette Medical Center Project [Member] | Asset Under Construction [Member] | Construction and Capital Commitments [Member]
Other Commitments [Line Items]
Property and equipment, at cost		$ 4.6	$ 12.8	$ 10.8	$ 24.5
Construction costs incurred during the period				93.7
Project placed into service				79
Total estimated costs of project, including equipment costs		105		$ 105
Expected project to be completed period				Late 2,018
Professional and General Liability Insurance [Member]
Other Commitments [Line Items]
Self-insured retention level		5		$ 5
Professional and General Liability Insurance [Member] | Quorum Health Resources [Member]
Other Commitments [Line Items]
Self-insured retention level		6		6
Worker's Compensation Liability [Member]
Other Commitments [Line Items]
Self-insured retention level		$ 0.5		$ 0.5
Arbitration with Community Health Systems, Inc. [Member]
Other Commitments [Line Items]
Number of transition services agreements | Agreement	2
Payment related to transaction service agreements sought	$ 12.5

Commitments and Contingencies -

Commitments and Contingencies - (Summary of Insurance Reserves Related to Professional and General Liability and Workers Compensation Liability) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	$ 21,605	$ 21,465
Insurance reserve for workers' compensation liability, current receivable	2,562	3,032
Total self-insurance reserves, current receivable	24,167	24,497
Insurance reserves for professional and general liability, long-term receivable	35,128	44,377
Insurance reserve for workers' compensation liability, long-term receivable	13,218	14,545
Total self-insurance reserves, long-term receivable	48,346	58,922
Insurance reserves for professional and general liability, current liability	25,088	24,348
Insurance reserve for workers' compensation liability, current liability	4,919	6,152
Total self-insurance reserves, current liability	30,007	30,500
Insurance reserves for professional and general liability, long-term liability	77,735	76,993
Insurance reserve for workers' compensation liability, long-term liability	18,504	18,558
Total self-insurance reserves, long-term liability	96,239	95,551
Insurance Reserves Indemnified By CHS, Inc. [Member]
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	21,605	21,465
Insurance reserve for workers' compensation liability, current receivable	2,562	3,032
Insurance reserves for professional and general liability, long-term receivable	35,128	44,377
Insurance reserve for workers' compensation liability, long-term receivable	13,218	14,545
Insurance reserves for professional and general liability, current liability	21,605	21,465
Insurance reserve for workers' compensation liability, current liability	2,562	3,032
Insurance reserves for professional and general liability, long-term liability	35,128	44,377
Insurance reserve for workers' compensation liability, long-term liability	13,218	14,545
All Other Self-insurance Reserves [Member]
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	0	0
Insurance reserve for workers' compensation liability, current receivable	0	0
Insurance reserves for professional and general liability, long-term receivable	0	0
Insurance reserve for workers' compensation liability, long-term receivable	0	0
Insurance reserves for professional and general liability, current liability	3,483	2,883
Insurance reserve for workers' compensation liability, current liability	2,357	3,120
Insurance reserves for professional and general liability, long-term liability	42,607	32,616
Insurance reserve for workers' compensation liability, long-term liability	$ 5,286	$ 4,013

Guarantor and Non-Guarantor S89

Guarantor and Non-Guarantor Supplemental Information (Narrative) (Details)	6 Months Ended
	Jun. 30, 2018
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Percentage of owned domestic subsidiaries which guaranteed senior notes	100.00%

Guarantor and Non-Guarantor S90

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating Statement of Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Condensed Income Statements Captions [Line Items]
Operating revenues		$ 585,215		$ 1,173,160
Provision for bad debts		55,069		115,374
Net operating revenues	$ 472,632	530,146	$ 959,452	1,057,786
Operating costs and expenses:
Salaries and benefits	232,631	265,309	479,631	529,911
Supplies	52,897	64,112	111,783	127,934
Other operating expenses	144,456	157,613	297,194	321,037
Depreciation and amortization	17,142	20,586	35,403	42,706
Rent	11,358	12,152	23,890	24,254
Electronic health records incentives earned	(445)	(1,777)	(586)	(4,229)
Legal, professional and settlement costs	5,417	3,934	8,830	4,469
Impairment of long-lived assets and goodwill	0	12,900	39,760	16,200
Loss (gain) on sale of hospitals, net	307	(4,321)	8,122	(5,191)
Loss on closure of hospitals, net	3,338	0	17,084	0
Transaction costs related to the Spin-off	0	0	0	31
Total operating costs and expenses	467,101	530,508	1,021,111	1,057,122
Income (loss) from operations	5,531	(362)	(61,659)	664
Interest expense, net	31,926	30,458	62,857	57,988
Equity in earnings of affiliates	0	0	0	0
Income (loss) before income taxes	(26,395)	(30,820)	(124,516)	(57,324)
Provision for (benefit from) income taxes	(454)	(245)	(88)	456
Net income (loss)	(25,941)	(30,575)	(124,428)	(57,780)
Less: Net income (loss) attributable to noncontrolling interests	665	55	1,146	411
Net income (loss) attributable to Quorum Health Corporation	(26,606)	(30,630)	(125,574)	(58,191)
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues		0		0
Provision for bad debts		0		0
Net operating revenues	0	0	0	0
Operating costs and expenses:
Salaries and benefits	0	0	0	0
Supplies	0	0	0	0
Other operating expenses	27	2,892	1,897	2,892
Depreciation and amortization	0	0	0	0
Rent	0	0	0	0
Electronic health records incentives earned	0	0	0	0
Legal, professional and settlement costs	0	0	0	0
Impairment of long-lived assets and goodwill	0	0	0	0
Loss (gain) on sale of hospitals, net	0	0	0	0
Loss on closure of hospitals, net	0		0
Transaction costs related to the Spin-off				0
Total operating costs and expenses	27	2,892	1,897	2,892
Income (loss) from operations	(27)	(2,892)	(1,897)	(2,892)
Interest expense, net	32,934	31,349	64,408	59,933
Equity in earnings of affiliates	(5,934)	(3,344)	58,917	(5,091)
Income (loss) before income taxes	(27,027)	(30,897)	(125,222)	(57,734)
Provision for (benefit from) income taxes	(421)	(267)	352	457
Net income (loss)	(26,606)	(30,630)	(125,574)	(58,191)
Less: Net income (loss) attributable to noncontrolling interests	0	0	0	0
Net income (loss) attributable to Quorum Health Corporation	(26,606)	(30,630)	(125,574)	(58,191)
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues		455,874		904,874
Provision for bad debts		48,050		97,609
Net operating revenues	362,258	407,824	734,795	807,265
Operating costs and expenses:
Salaries and benefits	160,448	182,437	330,181	363,459
Supplies	36,841	45,403	79,441	91,276
Other operating expenses	116,930	124,634	239,096	253,944
Depreciation and amortization	13,820	17,591	28,525	36,119
Rent	6,567	7,064	13,884	14,162
Electronic health records incentives earned	(381)	(1,981)	(430)	(3,438)
Legal, professional and settlement costs	5,417	3,934	8,830	4,469
Impairment of long-lived assets and goodwill	0	12,900	37,960	16,200
Loss (gain) on sale of hospitals, net	313	0	8,128	0
Loss on closure of hospitals, net	3,338		17,084
Transaction costs related to the Spin-off				23
Total operating costs and expenses	343,293	391,982	762,699	776,214
Income (loss) from operations	18,965	15,842	(27,904)	31,051
Interest expense, net	(1,026)	(970)	(1,548)	(2,026)
Equity in earnings of affiliates	(3,022)	2,554	40,831	5,132
Income (loss) before income taxes	23,013	14,258	(67,187)	27,945
Provision for (benefit from) income taxes	(84)	(140)	(420)	222
Net income (loss)	23,097	14,398	(66,767)	27,723
Less: Net income (loss) attributable to noncontrolling interests	0	0	0	0
Net income (loss) attributable to Quorum Health Corporation	23,097	14,398	(66,767)	27,723
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues		129,341		268,286
Provision for bad debts		7,019		17,765
Net operating revenues	110,374	122,322	224,657	250,521
Operating costs and expenses:
Salaries and benefits	72,183	82,872	149,450	166,452
Supplies	16,056	18,709	32,342	36,658
Other operating expenses	27,499	30,087	56,201	64,201
Depreciation and amortization	3,322	2,995	6,878	6,587
Rent	4,791	5,088	10,006	10,092
Electronic health records incentives earned	(64)	204	(156)	(791)
Legal, professional and settlement costs	0	0	0	0
Impairment of long-lived assets and goodwill	0	0	1,800	0
Loss (gain) on sale of hospitals, net	(6)	(4,321)	(6)	(5,191)
Loss on closure of hospitals, net	0		0
Transaction costs related to the Spin-off				8
Total operating costs and expenses	123,781	135,634	256,515	278,016
Income (loss) from operations	(13,407)	(13,312)	(31,858)	(27,495)
Interest expense, net	18	79	(3)	81
Equity in earnings of affiliates	0	0	0	0
Income (loss) before income taxes	(13,425)	(13,391)	(31,855)	(27,576)
Provision for (benefit from) income taxes	51	162	(20)	(223)
Net income (loss)	(13,476)	(13,553)	(31,835)	(27,353)
Less: Net income (loss) attributable to noncontrolling interests	665	55	1,146	411
Net income (loss) attributable to Quorum Health Corporation	(14,141)	(13,608)	(32,981)	(27,764)
Eliminations [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues		0		0
Provision for bad debts		0		0
Net operating revenues	0	0	0	0
Operating costs and expenses:
Salaries and benefits	0	0	0	0
Supplies	0	0	0	0
Other operating expenses	0	0	0	0
Depreciation and amortization	0	0	0	0
Rent	0	0	0	0
Electronic health records incentives earned	0	0	0	0
Legal, professional and settlement costs	0	0	0	0
Impairment of long-lived assets and goodwill	0	0	0	0
Loss (gain) on sale of hospitals, net	0	0	0	0
Loss on closure of hospitals, net	0		0
Transaction costs related to the Spin-off				0
Total operating costs and expenses	0	0	0	0
Income (loss) from operations	0	0	0	0
Interest expense, net	0	0	0	0
Equity in earnings of affiliates	8,956	790	(99,748)	(41)
Income (loss) before income taxes	(8,956)	(790)	99,748	41
Provision for (benefit from) income taxes	0	0	0	0
Net income (loss)	(8,956)	(790)	99,748	41
Less: Net income (loss) attributable to noncontrolling interests	0	0	0	0
Net income (loss) attributable to Quorum Health Corporation	$ (8,956)	$ (790)	$ 99,748	$ 41

Guarantor and Non-Guarantor S91

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	$ (25,941)	$ (30,575)	$ (124,428)	$ (57,780)
Amortization and recognition of unrecognized pension cost components, net of income taxes	(189)	120	(75)	242
Comprehensive income (loss)	(26,130)	(30,455)	(124,503)	(57,538)
Less: Comprehensive income (loss) attributable to noncontrolling interests	665	55	1,146	411
Comprehensive income (loss) attributable to Quorum Health Corporation	(26,795)	(30,510)	(125,649)	(57,949)
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	(26,606)	(30,630)	(125,574)	(58,191)
Amortization and recognition of unrecognized pension cost components, net of income taxes	(189)	120	(75)	242
Comprehensive income (loss)	(26,795)	(30,510)	(125,649)	(57,949)
Less: Comprehensive income (loss) attributable to noncontrolling interests	0	0	0	0
Comprehensive income (loss) attributable to Quorum Health Corporation	(26,795)	(30,510)	(125,649)	(57,949)
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	23,097	14,398	(66,767)	27,723
Amortization and recognition of unrecognized pension cost components, net of income taxes	(189)	120	(75)	242
Comprehensive income (loss)	22,908	14,518	(66,842)	27,965
Less: Comprehensive income (loss) attributable to noncontrolling interests	0	0	0	0
Comprehensive income (loss) attributable to Quorum Health Corporation	22,908	14,518	(66,842)	27,965
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	(13,476)	(13,553)	(31,835)	(27,353)
Amortization and recognition of unrecognized pension cost components, net of income taxes	0	0	0	0
Comprehensive income (loss)	(13,476)	(13,553)	(31,835)	(27,353)
Less: Comprehensive income (loss) attributable to noncontrolling interests	665	55	1,146	411
Comprehensive income (loss) attributable to Quorum Health Corporation	(14,141)	(13,608)	(32,981)	(27,764)
Eliminations [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	(8,956)	(790)	99,748	41
Amortization and recognition of unrecognized pension cost components, net of income taxes	189	(120)	75	(242)
Comprehensive income (loss)	(8,767)	(910)	99,823	(201)
Less: Comprehensive income (loss) attributable to noncontrolling interests	0	0	0	0
Comprehensive income (loss) attributable to Quorum Health Corporation	$ (8,767)	$ (910)	$ 99,823	$ (201)

Guarantor and Non-Guarantor S92

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Balance Sheet) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Apr. 29, 2016	Apr. 27, 2016
Current assets:
Cash and cash equivalents	$ 2,822	$ 5,617
Patient accounts receivable, net of allowance for doubtful accounts	327,480	343,145
Inventories	46,780	53,459
Prepaid expenses	25,364	21,167
Due from third-party payors	69,189	97,202
Current assets of hospitals held for sale	0	8,112
Other current assets	45,442	47,440
Total current assets	517,077	576,142
Intercompany receivable	0	0
Property and equipment, net	604,781	675,279
Goodwill	401,456	409,229
Intangible assets, net	53,445	64,850
Long-term assets of hospitals held for sale	0	7,734
Other long-term assets	87,824	95,607
Net investment in subsidiaries	0	0
Total assets	1,664,583	1,828,841
Current liabilities:
Current maturities of long-term debt	1,733	1,855
Accounts payable	154,575	171,250
Accrued liabilities:
Accrued salaries and benefits	82,125	77,803
Accrued interest	10,221	10,466
Due to third-party payors	40,670	47,705
Current liabilities of hospitals held for sale	0	2,577
Other current liabilities	45,912	43,687
Total current liabilities	335,236	355,343
Long-term debt	1,197,679	1,212,035			$ 1,250,497	$ 24,179
Intercompany payable	0	0
Deferred income tax liabilities, net	7,799	7,774
Other long-term liabilities	130,163	137,954
Total liabilities	1,670,877	1,713,106
Redeemable noncontrolling interests	2,301	2,325	$ 5,614	$ 6,807
Quorum Health Corporation stockholders' equity (deficit):
Preferred stock	0	0
Common stock	3	3
Additional paid-in capital	552,511	549,610
Accumulated other comprehensive income (loss)	(2,031)	(1,956)
Accumulated deficit	(573,790)	(448,216)
Total Quorum Health Corporation stockholders' equity (deficit)	(23,307)	99,441
Nonredeemable noncontrolling interests	14,712	13,969
Total equity (deficit)	(8,595)	113,410	$ 159,212	$ 215,569
Total liabilities and equity	1,664,583	1,828,841
Reportable Legal Entities [Member] | Parent Issuer [Member]
Current assets:
Cash and cash equivalents	1,455	1,051
Patient accounts receivable, net of allowance for doubtful accounts	0	0
Inventories	0	0
Prepaid expenses	83	33
Due from third-party payors	0	0
Current assets of hospitals held for sale		0
Other current assets	0	0
Total current assets	1,538	1,084
Intercompany receivable	3	3
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long-term assets of hospitals held for sale		0
Other long-term assets	0	0
Net investment in subsidiaries	1,431,461	1,488,021
Total assets	1,433,002	1,489,108
Current liabilities:
Current maturities of long-term debt	0	0
Accounts payable	39	132
Accrued liabilities:
Accrued salaries and benefits	0	0
Accrued interest	10,221	10,466
Due to third-party payors	0	0
Current liabilities of hospitals held for sale		0
Other current liabilities	222	516
Total current liabilities	10,482	11,114
Long-term debt	1,174,663	1,188,224
Intercompany payable	263,365	182,555
Deferred income tax liabilities, net	7,799	7,774
Other long-term liabilities	0	0
Total liabilities	1,456,309	1,389,667
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity (deficit):
Preferred stock	0	0
Common stock	3	3
Additional paid-in capital	552,511	549,610
Accumulated other comprehensive income (loss)	(2,031)	(1,956)
Accumulated deficit	(573,790)	(448,216)
Total Quorum Health Corporation stockholders' equity (deficit)	(23,307)	99,441
Nonredeemable noncontrolling interests	0	0
Total equity (deficit)	(23,307)	99,441
Total liabilities and equity	1,433,002	1,489,108
Reportable Legal Entities [Member] | Other Guarantors [Member]
Current assets:
Cash and cash equivalents	958	4,222
Patient accounts receivable, net of allowance for doubtful accounts	252,286	262,690
Inventories	37,453	43,276
Prepaid expenses	19,972	16,980
Due from third-party payors	59,286	93,323
Current assets of hospitals held for sale		8,112
Other current assets	31,957	32,867
Total current assets	401,912	461,470
Intercompany receivable	540,784	402,817
Property and equipment, net	468,084	543,073
Goodwill	235,814	243,618
Intangible assets, net	47,864	58,240
Long-term assets of hospitals held for sale		7,730
Other long-term assets	61,079	74,918
Net investment in subsidiaries	0	0
Total assets	1,755,537	1,791,866
Current liabilities:
Current maturities of long-term debt	1,387	1,434
Accounts payable	134,533	146,193
Accrued liabilities:
Accrued salaries and benefits	60,803	56,522
Accrued interest	0	0
Due to third-party payors	34,200	46,381
Current liabilities of hospitals held for sale		2,577
Other current liabilities	31,370	30,664
Total current liabilities	262,293	283,771
Long-term debt	23,000	23,809
Intercompany payable	259,908	173,341
Deferred income tax liabilities, net	0	0
Other long-term liabilities	226,605	195,132
Total liabilities	771,806	676,053
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity (deficit):
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	1,186,270	1,291,581
Accumulated other comprehensive income (loss)	(2,031)	(1,956)
Accumulated deficit	(200,508)	(173,812)
Total Quorum Health Corporation stockholders' equity (deficit)	983,731	1,115,813
Nonredeemable noncontrolling interests	0	0
Total equity (deficit)	983,731	1,115,813
Total liabilities and equity	1,755,537	1,791,866
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	409	344
Patient accounts receivable, net of allowance for doubtful accounts	75,194	80,455
Inventories	9,327	10,183
Prepaid expenses	5,309	4,154
Due from third-party payors	9,903	3,879
Current assets of hospitals held for sale		0
Other current assets	13,485	14,573
Total current assets	113,627	113,588
Intercompany receivable	259,905	172,098
Property and equipment, net	136,697	132,206
Goodwill	165,642	165,611
Intangible assets, net	5,581	6,610
Long-term assets of hospitals held for sale		4
Other long-term assets	26,745	20,689
Net investment in subsidiaries	0	0
Total assets	708,197	610,806
Current liabilities:
Current maturities of long-term debt	346	421
Accounts payable	20,003	24,925
Accrued liabilities:
Accrued salaries and benefits	21,322	21,281
Accrued interest	0	0
Due to third-party payors	6,470	1,324
Current liabilities of hospitals held for sale		0
Other current liabilities	14,320	12,507
Total current liabilities	62,461	60,458
Long-term debt	16	2
Intercompany payable	277,419	219,022
Deferred income tax liabilities, net	0	0
Other long-term liabilities	32,667	31,100
Total liabilities	372,563	310,582
Redeemable noncontrolling interests	2,301	2,325
Quorum Health Corporation stockholders' equity (deficit):
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	573,212	471,767
Accumulated other comprehensive income (loss)	0	0
Accumulated deficit	(254,591)	(187,837)
Total Quorum Health Corporation stockholders' equity (deficit)	318,621	283,930
Nonredeemable noncontrolling interests	14,712	13,969
Total equity (deficit)	333,333	297,899
Total liabilities and equity	708,197	610,806
Eliminations [Member]
Current assets:
Cash and cash equivalents	0	0
Patient accounts receivable, net of allowance for doubtful accounts	0	0
Inventories	0	0
Prepaid expenses	0	0
Due from third-party payors	0	0
Current assets of hospitals held for sale		0
Other current assets	0	0
Total current assets	0	0
Intercompany receivable	(800,692)	(574,918)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long-term assets of hospitals held for sale		0
Other long-term assets	0	0
Net investment in subsidiaries	(1,431,461)	(1,488,021)
Total assets	(2,232,153)	(2,062,939)
Current liabilities:
Current maturities of long-term debt	0	0
Accounts payable	0	0
Accrued liabilities:
Accrued salaries and benefits	0	0
Accrued interest	0	0
Due to third-party payors	0	0
Current liabilities of hospitals held for sale		0
Other current liabilities	0	0
Total current liabilities	0	0
Long-term debt	0	0
Intercompany payable	(800,692)	(574,918)
Deferred income tax liabilities, net	0	0
Other long-term liabilities	(129,109)	(88,278)
Total liabilities	(929,801)	(663,196)
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity (deficit):
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	(1,759,482)	(1,763,348)
Accumulated other comprehensive income (loss)	2,031	1,956
Accumulated deficit	455,099	361,649
Total Quorum Health Corporation stockholders' equity (deficit)	(1,302,352)	(1,399,743)
Nonredeemable noncontrolling interests	0	0
Total equity (deficit)	(1,302,352)	(1,399,743)
Total liabilities and equity	$ (2,232,153)	$ (2,062,939)

Guarantor and Non-Guarantor S93

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Statement of Cash Flows (Details) - USD ($) $ in Thousands	Apr. 29, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		$ 17,194	$ (27,481)	$ 14,601	$ (8,955)
Cash flows from investing activities:
Capital expenditures for property and equipment		(10,791)	(15,925)	(25,319)	(39,142)
Capital expenditures for software		(531)	(1,663)	(1,044)	(3,169)
Acquisitions, net of cash acquired		(26)	(1,887)	(58)	(1,887)
Proceeds from the sale of hospitals		507	15,874	39,170	20,156
Changes in intercompany balances with affiliates, net				0	0
Other investing activities		52	0	249	0
Net cash provided by (used in) investing activities		(10,789)	(3,601)	12,998	(24,042)
Cash flows from financing activities:
Borrowings under revolving credit facilities		115,000	130,000	247,000	302,000
Repayments under revolving credit facilities		(119,000)	(158,000)	(233,000)	(252,000)
Borrowings of long-term debt		55	72	67	72
Repayments of long-term debt		(30,820)	(4,738)	(31,447)	(11,847)
Payments of debt issuance costs	$ (29,146)	0	(2,891)	(2,268)	(2,938)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		(1,309)	(461)	(1,943)	(1,489)
Cash distributions to noncontrolling investors		0	(37)	(803)	(3,851)
Changes in intercompany balances with affiliates, net				0	0
Net cash provided by (used in) financing activities		(36,074)	(36,055)	(22,394)	29,947
Net change in cash, cash equivalents and restricted cash		(29,669)	(67,137)	5,205	(3,050)
Cash, cash equivalents and restricted cash at beginning of period		40,491	89,542	5,617	25,455
Cash, cash equivalents and restricted cash at end of period		10,822	22,405	10,822	22,405
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities				(62,144)	(68,468)
Cash flows from investing activities:
Capital expenditures for property and equipment				0	0
Capital expenditures for software				0	0
Acquisitions, net of cash acquired				0	0
Proceeds from the sale of hospitals				0	0
Changes in intercompany balances with affiliates, net				0	0
Other investing activities				0
Net cash provided by (used in) investing activities				0	0
Cash flows from financing activities:
Borrowings under revolving credit facilities				247,000	302,000
Repayments under revolving credit facilities				(233,000)	(252,000)
Borrowings of long-term debt				0	0
Repayments of long-term debt				(30,463)	(10,832)
Payments of debt issuance costs				(2,268)	(2,938)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares				0	0
Cash distributions to noncontrolling investors				0	0
Changes in intercompany balances with affiliates, net				81,279	25,659
Net cash provided by (used in) financing activities				62,548	61,889
Net change in cash, cash equivalents and restricted cash				404	(6,579)
Cash, cash equivalents and restricted cash at beginning of period				1,051	21,609
Cash, cash equivalents and restricted cash at end of period		1,455	15,030	1,455	15,030
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities				75,865	52,472
Cash flows from investing activities:
Capital expenditures for property and equipment				(16,707)	(13,390)
Capital expenditures for software				(957)	(2,670)
Acquisitions, net of cash acquired				0	(20)
Proceeds from the sale of hospitals				38,612	0
Changes in intercompany balances with affiliates, net				(97,540)	(30,637)
Other investing activities				262
Net cash provided by (used in) investing activities				(76,330)	(46,717)
Cash flows from financing activities:
Borrowings under revolving credit facilities				0	0
Repayments under revolving credit facilities				0	0
Borrowings of long-term debt				12	72
Repayments of long-term debt				(868)	(835)
Payments of debt issuance costs				0	0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares				(1,943)	(1,489)
Cash distributions to noncontrolling investors				0	0
Changes in intercompany balances with affiliates, net				0	0
Net cash provided by (used in) financing activities				(2,799)	(2,252)
Net change in cash, cash equivalents and restricted cash				(3,264)	3,503
Cash, cash equivalents and restricted cash at beginning of period				4,222	3,498
Cash, cash equivalents and restricted cash at end of period		958	7,001	958	7,001
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities				880	7,041
Cash flows from investing activities:
Capital expenditures for property and equipment				(8,612)	(25,752)
Capital expenditures for software				(87)	(499)
Acquisitions, net of cash acquired				(58)	(1,867)
Proceeds from the sale of hospitals				558	20,156
Changes in intercompany balances with affiliates, net				0	0
Other investing activities				(13)
Net cash provided by (used in) investing activities				(8,212)	(7,962)
Cash flows from financing activities:
Borrowings under revolving credit facilities				0	0
Repayments under revolving credit facilities				0	0
Borrowings of long-term debt				55	0
Repayments of long-term debt				(116)	(180)
Payments of debt issuance costs				0	0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares				0	0
Cash distributions to noncontrolling investors				(803)	(3,851)
Changes in intercompany balances with affiliates, net				16,261	4,978
Net cash provided by (used in) financing activities				15,397	947
Net change in cash, cash equivalents and restricted cash				8,065	26
Cash, cash equivalents and restricted cash at beginning of period				344	348
Cash, cash equivalents and restricted cash at end of period		8,409	374	8,409	374
Eliminations [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities				0	0
Cash flows from investing activities:
Capital expenditures for property and equipment				0	0
Capital expenditures for software				0	0
Acquisitions, net of cash acquired				0	0
Proceeds from the sale of hospitals				0	0
Changes in intercompany balances with affiliates, net				97,540	30,637
Other investing activities				0
Net cash provided by (used in) investing activities				97,540	30,637
Cash flows from financing activities:
Borrowings under revolving credit facilities				0	0
Repayments under revolving credit facilities				0	0
Borrowings of long-term debt				0	0
Repayments of long-term debt				0	0
Payments of debt issuance costs				0	0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares				0	0
Cash distributions to noncontrolling investors				0	0
Changes in intercompany balances with affiliates, net				(97,540)	(30,637)
Net cash provided by (used in) financing activities				(97,540)	(30,637)
Net change in cash, cash equivalents and restricted cash				0	0
Cash, cash equivalents and restricted cash at beginning of period				0	0
Cash, cash equivalents and restricted cash at end of period		$ 0	$ 0	$ 0	$ 0